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A novel method to quantify gamma H2AX foci in circulating tumour cells in 
patients receiving chemotherapy for colorectal cancer 
 
Abstract 
Colorectal cancer (CRC) is the third most common cancer in males and females. 
Circulating tumour cells (CTCs) are epithelial cancer cells that mediate haematogenous 
metastases and can be used as predictive and prognostic markers. Gamma-H2AX (γ-
H2AX) foci represent double strand DNA breaks and DNA damage. Assessing γ-H2AX 
foci in CTCs could be utilised as a biomarker to measure patient response to DNA-
interactive anti-cancer treatments in real time, aiding treatment decisions. The aim of this 
study was to develop a method to quantify changes in γ-H2AX in CTCs from metastatic 
CRC patients undergoing treatment with FOLFOX (oxaliplatin with fluorouracil 5FU and 
folinic acid chemotherapy) or FOLFORI (irinotecan with 5FU and folinic acid). Human CRC 
cell lines (HT-29; HCT-116) treated with oxaliplatin, SN-38 and topotecan alone or spiked 
into healthy donor blood were evaluated to assess γ-H2AX signal using both the 
CellSearch® System (Janssen Diagnostics) and the DEPArray™ System (Silicon 
Biosystems). The fluorescent signal in cells could not be quantified using CellSearch 
followed by DEPArray analysis, but when DEPArray was used alone, treated cells 
demonstrated a significantly increased intensity of fluorescein isothiocyanate-conjugated 
(FITC) anti-γ-H2AX antibody staining compared with control cells. This indicated the 
DEPArray system was able to quantify differences in signal intensity caused by induction 
of γ-H2AX in CTCs. To determine if this could be applied clinically, the effect of CellSearch 
scanning on FITC intensity detected by DEPArray was evaluated using topotecan treated 
HT-29 cells that were scanned or unscanned with CellSearch followed by DEPArray 
analysis; scanned cells expressed a statistically significant lower FITC signal intensity 
compared with unscanned cells. Evaluation of γ-H2AX in CTCs from CRC patients was 
inconclusive due to small patient numbers. This study suggests a potential barrier for 
clinical application using the method of DEPArray following CellSearch analysis, therefore 
alternative methods should be evaluated to determine a suitable assay for use in the clinic. 
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CHAPTER 1: Colorectal Cancer, its Treatment and Molecular Aberrations  
 
1.1. Background on CRC 
1.1.1. Incidence  
Colorectal cancer (CRC) is the third most common cancer in males and females and the 
fourth overall in the UK, accounting for 13% of all new cases [1]. Almost two-thirds of all 
CRCs originate in the colon and over one-third in the rectum [2]. Worldwide incidence rate 
is influenced by different environmental factors, especially poor diet, obesity and low 
socioeconomic status which account for 30% of increased risk [3-5]. Historically, the 
incidence has been 10-fold higher in Europe and the USA compared with Asia or Africa 
[6] but in the last 15 years this trend has changed globally, being quite stable in Western 
countries while increasing in several areas previously at low risk [6, 7]. More recent data 
from the United States SEER database and other Western cancer registries indicate that 
incidence rates are increasing in younger age [2, 8-10]. 5% of the normal population is 
potentially exposed to the risk of developing CRC, while the risk increases substantially in 
those patients with specific inherited conditions or inflammatory bowel disease. Overall, 
death rates have declined in the last 30 years with an improvement of 5-year survival rates 
throughout all stages due to implementation of screening programs, early diagnosis and 
improved treatment [2, 11, 12]. 
  
1.1.2. Risk Factors  
The majority of CRCs (about 75%) are sporadic. Age is considered a major risk factor with 
incidence rates increasing in each following decade after the age of 50 years [2, 13]. Only 
5% of CRCs are related to genetic factors; these cancers are more often localised in the 
right side of the colon and are characterised by early age of onset [14-21]. The most 
common hereditary CRC syndromes are Familial Adenomatous Polyposis (FAP) and 
Lynch Syndrome (hereditary non-polyposis colorectal cancer [HNPCC]). FAP is 
responsible for the majority of cancer in young age and is caused by germline mutations 
in the APC gene on chromosome 5 [22]. Lynch syndrome is an autosomal dominant 
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syndrome, with a germline mutation in one allele of mismatch repair genes (MMR), most 
commonly hMLH1, hMSH2, hMSH6, or PMS2 [23]. Along with genetic conditions, 
inflammatory bowel disease (ulcerative colitis and Crohn's disease) can also represent 
another important risk factor [24-26].  
 
1.1.3. Diagnosis and Symptoms  
The most common anatomic location of CRCs is the left side of the colon including the 
descending and sigmoid colon, although recently an increase in incidence of ascending 
colon and caecal cancers has been observed in the United States and internationally [27-
30]. Improvement in screening procedures such as flexible sigmoidoscopy with removal of 
adenomatous polyps in the descending colon could explain fewer occurrences of left-sided 
tumours, while right-sided CRCs are more difficult to detect especially for their different 
anatomical presentation (flat adenoma). Nevertheless, biology appears to vary between 
left and right side, the latter appears to carry more BRAF V600E mutations with 
microsatellite instability [27, 28]. 
Despite advances in screening and early detection of CRCs, one in five patients presents 
with symptoms suggestive of metastatic disease [31], such as change in bowel habits, 
anaemia and fatigue [32]. If CRC is suspected, initial evaluation includes medical history, 
physical examination, FOB testing and flexible sigmoidoscopy or colonoscopy which 
remains the gold standard diagnostic test for detection of the majority of endoluminal 
adenocarcinomas of the colon and rectum [33]. All lesions detected should be biopsied for 
histological examination [32]. CT colonography (virtual colonoscopy) can be used in cases 
where direct endoscopy is precluded for medical or technical reasons, although biopsies 
cannot be performed during this procedure [32]. Following diagnosis of CRC, a CT scan 
of the chest, abdomen and pelvis should be performed to assess metastatic disease [32, 
33]. There is no diagnostic role for routine laboratory blood tests in screening or staging of 
CRC. Elevated serum CEA and CA19-9 levels may be present in a percentage of patients 
with CRC, although this test is neither sensitive enough or specific enough for screening, 
in the preoperatively and postoperatively setting the levels are important in guiding surgical 
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treatment planning, assessment of prognosis and helping to detect recurrences earlier 
[34].  
Preoperative staging of a newly diagnosed CRC includes CT scan of the chest, abdomen 
and pelvis while additional procedures (rigid sigmoidoscopy, transrectal endoscopic 
ultrasound, and/or magnetic resonance imaging [MRI]) maybe indicated for locoregional 
staging of patients with rectal cancer to assess the extent of local disease and assist with 
treatment planning such as initial radiotherapy (RT), chemo-radiotherapy or surgery. 
Positron emission tomography (PET) of the chest/abdomen/pelvis is usually used in cases 
of isolated liver metastases that can undergo surgical resection. 
 
1.1.4. Current Classification and Prognostic Factors in CRC  
Pathologic stage at diagnosis remains the best indicator of long-term prognosis for both 
colon and rectal cancer and the strongest predictor of postoperative outcome; this has 
been investigated and confirmed by multiple correlative studies between many other 
prognostic factors for CRCs [35]. The most robust determinants of prognosis and five-year 
survival rates include local involvement, regional lymph node (LN) metastasis, residual 
disease after definitive therapy and the presence of distant metastases. 
Local involvement (pT category of TNM) independently influences survival [36-39]; 
regional LN metastasis (pN category of TNM staging) represents an indication for adjuvant 
chemotherapy for both colon and rectal cancer and is one of the strongest predictors of 
outcome for both stage II (node-negative) and stage III (node-positive) disease [40-48]. 
Following surgical resection, residual disease after definitive therapy, has also been 
demonstrated to be a poor prognostic factor. In a report of 152 patients with T4 colon 
cancers, 42 patients with incompletely resected cancers had an inferior  
10-year recurrence-free survival when compared with those with fully resected T4N0 or 
T4 node-positive disease (19 vs 88 and 58%, respectively) [49-52]. 
Lymphovascular invasion is also an important prognostic determinant and an independent 
adverse prognostic factor for CRCs [36, 53-55]. Nevertheless, in stage IV, location and 
extent of distant metastatic disease are the most determinants of prognosis. The tumour 
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marker CEA, as previously mentioned, has prognostic significance in the preoperative 
setting independent of tumour stage [54, 56-58], showing an adverse impact on survival if 
levels are ≥5.0 ng/mL. CEA should be routinely measured in patients undergoing 
potentially curative resections for CRC and post-operatively to ensure elevated levels 
normalise. In contrast, there are insufficient data about the use of CEA as to determinant 
for adjuvant therapy [58].  
The majority of CRCs are adenocarcinomas (Table 1.1) [59] which are further classified 
as low-grade tumours (well/moderately differentiated) and high-grade tumours 
(poorly/undifferentiated) (Table 1.2) [60]. Mucinous carcinoma is a subtype of CRC 
producing extracellular mucin, representing a small percentage of all CRCs [61, 62], often 
localised in the right side of the colon [63, 64] and are further characterised by late stage 
at diagnosis, MSI instability, BRAF mutation and poor response to treatment [65, 66]; a 
very aggressive variant of this subtype accounting only 1–2%, is signet ring cell carcinoma 
[61, 67, 68]. Small cell carcinomas with comparable poor account and neuroendocrine 
differentiation represent 10% of all CRCs. Adenosquamous carcinomas [69] represent 
only 0.05–0.2% of CRCs [70, 71] and are characterised by higher overall and colorectal-
specific mortality; while the medullary carcinoma subtype is a non-gland forming cancer 
[72] usually associated with microsatellite instability and HNPCC syndrome. 
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Table 1.1: World Health Organisation classification of the carcinoma of the colon  
and rectum  
Adenocarcinoma 
     Cribriform comedo-type adenocarcinoma  
     Medullary carcinoma 
     Micropapillary carcinoma  
     Mucinous (colloid) adenocarcinoma (>50% mucinous) 
     Serrated adenocarcinoma 
     Signet-ring cell carcinoma (>50% signet-ring cells) 
Adenosquamous carcinoma 
Spindle cell carcinoma 
Squamous cell (epidermoid) carcinoma 
Undifferentiated carcinoma 
Adapted from World Health Organization Classification of Tumours of the Digestive 
System, 4th ed, Hamilton SR et al., Criteria for histological grading of colorectal 
adenocarcinomas, p.138 [59]. 
 
Table 1.2: Criteria for histological grading of colorectal adenocarcinoma 
Criterion Differentiation 
category 
Numerical 
grade 
Descriptive 
grade 
>95% with gland 
formation Well differentiated 1 Low 
50 to 90% with 
gland formation 
Moderately 
differentiated 2 Low 
>0 to 49% with 
gland formation Poorly differentiated 3 High 
High level of 
microsatellite 
instability 
Variable Variable Low 
  Adapted from Colorectal carcinoma: Pathologic aspects, Fleming M et al. 
 J Gastrointestinal Oncol. 2012;3:153–173 [60]  
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The category ‘undifferentiated carcinoma’ (grade 4) is reserved for carcinomas with no  
gland formation, mucin production, or neuroendocrine, squamous, or sarcomatoid 
differentiation [59].  
 
1.1.5 Staging of CRC  
The 2010 TNM staging classification of the AJCC/UICC (Table 1.3) is the staging system 
for CRC currently in use [35] and has been implemented with few changes compared to 
the 2002 classification [35]. 
 
Stage categories 
T–T4 category has been subdivided into T4a (tumour penetrates to the surface of the 
visceral peritoneum) and T4b (tumour directly invades or is adherent to other organs and 
structures). 
N – Recommendation of 6th edition – to harvest at least 12 to 14 regional LN – is restated 
pN1 – metastasis in one to three regional LN – has been subdivided in N1a (metastasis in 
one regional lymph node), N1b (metastasis in 2–3 regional lymph nodes) and N1c (tumour 
deposits in the subserosa, mesentery or non-peritonealized pericolic or perirectal tissue 
without regional LN metastasis). 
Tumour deposits (TD, formerly named satellite nodules) defined as discrete foci of tumour 
found in the pericolic, perirectal or mesenteric fat, in the absence of residual  
LN tissue, but within the lymph drainage area of primary tumour are included both in Site-
Specific Factors (or Prognostic Factors) category and also in N category. 
pN2 – metastasis in four or more regional LN – has been subdivided in pN2a – metastasis 
in four to six regional LN – and pN2b – metastasis in seven or more nodes. 
M – MX is no longer included in TNM 7. The MO category cannot be documented on 
pathological evaluation, but only clinical, based on history and physical exam. M1 has 
been subdivided into M1a (metastasis confined to one organ or site) and M1b (metastasis 
in more than one organ/site or the peritoneum). 
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Anatomic Stage/Prognostic Groups 
Stage II – is now subdivided into IIA (T3N0), IIB (T4aN0) and IIC (T4bN0). 
Stage III – T4bN1 (previously classified as IIIB), has been reclassified as IIIC. A number 
of N2 categories (formerly included in stage IIIC) have been restaged as follows: 
T1N2a in stage IIIA and T1N2b, T2N2a-b and T3N2a in stage IIIB. 
 
Table 1.3: Anatomic stage/prognostic groups [28] 
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through the muscularis propria into pericolorectal tissues 
T4a Tumour penetrates to the surface of the visceral peritoneum 
T4b Tumour directly invades or is adherent to other organs or structures 
Regional lymph node (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1−3 regional lymph nodes 
N1a Metastasis in one regional lymph node 
N1b Metastasis in 2−3 regional lymph nodes 
N1c Tumour deposit(s) in the subserosa, mesentery, or nonperitonealized 
pericolic or perirectal tissues without regional nodal metastasis 
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N2 Metastasis in four or more regional lymph nodes 
N2a Metastasis in 4−6 regional lymph nodes 
N2b Metastasis in seven or more regional lymph nodes 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis confined to one organ or site (eg, liver, lung, ovary,  
non-regional node) 
M1b Metastases in more than one organ/site or the peritoneum 
Stage T N M Dukes MAC 
0 Tis N0 M0 − – 
I 
T1 N0 M0 A A 
T2 N0 M0 A B1 
IIA T3 N0 M0 B B2 
IIB T4a N0 M0 B B2 
IIC T4b N0 M0 B B3 
IIIA 
T1-2 N1/N1c M0 C C1 
T1 N2a M0 C C1 
IIIB 
T3-T4a N1/N1c M0 C C2 
T2-T3 N2a M0 C C1/C2 
T1-T2 N2b M0 C C1 
IIIC 
T4a N2a M0 C C2 
T3-T4a N2b M0 C C2 
T4b N1-N2 M0 C C3 
IVA Any T Any N M1a – – 
IVB Any T Any N M1b – – 
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1.1.6. Treatment of CRC  
1.1.6.1. Management of Localised Disease 
1.1.6.2. Management of Early Stage Rectal Cancer 
Treatment differs based on the initial stage of the disease. The treatment of choice for 
Stage I rectal cancer is radical hemicolectomy with LN dissection, and there is no indication 
for adjuvant therapy. For low risk tumours (T1, <3 cm and well differentiated (G1/G2) 
lesions), local excision can be curative, combined with TME in case of a postoperative 
higher T stage. For locally advanced disease (T2-4; N0-2; M0), neo-adjuvant chemo-
radiotherapy with a fluoropyrimidine followed by surgery and adjuvant chemotherapy is the 
standard practice supported by data from randomized trials that showed a reduction in the 
incidence of local recurrence [73]. The dose of radiation generally used is 50.4 Gys 
fractionated over 5 weeks, although several studies suggest that a shorter radiation 
regimen is as affective [74, 75]. In the adjuvant setting capecitabine or infusional 5-
fluorouracil (5-FU) can be used since no difference in survival rates were found in previous 
studies [76]. 
The German CAO/ARO/AIO-94 randomized Phase III study compared pre and post 
chemo-radiotherapy in locally advanced rectal cancer and showed a significant 
improvement in local recurrence free survival (P=0.048) in the pre-operative arm, with a 
10 year relapse rate of 7.1% compared to 10.1% of the post RT arm [77], despite the 
occurrence of distant metastasis being similar in both arms. The addition of oxaliplatin to 
the standard 5-FU infusion did not show a better outcome [78, 79], while 5-FU bolus as 
adjuvant treatment compared with 5-FU, leucovorin, oxaliplatin (FOLFOX) resulted in a 
shorter disease-free survival (DFS) [77]. 
 
1.1.6.3. Management of Early Stage Colon Cancer 
Surgery is the mainstay of treatment for localized colon cancer. Laparoscopic-assisted 
colectomy is comparable to colectomy in terms of oncologic outcomes and is associated 
with shorter hospital stay and a small number of moderate-to-severe postoperative 
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adverse events [80]. Therefore, it is a reasonable alternative to colectomy and is an 
acceptable option for uncomplicated patients where restoration of bowel continuity is 
usually feasible using a primary anastomosis. However, a temporary proximal diverting 
colostomy or ileostomy may be necessary in case the patient is medically unstable or in 
the presence of complications such as diffuse peritonitis or free perforation. 
 
1.1.6.4. Adjuvant Chemotherapy  
In stage II (node negative) disease, the benefits of chemotherapy 5-FU or capecitabine, 
plus/minus the addition of oxaliplatin, in increasing the 5-year survival rate are very low 
(2−3%) and it is not recommended [81]. Treatment decisions must be individualized based 
on the presence of high-risk clinicopathologic features such as fewer than 12 nodes in the 
surgical specimen; T4 tumour stage; presence of perforation/obstruction, poorly 
differentiated histology and lymphovascular or perineural invasion (Table 1.4). It is 
important to assess the MMR status because MMR-deficient tumours have an excellent 
prognosis and do not benefit from 5-FU adjuvant chemotherapy [82]. 
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Table 1.4: Definitions of ‘high risk’ stage II colon cancer from expert groups* 
  ASCO (2004) NCCN (2014) ESMO (2012) 
T4 primary tumour + + + 
Inadequately 
sampled nodes 
+ 
(<13) 
+ 
(<12) 
+ 
(<12) 
Poorly differentiated 
tumour + + + 
Perforation + + 
(localized) + 
Obstruction   + + 
LVI +  + + 
PNI +  + + 
Close/indeterminate 
or positive margins   +   
High preoperative 
levels of serum CEA     
 
LVI: lymphovascular invasion; PNI: perineural invasion; CEA: carcinoembryonic antigen. 
*ie, the American Society of Clinical Oncology (ASCO), the National Comprehensive 
Cancer Network (NCCN), and the European Society for Medical Oncology (ESMO). 
 
In 2015, updated data showed an increasing absolute survival benefit for oxaliplatin in 
stage III disease with time (67 vs 59%, P=0.043) [83]. Standard treatment include a six-
month course of a combination of oxaliplatin with infusional 5-FU (FOLFOX) or with 
capecitabine (XELOX) [84]. Postoperative RT is not usually considered a routine 
component of care for completely resected colon cancer. 
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1.1.6.5. Management of Metastatic Disease 
CRCs disseminate prevalently through the haematogenous and lymphatic system to the 
regional LN, liver and lungs, but can also metastasise locally through contiguous and 
transperitoneal spread. Because of the portal venous drainage of the colon, the first site 
of haematogenous dissemination is usually the liver, while the lungs are a common site if 
the tumour develops in the distal rectum drained by the inferior vena cava. Approximately 
20% of newly diagnosed CRCs are metastatic at presentation (synchronous metastasis). 
In the majority, the intent of therapy is palliative, while for selected patients with limited 
metastatic disease, long-term survival can be achieved with metastasectomy plus removal 
of the primary tumour in conjunction with systemic chemotherapy. Unfortunately, only 
about 20–30% remain disease free. Initial therapeutic options were chemotherapy 5-FU 
and leucovorin based chemotherapy [85-87] that increased survival from 6 months up to 
12 months compared with untreated patients. Currently, the regimens used are a 
combination of infusional 5-FU and leucovorin with the addition of irinotecan (FOLFIRI) 
[88, 89] or oxaliplatin (FOLFOX) [90, 91]; use of these combinations have resulted in 
improved median survival to >20 months. Addition of the vascular endothelial growth factor 
–A (VEGF-A) antibody bevacizumab, or the epidermal growth factor receptor (EGFR) 
antibodies cetuximab and panitumumab to standard regimes has further improved overall 
survival (OS) up to 24 months [92-95] in selected patients. Sequential exposure to all 
active agents gives the best overall outcomes and data from the FIRE-3 and CALGB 
80405 studies showed an improvement in OS in a subset of molecularly defined patients 
[96]. 
 
1.1.6.6. Initial Therapy of Metastatic Disease 
The first line of treatment is the most effective in terms of response rate (RR), progression 
free survival (PFS) and OS, especially in combination with an antibody against VEGF-A or 
EGFR [92, 93]. Multiple Phase III studies showed that a doublet chemotherapy regimen 
(FOLFOX, XELOX or FOLFIRI) is more active than monotherapy with fluoropyrimidine [89, 
90, 97] or than sequential use of single agents (Table 1.5). Both FOLFOX and FOLFIRI 
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regimens showed similar first-line efficacy, and the decision to use one or the other should 
mainly be based on the expected toxicity profiles. 
 
Table 1.5: Irinotecan and oxaliplatin-based regimens for metastatic colorectal cancer 
Regimen 
[reference] Irinotecan Oxaliplatin Leucovorin Fluorouracil/ 
capecitabine 
Schedule 
FOLFIRI  
[98] 
180 mg/m
2
 
day 1 
  400 mg/m
2
 over 
2 hours day 1 
Fluorouracil 400 mg/m
2
 
bolus day 1, followed by 
2400 to 3000 mg/m
2
 
over 46 hours, 
continuous infusion 
Every  
2 weeks 
Douillard 
regimen  
[88] 
180 mg/m
2
 
day 1 
  
200 mg/m
2
 
leucovorin over 
2 hours days 1 
and 2 before 
fluorouracil 
Fluorouracil 400 mg/m
2
 
bolus then 600 mg/m
2
 
over 22 hours days 1 
and 2 
Every  
2 weeks 
FOLFOX 4 [99]   85 mg/m
2
 
day 1 
400 mg/m
2
 over 
2 hours days 1 
and 2 before 
fluorouracil 
Fluorouracil 400 mg/m
2
 
bolus then 600 mg/m
2
 
over 22 hours days 1 
and 2 
Every  
2 weeks 
FOLFOX 6 [98]   100 mg/m
2
 
day 1 
400 mg/m
2
 over 
2 hours day 1 
Fluorouracil 400 mg/m
2
 
bolus day 1, followed by 
2400 to 3000 mg/m
2
 
over 46 hours, 
continuous infusion 
Every  
2 weeks 
Modified 
FOLFOX 6 [85, 
86] 
  85 mg/m
2
 
day 1 
350 mg total 
dose over 2 
hours day 1 
Fluorouracil 400 mg/m
2
 
bolus day 1, followed by 
2400 mg/m
2
 over 46 
hours 
Every  
2 weeks 
FOLFOX 7 [100]   130 mg/m
2
 
day 1 
400 mg/m
2
 over 
2 hours day 1 
Fluorouracil 400 mg/m
2
 
bolus, then 2400 mg/m
2
 
over 46 hours 
Every  
2 weeks 
Modified 
FOLFOX 
7(Optimox) [101] 
  100 mg/m
2
 
day 1 
400 mg/m
2
 over 
2 hours day 1 
Fluorouracil 3000 
mg/m
2
 over 46 hours 
Every  
2 weeks 
Modified 
FOLFOX 
7(CONcePT) 
[102] 
  85 mg/m
2
 
day 1 
200 mg/m
2
 over 
2 hours day 1 
Fluorouracil 2400 
mg/m
2
 over 46 hours 
Every  
2 weeks 
XELOX 
[86] 
  130 mg/m
2
 
day 1 
  
Capecitabine 1000 
mg/m
2
 orally twice per 
day on days 1 to 14 
Every  
3 weeks 
FOLFOXIRI 
[103] 
165 mg/m
2
 
day 1 
85 mg/m
2
 
day 1 
400 mg/m
2
 
leucovorin over 
2 hours day 1 
Fluorouracil 3200 
mg/m
2
 over 48 hours 
Every  
2 weeks 
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The combination of 5-FU, irinotecan and oxaliplatin (FOLFOXIRI) compared with FOLFIRI 
suggests a significantly improved outcome with FOLFOXIRI [103, 104]. Benefits of a six-
month course of FOLFOXIRI included a significantly higher RR (66 vs 41%) and a greater 
number of secondary surgical resections of liver metastases (36 vs 12%) [103]. At a 
median follow-up of over 60 months, FOLFOXIRI was associated with significantly longer 
median PFS (mPFS) (9.8 vs 6.8 months) and OS (23.4 vs 16.7 months), with a  
5-year survival rate of 15 vs 8% [104]. Patients with BRAF mutated tumours in the 
FOLFOXIRI plus bevacizumab arm reached an improvement in OS (24 months) when 
compared with the OS (16/17 months) from subgroup analysis in the CRYSTAL and FIRE-
3 trials [105, 106]. This combination is particularly toxic and should only be considered in 
extremely fit patients. 
Following response, oxaliplatin should be discontinued after 3−4 months of therapy to 
avoid neurotoxicity, but the infusional fluoropyrimidine, with or without bevacizumab, 
should be continued [107, 108]. Several trials compared different maintenance therapies 
compared with a drug holiday in terms of PFS and OS demonstrating that any treatment 
after FOLFOX plus bevacizumab as induction therapy had a better PFS than no treatment 
[101, 109-111]. Infusional fluoropyrimidine or capecitabine with or without bevacizumab 
would be more appropriate for frailer patients and the AVEX study has shown an 
advantage in OS in an elderly population [112]. 
Results from clinical trials showed that assay of RAS mutations permit the selection of 
individuals with RAS wild-type (WT) tumours who might benefit from agents that target 
EGFR. The approval for the use of cetuximab or panitumumab was initially granted after 
identification of KRAS exon 2 WT tumours [113] but more recent data showed that the 
benefit of treatment was abolished in cases with the presence of more rare mutations in 
KRAS exons 3 and 4 and NRAS exons 2, 3 and 4 [113, 114]. In the presence of RAS 
mutations, bevacizumab can be added to FOLFOX, FOLFIRI or FOLFOXIRI and used in 
addition to cetuximab or panitumumab in RAS WT status [115].  
There are few studies testing the efficacy of bevacizumab vs cetuximab or panitumumab 
with FOLFOX, FOLFIRI or both. In one study comparing FOLFIRI plus cetuximab vs 
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FOLFIRI plus bevacizumab, the mPFS turned out to be similar (10.0 months in the 
cetuximab arm vs 10.3 months in the bevacizumab arm, P=.55), although median OS 
(mOS) was significantly longer in the cetuximab arm (28.7 vs 25.0 months, P=.017) [105, 
116]. In one study [117], oxaliplatin based therapy with cetuximab showed a trend towards 
longer OS vs bevacizumab treated patients, while OS was comparable for FOLFIRI based 
therapy; in contrast another study showed a benefit in OS with cetuximab-FOLFIRI [105]. 
The PEAK study (Panitumumab Efficacy in combination with mFOLFOX6 against 
bevacizumab plus mFOLFOX6 in metastatic CRC (mCRC) subjects with WT KRAS 
tumours) was a Phase II study designed to address whether to include anti-EGFR vs anti-
VEGF monoclonal antibodies in the first-line treatment of patients with mCRC. The primary 
objective was PFS and a secondary objective was to evaluate PFS and OS in RAS WT 
patients. No statistically significant PFS difference was detected in patients with exon 2 
WT KRAS mCRC (PFS 10.9 vs 10.1 months, HR =0.87, P=0.35), but an improvement in 
OS was seen in the panitumumab arm (34.2 vs 24.3 months, HR =0.62, P=0.009) [118]. 
There are still only limited data on the benefit of adding bevacizumab to an oxaliplatin-
based regimen and the available data suggest that incremental benefit is modest at best. 
Whether it is preferable to add cetuximab or panitumumab rather than bevacizumab to 
first-line chemotherapy is still unclear, since data are conflicting. 
 
1.1.6.7. Treatment at Progression  
In the absence of direct clinical trial data for second-line chemotherapies, a significant 
survival benefit has been shown following irinotecan-based first-line treatment with the 
addition of bevacizumab to FOLFOX [119]. After progression on FOLFOX or XELOX, 
FOLFIRI with aflibercept, a soluble ‘decoy’ receptor that binds to VEGF-A, VEGF-B and 
placental growth factor (PIGF), showed a significant increase in OS [120]. Aflibercet 
recieved FDA approval based on the placebo-controlled VELOUR trial plus FOLFIRI, in 
oxaliplatin-refractory mCRC patients; mOS was significantly longer in patients treated with 
aflibercept (13.5 vs 12.1 months) [120].  
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On the contrary, treatments with anti-EGFR in the second line did not show an OS benefit 
irrespective of the chemotherapy previously administered [121], while an increase in 
survival has been shown in later lines of chemotherapy for patients with RAS WT tumours, 
with or without irinotecan [95, 122]. In addition, the kinase inhibitor regorafenib significantly 
prolonged OS, albeit with little objective antitumour response when tested against best 
supportive care (CORRECT trial) [123]. New compounds such as TAS-102 (trifluridine and 
tipiracil hydrochloride) and TAS-114 (dUTPase inhibitor) that interfere with thymidylate 
metabolism, have shown encouraging results in Phase II trials and TS-102 showed 
significant OS benefit against placebo in the Phase III trial (RECOURSE) in refractory 
mCRC [124]. After failure of all conventional ‘lines of therapy’, it is acceptable to re-utilize 
the regimen initially used in the treatment sequence since tumours may regain sensitivity 
to previously used drugs [125]. 
In the last two decades, the development of new drugs and the evaluation of the best 
therapy sequence and combinations of treatments have considerably increased the OS 
from 6 months to more than 30 months. The investigation of mechanisms of CRC 
carcinogenesis, secondary resistance and new molecular biomarkers will contribute to 
more personalised treatment in the future. 
 
1.2. Biomarkers  
Identical histological subtypes of CRCs can have different prognoses and response to 
treatment. Clinicopathological staging remains the mainstay of prognostication and 
treatment selection but there is a clear need for robust diagnostic, predictive and 
prognostic markers for routine clinical use [126]. 
Investigations into the molecular mechanisms involved in pathogenesis and progression 
of CRCs have demonstrated underlying genetic and epigenetic lesions that can provide 
important information along with clinicopathologic features, guiding treatment 
management in a personalised fashion (Table 1.6) [127, 128]. The most well-known 
genetic and epigenetic abnormalities in CRCs are chromosomal instability (CIN), MSI and 
methylation changes [126]. 
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CIN is present in 85% of CRCs and is characterised by the presence of aneuploidy. It is 
usually mutually exclusive of MSI which presents with a normal karyotype and unique gene 
mutations involving the DNA Mismatch Repair (MMR) family [126]. MSI account for about 
15% of CRCs, can be sporadic and are characterised by silencing of MLH1 by aberrant 
DNA methylation [126, 129] frequently carrying BRAF V600E mutations [130, 131] or can 
be hereditary as in the Lynch syndrome due to germline mutations in one of the MMR 
genes (MLH1, MSH2, MSH6 and PMS2). 
Results from meta-analyses have shown that MSI CRCs have a better prognosis of CIN 
tumours [132, 133] independently of stage but, although they can be considered as 
prognostic markers, have not yet been included into routine practice. 
Other genetic aberrations commonly found in CRCs are CpG Island Methylator Phenotype 
(CIMP) and global DNA hypomethylation resulting in deregulation of specific important 
signalling pathways such as APC/ß-catenin/WNT-β-catenin pathway, transforming growth 
factor β (TGF-β) pathway, EGFR/MAPK pathway and phosphatidyl inositol 3-kinase (PI3K) 
pathway [134, 135]. 
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Table 1.6: Molecular classification of colorectal carcinoma 
 
Heredity 
Chromosomal 
instability 
pathway 
Mismatch 
repair 
pathway 
Serrated/CIMP 
pathway 
Hybrid 
pathway 
Hereditary and 
sporadic 
Hereditary 
Hereditary and  
sporadic 
Sporadic 
CIMP status Negative Negative High High Low 
MSI status MSS MSI-H MSI-H MSI-L 
MSI-L or 
MSS 
Chromosomal 
instability 
Present Absent Absent Absent Present 
KRAS 
mutation 
+++ +/- − − +++ 
BRAF 
mutation 
− − +++ +++ − 
MLH1 status Normal Mutation Methylated 
Partial 
methylation 
Normal 
MGMT 
methylation 
--- --- +/- +++ ++ 
CIMP: CpG island methylator phenotype; MSS: microsatellite stability; MSI: microsatellite 
instability; MSI-H: high-level microsatellite instability; MSI-L: low-level microsatellite 
instability; MGMT: O-6-methlyguanine DNA methyltransferase; +++: present; +/-: might or 
might not be present; ---: absent. 
Adapted from: Noffsinger AE. Serrated polyps and colorectal cancer: New pathway to 
malignancy. Annu Rev Pathol 2009;4:343 [128]  
 
1.2.1. Signalling Pathway and Biomarkers in CRC 
To date, mutant KRAS is the only predictive marker that has been clinically validated in 
the treatment of CRC, while further validations are still needed for mutant BRAF, PIK3CA 
and PTEN [136]. Research efforts are also focused on ascertaining molecular features of 
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CRC that can predict response to adjuvant chemotherapy such as 5-FU, irinotecan and 
oxaliplatin [135]. 
 
1.2.2. Transforming Growth Factor Beta (TGF-β) Pathway 
Deregulation of the tumour-suppressor TGF-β signalling is very common in CRCs [137] 
and can involve receptor genes (TGFBR2 and TGFBR1), intra-cellular signalling pathway 
genes (SMAD2, SMAD4) and TGF-β super family members (ACVR2) [138-140]. SMAD4 
is a tumour suppressor gene located on 18q [141], it is lost in >50% of CRCs correlating 
with worse prognosis [142]; SMAD4 can be deleted by the loss of the long arm of 
chromosome 18 (18q loss of heterozygosity; LOH). There is a strong association between 
18qLOH and CIN suggesting a role as an independent prognostic marker, but further data 
need to validate their roles as prognostic biomarkers [135]. 
 
1.2.3. EGFR/ Ras/Raf /MAPK Pathway 
KRAS is a member of the RAS family of proto-oncogenes and is mutated in approximately 
40% of CRCs (codons 12 or 13). The KRAS protein is a downstream effector of EGFR 
signalling through the BRAF gene in the Ras/Raf/MAPK signalling pathway, promoting cell 
growth and survival [143, 144]. The most common BRAF mutation (10–15%) is the result 
of the substitution of glutamic acid for valine at codon 600 (V600E) [134] and is mutually 
exclusive with KRAS mutations in promoting tumourigenesis [145].  
Evidence from previous studies showed that mutant BRAF could be a reliable prognostic 
marker of OS in Stage II and III CRCs and a marker of poor prognosis in advanced disease 
is association with mutant KRAS [146, 147]. The relationship between KRAS mutational 
status in metastatic CRC and benefit from anti-EGFR therapy has been extensively 
studied in four large Phase III randomized studies [148-151] establishing its use as a 
predictive marker for anti-EGFR mAb resistance. However, only a minority (30%) of KRAS 
codon 12/13 wild-type tumours respond to anti-EGFR mAb therapy [136]. Further 
investigations have shown mutations of BRAF V600E, PIK3CA and loss of PTEN protein 
expression [134] as potential markers for resistance of anti-EGFR mAb therapy, leading 
to the evolving use of BRAF mutation testing in KRAS-WT patients prior to treatment. 
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1.2.4. Phosphatidylinositol 3-kinase (PI3K) Pathway 
PI3K Pathway is regulated by EGFR signalling partly via KRAS activation, and mutations 
are observed in up to 40% of CRCs, especially involving the PIK3CA gene (32% of CRCs) 
[152] and the tumour suppressor gene PTEN (30% of MSI tumours and 9% of CIN 
tumours) [153]. These two genes could potentially be used as predictive markers for 
therapies targeting the PI3K, mTORC and the MAPK pathway (Figure. 1.1) [154, 155]. 
Nevertheless, there is still a lack of consensus and further studies are needed to determine 
if these genes should be incorporated into clinical practice [156]. 
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Figure 1.1: The complexity of the intracellular EGFR pathway.  
Cbl, casitas B-lineage lymphoma; DAG, diacyl glycerol; EGFR, epidermal growth factor 
receptor; ERK, extracellular-signal-regulated kinase; FAK, focal adhesion kinase; GDP, 
guanosine diphosphate; Grb2, growth factor receptor-bound protein 2; GSK3, glycogen 
synthase kinase 3; GTP, guanidine triphosphate; HER, human epidermal receptor; IP3, 
inositol-1,4,5-trisphosphate; MEK, methyl ethyl ketone; mTOR, mammalian target of 
rapamycin; PDK, phosphoinositide-dependent kinase; PI3K, phosphatidylinositol 3-
kinase; PLC, phospholipase C; PTEN, phosphatase and tensin homologue; RAS, rat 
sarcoma; SOS, salt overly sensitive; STATs, signal transducer and activator of 
transcription 
Aprile G, et al. OA Molecular Oncology 2013;1(1):7 [157] 
 
1.2.5. Predictive Biomarkers for Risk Stratification and Early Detection 
Molecular markers could be further used in risk stratification for early-stage CRCs 
detection and identification of high-risk subjects. So far, germline mutations in genes 
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responsible of hereditary colon cancer syndromes and MSI tumour status are the most 
solid molecular markers. In addition, other markers for use in non-invasive colorectal 
cancer screening assays [158-160] have been identified such as the methylated vimentin 
(VIM) gene, present in the majority of CRCs (53–84%), detected with the stool-based 
methylated VIMENTIN (mVim) assay [161, 162]. The methylation assay is undoubtedly an 
area that is likely to endure rapid advances in the future. 
 
1.2.6. Predictive Biomarkers for Chemotherapy 
MSI and 18qLOH abnormalities are currently the most encouraging biomarkers for guiding 
adjuvant chemotherapy in CRCs, since previous studies showed adverse response to 5-
FU based regimens [163-166] in patients carrying these molecular alterations. However, 
data from the literature showed that the tumour stage and the differences in sporadic MSI 
vs Lynch syndrome CRCs may also affect 5-FU resistance. 
Several clinical trials are assessing the predictive value of 18qLOH and MSI including the 
ongoing Phase III study (NCT00217737) with 5-FU, oxaliplatin and bevacizumab on stage 
II CRCs [135], the Phase III study of olaparib on stage IV CRC (NCT00912743), and the 
retrospective analysis of 5-FU alone or in combination with irinotecan on Stage II or III 
CRCs (CLB-9581/CLB-89803). 
High expression of Topoisomerase I (Topo I) has been found to be associated with 
responsiveness to the Topo I inhibitor irinotecan in a large randomized trial that compared 
5-FU alone with 5-FU combined with irinotecan or oxaliplatin in advanced CRCs; validation 
by independent studies is required before Topo I can be used as a predictive biomarker in 
the clinical setting [167]. 
Germline polymorphisms affecting the PK and PD of chemotherapy could potentially be 
used as biomarkers for guiding treatment selection, even if only few of them have been 
appropriately validated for clinical use [168, 169]. The commercial genotyping test that has 
been approved by the FDA to aid irinotecan dosing checks the enzyme UDP-
glucuronosyltransferase (UGT1A1), involved in the detoxification of the irinotecan 
metabolite SN-38. A homozygous polymorphism of the gene reduces the activity of the 
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enzyme affecting an inter-individual variation of the toxicity via the alternation of 
bioavailability of SN-38 [170, 171]. 
Molecular testing on CRC and identification of specific genetic or epigenetic markers can 
reduce medical costs and improve patient outcomes by targeting therapies on a stratified 
patient population. Indications for mutational analysis is likely to expand in the future and 
clinical trials are currently assessing the efficacy of specific inhibitors of the PI3K signalling 
pathway [134, 172, 173] or investigating other multikinase target inhibitors in the setting of 
resistance to anti-EGFR mAb therapies [174, 175]. The identification of PIK3CA mutations 
or PTEN loss are expected to become applicable for the treatment of CRCs as well as the 
detection of BRAF mutations to select a group of patients likely to respond to BRAF 
inhibitors in combination with anti-EGFR mAb therapy; this approach is currently being 
investigated (NCT00343772) [174, 175]. 
 
1.3. The Rationale for studying Circulating Tumour Cells (CTCs) in CRC  
1.3.1. Background 
Circulating tumour cells (CTCs) are epithelial cancer cells estimated to account for 1 cell 
in 107 circulating nucleated cells [176], and are the mediators of haematogenous 
metastases [177]. CTCs can be isolated from a peripheral blood draw, and used as 
predictive and prognostic markers [178]. CTCs are most commonly detected in higher 
numbers in advanced prostate cancer (60–75% of patients) compared to breast, 
colorectal, gastric and oesophageal cancer, while they are much less common in other 
tumour types [179].  
In recent years the identification and characterisation of CTCs has improved in terms of 
sensitivity and specificity and a number of methods based on different physical and 
molecular properties of these cells have been described. However to date, the only FDA 
approved and validated detection method is the CellSearch® (Janssen Diagnostics) 
platform.  
CellSearch detects CTCs through positive selection with antibodies against the epithelial 
cell adhesion molecule EpCAM and CKs that are expressed by CTCs in a broad range of 
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tumours such as colorectal, pancreatic, gastric, prostate, lung and neuroendocrine 
cancers [176, 180-185]. EpCAM detection is the most widely used approach to identify 
CTCs [186], however there is broad morphological and immunophenotypical variation 
within CTCs derived from the same tissue of origin and similarly, during epithelial to 
mesenchymal transition which occurs in CTCs, the expression of epithelial markers may 
be down-regulated and become undetectable with EpCAM-based CTC detection assays 
[179, 187]. Therefore, accurate detection of CTCs based on morphological and 
immunophenotypical profiling is still challenged. 
Initial analysis of the CellSearch technology demonstrated that the prevalence of CTCs in 
the blood is related to tumour type and stage of disease. The first of these studies was 
carried out in breast cancer patients [188] and showed that ∼60%–70% of metastatic 
breast cancer patients have ≥2 CTCs, whereas CTCs were very rarely observed in normal 
control subjects [179]. Statistically, it has been shown that patients with ≥5 CTCs at 
baseline had poorer PFS and OS than patients with <5 CTCs [188]. Subsequent studies 
demonstrated similar results for metastatic prostate and colorectal cancers, with the 
identified threshold number needed for stratification into the poor prognosis group being 
≥5 CTCs at baseline for prostate cancer patients, and ≥3 CTCs at baseline for colorectal 
patients [189-191]. 
 
1.3.2. Current CTC Data in Breast and Prostate Cancer 
 
The CellSearch platform was approved for use by the US FDA in 2004 based on data 
generated in metastatic breast cancer [188]. Prospective, multicentre studies validated a 
cut-off to discriminate between favourable or unfavourable prognostic groups for PFS and 
OS, corresponding to a CTC count ≥5 per 7.5 mL of blood in breast and in prostate cancer 
and ≥3 CTCs in advanced CRCs [188-190]. On multivariate analysis, in patients with 
metastatic breast cancer, the CTC count at baseline and first follow-up was the strongest 
predictor of PFS and OS compared with other clinical and pathological factors including 
ER, PR, HER2 status, ECOG performance status, time to metastasis and type of therapy. 
Specifically, the presence of 5 or more CTCs in 7.5 mL of blood at time of diagnosis was 
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associated with worse outcome in terms of PFS and OS, and the level of CTCs at each 
follow-up time point was better than imaging in predicting PFS and OS [188, 192]. 
In the adjuvant setting, in early breast cancer, the presence of CTCs both before and after 
chemotherapy was also demonstrated to be associated with poor disease-free survival 
(DFS), breast cancer-specific survival and OS [193].  
In castrate-refractory prostate cancer, CTC count at baseline and after treatment was the 
strongest predictor of OS, with greater prognostic significance than changes in PSA, 
symptoms and imaging, and is increasingly being incorporated into clinical trials [191, 194]. 
The cut-off to discriminate between favourable and unfavourable groups corresponded to 
CTC count ≥5 in 7.5 mL of blood and identified patients with a shorter OS across studies 
of both chemotherapy and hormonal agents [189]. Data showed that a CTC count 
decrease from ≥5 to <5 was associated with a better prognosis and survival in contrast to 
a CTC count increase from <5 to ≥5 [189]. Changes in CTC levels before and after 
treatment have also been incorporated in Phase I/II studies as an indirect PD biomarker 
to confirm active doses of drugs tested, further demonstrating an early indication of 
antitumour activity reflected by significant PSA declines modification [194]. 
 
1.3.3. Current CTC Data in CRC 
In CRC, CTC count has also been demonstrated to be a prognostic and predictive factor 
for patients with metastatic disease. The presence of ≥3 CTCs at baseline and follow up, 
is associated with an unfavourable PFS and OS, and is the strongest independent 
prognostic marker compared with other clinical factors [195]. Patients with ≥3 CTCs at 
baseline had a shorter median PFS and OS with an improvement in PFS and OS if CTCs 
decreased from ≥3 to <3 after 3–5 weeks on treatment [195, 196]. The negative impact of 
elevated baseline CTC count has been evaluated in a number of clinical subgroups, 
demonstrating a statistically inferior OS in all subgroups including line and type of therapy 
administered, age (≥65 years) and ECOG performance status [195], while PFS was 
statistically inferior in many but not in all factors. In more recent studies, improved detection 
of CTCs in mCRC patients following combined CellSearch and Adna Test® analysis (the 
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AdnaTest® uses an RT-PCR platform targeting transcripts for EpCAM, EGFR, CEA to 
identify tumour cells within the EpCAM-enriched cell fraction) demonstrated a significant 
correlation with overall survival (P=0.046) [197]. In a study where the use of a multigene 
biomarker chip for detecting CTCs for postoperative surveillance of stage I–III CRC 
patients was used, the sensitivity and specificity of the biochip was shown to be 
significantly greater for predicting postoperative relapse than elevated postoperative 
serum CEA levels. Moreover, the median time between positive biochip result and 
postoperative relapse detection was significantly earlier than that between elevated 
postoperative serum CEA level and postoperative relapse detection (10.7 vs. 2.8 months; 
P<0.001) and positive biochip results were strongly correlated with lower disease-free 
survival and OS of CRC patients (both P<0.001) [198]. A prospective study by Hinz et al. 
evaluated CTC or disseminated tumour cells detected using CK20 RT-PCR at the time of 
surgery, as well as their correlation with tumour characteristics, OS and disease free 
survival. This study reported that the detection of CTCs with CK20 RT-PCR was a highly 
specific and independent prognostic marker in patients with CRC [199]. A study evaluating 
the expression of epithelial and mesenchymal markers in CTCs and their clinical relevance 
in a large cohort of Chinese patients with CRC used the CanPatrol™ TC enrichment 
technique to isolate and classify CTCs. CTCs were identified in 87% of patients and three 
phenotypes were identified based on the expression of epithelial and mesenchymal 
markers: epithelial CTCs, biophenotypic (epithelial/mesenchymal) CTCs, and 
mesenchymal CTCs. Total, biophenotypic and mesenchymal CTCs were all shown to 
correlate with clinical stage, lymph node and distant metastasis [200]. 
These data confirm the importance of CTCs as a potential stratification factor for OS in 
future mCRC clinical trials, especially considering the limited number of informative 
stratification factors in advanced CRCs [201, 202]. In addition, CTCs provide an 
opportunity to interrogate the molecular characteristics of the tumour in real-time, 
potentially guiding therapeutic interventions. 
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CTCs are an attractive tumour marker for survival, likely to streamline drug development 
and clinical trials, both to improve efficacy, shorten timelines in development of new drugs 
and assessing at earlier time points whether a treatment should be discontinued. 
CTC count may also be useful to detect malignancy in early stage of disease and predict 
the risk of early metastases or relapse raising the possible use in clinical practice to prompt 
a change in treatment, as well as performing molecular analysis for future personalised 
targeted therapy. Thus, several clinical trials are ongoing to incorporate molecular analysis 
and assess the utility of CTC changes to drive therapeutic modification [194]. 
 
1.3.4. The Role of CTCs in Clinical Trials 
CTC assessments present an opportunity to develop new PD and PK biomarkers to 
evaluate drug-target inhibition and assist in making ‘go’ or ‘no-go’ decisions, especially in 
early drug development [203]. Minimally invasive PD assays such as the use of CTCs as 
a PD endpoint in monitoring the efficacy of new drugs has great advantages, allowing 
serial controls of drug effects while reducing the need of biopsies and the risk associated 
with these procedures. Therefore, longitudinal assessment of CTCs is being incorporated 
into clinical trials as prognostic, predictive and intermediate biomarkers of response [204]. 
A longitudinal approach may also enable detection of molecular changes in CTCs 
reflecting tumour genotype that may be driving disease resistance or progression [205]. 
CTC counts are currently incorporated into the treatment decision algorithm in a number 
of Phase III trials of metastatic breast cancer, are under evaluation to select between 
chemotherapy vs endocrine therapy [206], and to guide an early change of treatment. 
In the adjuvant setting, trials are assessing HER2-positive CTCs in HER2-negative primary 
tumours and testing the role of HER2-directed therapies in these patients [206]. 
In the prostate cancer setting, CTC count ≥5 is now included in the eligibility criteria of 
some trials to select a poorer prognostic group of patients that may demonstrate the utility 
of the therapeutic agent in a more time-efficient manner [189]. However, there is bias 
related to inter-individual variability to consider with regard to simple CTC count, therefore 
future studies should also take into account the relative changes of CTC level reduction to 
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monitor a clinical response, instead of simply looking at changes from unfavourable (>5 
CTCs) to favourable groups (<5 CTCs). 
 
1.3.5. Molecular Characterisation of CTCs 
The molecular characterisation of CTCs has strong potential to be translated into 
individualised targeted treatment. Various protein based assays counting HER-2 [207], the 
phosphorylated nuclear DNA double strand damage biomarker (γ-H2AX) [208], EGFR 
[209], insulin like growth factor I receptor (IGF-IR) [210] expression, AR signalling [211], 
and KRAS, BRAF and PIK3CA mutations [212, 213] in CTCs have been included into 
clinical trials as exploratory PD biomarkers. 
The role of γ-H2AX expression on CTCs to detect PD changes after treatment has been 
investigated in patients undergoing clinical studies [214, 215]. A combined NCI analysis of 
eight National Cancer Institute Phase I and II trials in a variety of solid tumours had a 
population of statistically evaluable patients of approximately 30% for al trials (CTC 
biomarker evaluation was limited by the total number of CTCs collected from each blood 
sample). Data obtained from multiple trials of Topo 1 and PARP inhibitors showed that the 
γ-H2AX-positive CTC baseline level was less than 20% in 34/50 patients. The fraction of 
CTCs expressing γ-H2AX independent of changes in the total CTC count, increased in 
patients following treatment with different Topo 1 inhibitors alone or in combination with 
other drugs. Furthermore, correlations between γ-H2AX levels and overall responses were 
demonstrated in patients with refractory cancer in a Phase II randomized trial of the 
veliparib in combination with metronomic oral cyclophosphamide. This  increase of γ-H2AX 
in CTC post-treatment compared with baseline confirms the potential utility of CTC based 
PD biomarker analysis in such settings [215].  
More recently, the genetic characteristics of CTCs have been investigated. In CRC 
mutations that are being investigated in CTCs include KRAS, BRAF and PIK3CAI. As 
stated previously (Section 1.3.3), in patients with mCRC, 80% of patient blood samples 
were positive for CTCs and at least one of these mutations were detected in 78% of 
samples. High concordance rates of mutations in CTCs were observed with 78%, 74% 
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and 91% of cells have mutations in KRAS, BRAF and PIK3CA, respectively [213]. Another 
small study characterised KRAS mutations in CTCs from patients with mCRC and 
compared these with patients matched primary tumour samples and correlated the 
detected mutations with clinical and pathological features of patients. In this study, KRAS 
mutations were detected in 33% and 37.5% of CTCs and primary tumours, respectively; a 
significant concordance (71%, P=0.017) of matched cases was observed. KRAS mutation 
neither on 
primary tumour nor in CTCs was associated with clinical-pathological parameters 
analysed. The concordance between KRAS mutation detection between CTC and primary 
tumours suggests that CTCs could be used as a surrogate of primary tumours in clinical 
practice when the knowledge of mutational profile is required but the primary tumour is not 
available [212]. 
The possibility to provide longitudinal assessment of a tumour’s molecular profile and 
possible causes of drug resistance using CTCs as a PD marker are very appealing and, 
in the future, the simple cell count or characterization of protein biomarkers on CTCs may 
be replaced with single cell profiling, monitoring tumour genome changes that could be 
associated with treatment resistance.  
  
1.4. Gamma H2AX as a Protein Biomarker and its use in Drug Efficacy 
Measurements  
1.4.1. Gamma H2AX: Functional Role in DNA Damage Response (DDR) 
DNA lesions occur in the context of chromatin, a complex of double helix DNA enfolded 
with histone proteins in nucleosomes linked together by other histones [216]. Nucleosomal 
histones belong to four families: H2A (further subdivided in H2AZ and H2AX [217], H2B, 
H3 and H4, while the linker histones pertain to the H1 family [218, 219] (Figure. 1.2). 
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Figure 1.2: Nucleosomal histones.  
Redrawn from: Stryer L, et al. Biochemistry 1995 (fourth ed.) [220] 
 
The H2A family is characterised by an omega-4 serine residue, which is converted into the 
phosphorylated form gamma-H2AX (γ-H2AX) after double-strand break (DSB) damage 
[221-223]. It is essential to repair and conserve chromatin architecture immediately after 
DNA damage, to prevent genome instability. The DNA damage response (DDR) is 
primarily responsible for detecting and restoring the integrity of DNA through two major 
mechanisms, homologous recombination and non-homologous end joining which will be 
activated, and H2AX phosphorylation [224, 225]. When a DSB takes place, the tri-
protein MRN complex (MRE11-RAD50-NBS1) recognizes the DNA damage and 
recruits and activates PI3-kinase related kinases including ataxia telangiectasia 
mutated (ATM), ATR (AT and Rad3-related protein) and DNA-dependent protein kinase 
(DNA-PK). ATM, ATR and DNA-PK phosphorylate H2AX on its c-terminal Ser139 
residue [226, 227] which is crucial to activating the DNA damage response pathway, 
resulting in γ-H2AX which attracts the Mediator of Damage Checkpoint protein 1 
(MDC1), which is also phosphorylated by ATM (Figure. 1.3). MDC1 in turn serves as 
a scaffold for the recruitment of other proteins required for the activation of BRCA1 
by ATM, promoting cell cycle arrest and DNA repair. ATM phosphorylates other 
target substrates like the checkpoint protein Chk2 and p53, which are also 
Core DNA 
Linker DNA 
H1 
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responsible for cell cycle arrest or apoptosis if the damage cannot be repaired. The 
repair of the DSB is associated with γ-H2AX dephosphorylation by the phosphatase 
PP2A and the removal of γ-H2AX  prevents further recruitment of DDR and repair factors 
[217]. Cellular stress can induce a cellular response through the histone post-translational 
modifications (PTMs) [228], therefore the importance of identifying alterations in histone 
PTM homeostatic levels may generate important clinical information on the disease or on 
its treatment efficacy [229]. Because of its critical role in DSB repair and genome stability, 
γ-H2AX has recently become one of the most widely known examples of a histone PTM 
and the most common marker of DNA DSB damage. 
 
 
Figure 1.3: Crosstalk between chromatin state and DNA damage response in cellular 
senescence and cancer.  The DNA damage response (DDR) pathway is composed of two 
main DNA damage sensors, the MRE11–RAD50–NBS1 (MRN) complex that detects DNA 
double-strand breaks, and replication protein A (RPA) and the RAD9–RAD1–HUS1 
complex which detect exposed regions of single-stranded DNA. These sensors recruit the 
apical kinases ataxia- telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-
related (ATR), which is bound by ATR-interacting protein (ATRIP). These in turn 
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phosphorylate (P) the histone variant H2AX on Ser139 (known as γH2AX) in the region 
proximal to the DNA lesion. 
From: Sulli G et al. Nature Reviews Cancer 2012;12:709–720 [230] 
 
1.4.2. Gamma H2AX as a Protein Biomarker for DNA DSBs and its Applications  
DSBs are highly cytotoxic, and this is exploited in conventional cancer treatment, with 
radiation therapy and chemotherapy treatments generating large numbers of DSBs. These 
include chemotherapeutic drugs that induce DNA cross-links or function as topoisomerase 
inhibitors, inducing DSB’s in all cells. Cancer cells are particularly susceptible to these 
drugs, as they are rapidly dividing and often have inactivated components of their DNA 
repair machinery and deregulated cell cycle checkpoints [231]. Therefore, biomarkers for 
DNA damage such as γ-H2AX foci could allow in vivo measurement of individual response 
to specific treatment in real time as well as planning of treatment for each individual patient 
[232-235]. In vitro experiments using fixed mitotic cells of the Indian muntjac (Muntiacus 
muntjak) or normal human fibroblast W138 cells treated with ionizing radiation showed an 
increase of γH2AX foci in the nucleus in a dose-dependent manner at early stages of DDR 
while DNA repair correlates time-wise with γH2AX loss or dephosphorylation and with the 
decrease in number and size of the γH2AX foci [236]. Muntjac mitotic chromosomes 
exhibit small γ-H2AX foci three minutes after exposure to ionizing radiation (IR) which 
become brighter and larger nine minutes after treatment, and reach maximal brightness 
and size 30 minutes following IR. These findings suggest that H2AX molecules in a small 
region near the DSB site are phosphorylated first, and are followed by molecules at 
increasing distances from the break site. Many DNA repair and/or checkpoint protein 
species accumulate on the growing γ-H2AX focus, which may serve to open the chromatin 
structure and form a platform for the accumulation of DNA damage response and repair 
factors [236]. 
Persistence of γ-H2AX foci after DNA damage indicates that some breaks remain 
unrepaired making γ-H2AX a potential effective PD biomarker following treatment with IR 
and chemotherapies. This role has been evaluated in several clinical trials [208, 237, 238] 
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(Table 1.7) testing drugs generating DSB DNA damage including DNA synthesis inhibitors, 
DNA alkylating agents, Topo I and II inhibitors [239, 240] and other therapies [239, 241-
243]. 
 
Table 1.7: Non-exhaustive list of clinical studies using the γ-H2AX assay to measure the 
effects of chemotherapeutic drugs in cancer patients. The top of the table includes 
published clinical studies while the bottom part contains some studies obtained from the 
ClinicalTrials.gov database. 
 
From: Ivashkevich A, et al. Cancer Lett 2012;Dec 31;327(1–2):123–133. [244] 
 
Such anticancer drugs affect the mechanisms of DNA replication and H2AX 
phosphorylation in several ways [245-247]. ATM kinase is considered as a major 
physiological mediator of H2AX phosphorylation in response to DSB formation [247]. 
H2AX can also be phosphorylated by ATR and DNA-dependent protein kinases (DNA-
PK). ATR phosphorylates H2AX in response to single-stranded DNA breaks and during 
replication stress, such as replication fork arrest. DNA-PK mediates phosphorylation of 
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H2AX in cells under hypertonic conditions and during apoptotic DNA fragmentation [247]. 
However, DNA damage caused by ionizing radiation leads to phosphorylation of H2AX 
that is mediated by all PIKK kinases, ATM, ATR, and DNA-PK [247]. In addition, DNA 
Topo I and II inhibitors impede DNA replication through the impact of replication forks. 
DNA Topo I inhibitors including SN-38, topotecan and camptothecin work predominantly 
in S-phase cells while DNA Topo II inhibitors, such as etoposide and mitoxantrone, 
generate γ-H2AX in all phases of the cell cycle [248, 249].  
There are several reasons for the clinical use of γ-H2AX inclusing its role in investigating 
the potential genotoxicity of a new investigational drug and the possibility to tailor 
treatments to patients, taking into account individual sensitivities and/or previous 
treatments, or as an indicator of cellular radiosensitivity to potentially predict individual 
responses to IR in the clinical setting [250]. γ-H2AX could be used as a biomarker to 
predict patient outcomes [251] and recent studies have employed γ-H2AX as a biomarker 
for clinical diagnosis of cancer development. High levels of γ-H2AX are present in both 
precancerous and cancer lesions indicating an increased level of DNA damage as a 
general feature of cancer development [252-254]. In addition, γ-H2AX foci have been 
proposed as prospective biomarkers of aging due to the accumulation of DSBs in 
senescing cells [250].  
 
1.4.3. Gamma H2AX as PD Biomarkers to Monitor Drug Activity in CTCs  
Currently, patient response to treatment is evaluated by imaging techniques, requiring 
several weeks until tumour shrinkage may be detected [214]. In addition, tumour markers 
may not correlate positively with tumour outcome, therefore it would be valuable to 
measure patient drug response at the molecular level [255]. The use of specific antibodies 
permits the visualization of γ-H2AX foci at individual DSB sites, allowing the efficiency of 
a drug in a patient to be measured by detecting changes in γ-H2AX levels before and after 
treatment. 
Tumour biopsy is pivotal to evaluate the effect of drugs on DNA metabolism. Sequential 
biopsies in a clinical trial would allow following the PD effects throughout the time of 
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exposure to the drug being tested [214]. However, sequential biopsies may not be feasible 
for technical or safety reasons and are not generally acceptable for patients. Nevertheless, 
tumour heterogeneity due to differences in vascularity and genetic mutations may affect 
γ-H2AX formation and removal, confounding the relationship of γ-H2AX formation with 
tumour prognosis or tumour response to treatment. In addition, genetic variability may 
impact the expression or function of proteins that metabolize the drug or may affect the 
drug target itself, thereby affecting treatment efficacy. Thus γ-H2AX responses may differ 
among different metastases in the same patient as well as among different cells of the 
same tumour mass [217].  
Less invasive methods based on tumour cell response through the identification of 
biomarkers to detect on-target drug effect during treatment can allow monitoring specific 
treatment to the patient. 
Recently, as discussed in Section 1.3.4., the presence of CTCs in the bloodstream has 
been shown to predict disease progression in several cancers [256]. In addition, the 
characterisation of tumour type through the assessment of biomarkers in CTCs has also 
been used [257, 258]. CTCs isolated from peripheral blood of patients with a variety of 
advanced malignancies over the course of treatment with investigational agents as part of 
a Phase I clinical study showed increased numbers of γ-H2AX positive CTCs from 2% at 
baseline to 38% after a single day of treatment; this increase was irrespective of decreases 
in the total CTC count. Therefore, such assessments could be used to optimize cancer 
treatments assessing the drug effectiveness in real time [214]. In addition to the evaluation 
of CTCs and the expression of γ-H2AX in cells from peripheral blood of patients with a 
variety of advanced malignancies, there are several other tissue-based approaches that 
have assessed γ-H2AX in normal surrogate tissues as many chemotherapeutic agents 
also target the patient’s normal cells [214]. Compared to tumour cells, γ-H2AX responses 
in normal cells may be more uniform, reproducible, and informative. Levels of γ-H2AX 
have been quantified by microscopy or flow cytometry in PBMCs, and by microscopy in 
skin biopsies, plucked hair bulbs and buccal cells. PBMCs contain low γ-H2AX focal 
background levels (on average less than one focus per 5–10 cells), which improve the 
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detection of low levels of DNA damage allowing measurement of IR doses as small as 1 
mGy [214]. The major disadvantage of PBMCs is their state of terminal differentiation, 
which might make them less useful for studies of chemotherapeutic drugs that produce 
DSBs by interfering with DNA replication [214]. Another accessible tissue that does contain 
proliferating cells is the skin. Skin biopsies are necessary to obtain the basal keratinocytes, 
an issue which limits their routine use due to its invasive nature. It is noticeable in sections 
of skin biopsies that hair follicle cells often exhibit the largest γ-H2AX response after drug 
treatment [214]. An alternative and less invasive procedure for obtaining at least some of 
these follicle cells, is plucking hairs. A Phase I trial included the use of γ-H2AX detection 
in plucked eyebrow hair bulbs to confirm the effects of a PARP inhibitor in vivo [259]. Like 
plucked hairs, the use of exfoliative oral cells has been previously promoted as a non-
invasive technique for cancer diagnosis [232] and for γ-H2AX detection [260]. 
 
1.4.4. Gamma H2AX assay types  
Detection of γ-H2AX foci after exposure to DNA-damaging agents is a more reliable DSB 
marker than other repair proteins as it is formed de novo in the cell, it is far more sensitive 
than other methods in detecting DSBs and allows the distinction of the temporal and spatial 
distribution of DSB formation. 
Other techniques such as constant or pulsed field gel electrophoresis and comet assays 
can only detect DSBs induced by large doses of IR (5–50 Gy), and  in contrast to the 
Comet assay [261], the analysis of γ-H2AX foci does not involve lyses at high 
temperatures. Discrete nuclear γ-H2AX foci can be measured by flow cytometry, western 
blotting or immunofluorescence and antibodies directed against both H2AX and γ-H2AX 
are now commercially available [236, 262-264]. However, fluorescence microscopy is still 
the preferred and most sensitive method for γ-H2AX detection for clinical applications, 
being able to detect a single DSB, given that each break has been found to correspond to 
one γ-H2AX focus [244]. Analysis by microscopy may discriminate γ-H2AX responses 
induced by different drugs or IR, based on the different timing of interference with DNA 
replication. In fact, drugs that interfere with DNA replication induce foci primarily in 
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proliferating cells in contrast to IR that affect virtually all cells [217]. Furthermore, 
microscopy is more specific than flow cytometry, being able to distinguish foci from the 
background, allowing the analysis of tissue samples instead of single cells such as PBMCs 
and bone marrow cells. Other types of assays, such as electro chemiluminescent-based 
detection system and whole cell ELISA [244] also utilize cell and tissue extracts, however 
they are as yet not available for the clinic. There is therefore an ongoing demand for the 
development of high throughput γ-H2AX foci counting systems for clinical assays, intended 
to speed up analysis and automate microscopic examination [217]. 
 
1.5. Aims of this thesis  
Current methods available for detection of γ-H2AX in patient samples, such as γ-H2AX 
immunofluorescence, FACS analysis, alkaline comet assay and immunohistochemistry, 
have showed limited applicability to the clinic to monitor tumour response to chemotherapy 
and radiotherapy as they cannot be used to evaluate γ-H2AX expression on isolated CTCs 
from whole blood. Therefore, γ-H2AX response to drug treatment can only be established 
in non-tumour cells (e.g., peripheral blood mononuclear cells).  
γ-H2AX induction has been studied in cancer cells treated with different chemotherapy 
agents and in CTCs from patient blood samples processed using the CellSearch system 
in conjunction with γ-H2AX-AF488 antibody staining. γ-H2AX signal was detected as a 
percentage of γ-H2AX-positive CTCs per total CTCs recovered following chemotherapy 
[214]. However, the CellSearch platform is not designed to quantify levels of 
immunofluorescence and this my limit its sensitivity to detect changes in γ-H2AX 
phosphorylation in response to DNA damaging chemotherapy at a single cell level. The 
DEPArray system is a recently developed platform that combines fluorescent microscopy 
with cell sorting and allows quantification of the fluorescent signal. To date, it has not been 
used to evaluate the molecular response to therapy in CTCs.  
Hypothesis 
The overarching hypothesis for this thesis was that, using the DEPArray technology, γ-
H2AX foci can be measured quantitatively in CTCs, and that short-term increases in γ-
57 
 
H2AX foci correlate with long terms response to chemotherapy with DNA damaging 
agents.  
To test this hypothesis, it was necessary to develop a novel assay and the experimental 
steps required to develop this assay are described in the results chapters as follows:  
Chapter 3: To define the optimal dose of oxaliplatin and SN-38 required to induce γ-H2AX 
foci on human adenocarcinoma colorectal cells by performing dose-response experiments 
with increasing concentrations of oxaliplatin and SN-38.  
Chapter 4:  To define the optimal time to measure γ-H2AX foci in human adenocarcinoma 
colorectal cells following treatment with oxaliplatin and SN-38 at the doses determined in 
Chapter 3. 
Chapter 5: To evaluate changes in γ-H2AX signal according to both the CellSearch 
System (Janssen Diagnostics) and the DEPArray™ System (Silicon Biosystems) using 
conditions defined by chapters 3 and 4.  
Chapter 6: To test the assay in samples obtained from patients with colorectal cancer 
undergoing chemotherapy. 
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CHAPTER 2 
Materials and Methods 
2.1. General materials 
All chemicals were from Sigma-Aldrich Co Ltd. (Dorset, UK) unless otherwise stated. 
 
General materials used in these studies are as follows: 
Lab-Tek II chamber slides (Cat. No. 154526, Thermo Fisher Scientific) 
Trypsin-EDTA (Autogen Bioclear UK Ltd., Wiltshire, UK) 
Haemocytometer (DHC-BO2-Burker Turk [INCYTO]) 
Trypan blue solution, 4% 
Green 21 gauge needles (Exchange Supplies) 
PBS (stored at 4˚C) 
Fixation buffer: 50% methanol and 50% acetone (stored at -20˚C)  
Permeabilization buffer: 0.5% Triton X-100 in PBS (stored at room temperature) (cell 
culture experiments) 
Permeabilization buffer: 0.2% triton X-100 in ice cold PBS (cell suspension experiments) 
Blocking buffer: 0.2% skimmed dry milk, 0.1% Triton X-100, in PBS (stored at 4˚C) (cell 
culture experiments) 
Blocking buffer: 10% FBS, 5% BSA in PBS (store at 4˚C) (cell suspension experiments) 
Washing buffer: 0.1% Triton X-100 in PBS (stored at 4˚C) 
Mouse anti-H2AX monoclonal primary antibody diluted in blocking buffer (1:1000) (Merck 
Millipore, UK) (stored at -20˚C) 
Goat anti-mouse Alexa Fluor® 488 IgG secondary antibody diluted in blocking buffer 
(1:1000) (Life Technologies Ltd., UK) (stored at 4˚C) 
Propidium iodide (PI) 2 μg/mL (stored at 4˚C) 
ProLong® Gold Antifade reagent and ProLong® Gold Antifade with 4’,6-DAPI (Invitrogen, 
Life Technologies Ltd., UK) 
Freezing media (FCS + 10% DMSO) (Sigma-Aldrich Co., UK) 
T75 flask, 75 cm2 (Sigma-Aldrich Co., UK) 
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Slide container (Shandon EZsingle cytofunnel)  
Paraformaldeide (PFA) 4% 
1.5 mL microcentrifuge tubes (Sigma-Aldrich Co., UK) 
Falcon™ 15 mL conical centrifuge tubes (Sigma-Aldrich Co., UK) 
Microscope Slides (25 mm × 75 mm; Sigma-Aldrich Co.) 
Phosphatebuffered saline (PBS) (stored at 4˚ C) 
Bovine serum album 
Hoechst staining 33342 (Life Technologies H3570) 10 µg/mL 
Cytospin™ 4 Cytocentrifuge (Thermo scientific) 
Micro Cover Glasses (24 mm x 60 mm) (VWR® SuperSlips™) 
ProLong® Gold Antifade reagent and ProLong® Gold Antifade with 4’,6- DAPI) (Invitrogen, 
Life Technologies Ltd.) 
 
2.2. Investigational drugs 
Oxaliplatin was obtained from Mayne Pharma (Raleigh, NC, USA) as an injectable 
aqueous 3.3 mM stock solution (12.500 μM in 2 mL). SN-38 was obtained from Mayne 
Pharma as an injectable aqueous solution 200 mg/1 mL. Topotecan was obtained from 
Sigma-Aldrich (Sigma-Aldrich) and a stock 10mM solution was made in DMSO and stored 
at -20°C until use. All drug stock solutions were prepared fresh for each experiment and 
serially diluted as appropriate for different experiment procedures. Further dilutions were 
made in cell-specific medium for treating cell lines. 
 
2.3. Cells and culture conditions 
The cell lines used in these experiments are detailed in Table 2.1. The human colon 
adenocarcinoma cell line HT-29 was initially used (Chapter 3–5) to fully characterize the 
DNA damage response during oxaliplatin treatment by measuring the expression levels of 
γ-H2AX in the cells; HT-29 cells are sensitive to the chemotherapeutic drugs 5-fluorouracil 
and oxaliplatin, which are standard treatment options for colorectal cancer [265]. In 
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addition to HT-29 cells, HCT-116 cells were also utilised (Chapter 4–5); these cells were 
chosen because the kinetics of oxaliplatin-induced DNA damage have previously been 
investigated by analysis of the expression levels of phospho-p53 (Ser-15) and γ-H2AX in 
HCT-116 cells [266]. Cell lines were purchased from the American Type Culture Collection 
(ATCC) and from the European Collection of Cell Cultures (ECACC). All cells were 
maintained in McCoy’s 5A (modified) medium (Gibco, Thermo Fisher Scientific, Waltham, 
MA, USA) supplemented with 10% foetal calf serum (FBS; Gibco), 2 mM L-glutamine, and 
Penicillin Streptomycin antibiotics. 
Cells were grown at 37°C in a 5% CO2 humidified incubator and passaged approximately 
three times weekly. Adherent cell lines were passaged using 5 mL trypsin-EDTA solution 
(Autogen Bioclear UK Ltd., Wiltshire, UK) for 5 minutes at 37˚C to detach cells. 5 mL of 
cell medium was added and cells were centrifuged at 350 × g for 5 minutes at room 
temperature. The supernatant was discarded and the cell pellet was resuspended in cell 
medium. Cell lines were tested for mycoplasma twice a year, and grown for approximately 
30 passages, at which point new stored aliquots were used. The aliquots were prepared 
by freezing cells in 10% DMSO in FBS overnight at -80˚C followed by long-term storage 
in liquid nitrogen. When needed, cell lines were defrosted quickly in a 37˚C water bath, 
resuspended in medium, and centrifuged at 350 × g for 5 minutes. The supernatant was 
discarded and cells were resuspended in fresh medium. 
 
Table 2.1: Cancer cell lines used  
Cancer cell origin Cell line                                                                 Medium
Solid 
 
Solid 
HT-29 colon cancer cell line 
ECACC n. 85061109 
 
HCT-116 colorectal cancer 
cell line ECACC n. 91091005 
McCoy′s 5A  
(modified)  
McCoy′s 5A  
(modified) 
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2.4. γ-H2AX immunofluorescence staining for adherent colon cancer cell lines 
treated with varying concentrations of oxaliplatin and SN-38 (Chapter 3) 
2.4.1. Sample preparation 
HT-29 cells were prepared, counted, and plated for experiments. An aliquot of each cell 
line containing 8 × 104 cells/mL cells was obtained from a stock in liquid nitrogen that was 
quickly thawed at room temperature, and 9 mL of medium was added to each sample and 
pipetted into a 15-mL conical tube. Tubes were spun in a Jouan CT422 centrifuge 
(Thermoelectron, Basingstoke, UK) at 270 × g for 5 minutes. Supernatant was poured off, 
the pellet was resuspended in 10 mL of medium. The whole cell sample was transferred 
to a T75 flask. Flasks were placed into an incubator (37°C, 5% CO2) overnight for the cells 
to attach. 
Cells were assessed for confluency under the microscope. Once they reached 80% to 
90% confluence, they were split to enable growth and multiplication to continue. The 
medium was poured off, and 5 mL of trypsin (Autogen Bioclear UK Ltd., Wiltshire, UK) was 
pipetted into the flask, which was incubated for 5 minutes at 37˚C and 5% CO2. Once 
incubated, trypsin was pipetted off, added to 10 mL of McCoy's 5A (modified) medium 
containing 10% FCS in a 15 mL conical tube, and centrifuged at 270 × g for 5 minutes. 
The supernatant was poured off and the cell pellet was resuspended in 10 mL of complete 
medium. A variable amount of the suspension, according to the size of the cell pellet, was 
pipetted into sterile T75 flask. Cells were split again once they neared confluency. This 
was repeated until cells were ready to use for the following experiments. Cells were only 
used if they were at the point of reaching confluency, as this indicated they were in the 
exponential phase of growth. 
 
2.4.2. Treatment in vitro with oxaliplatin or SN-38 
HT-29 cells were treated in vitro with varying concentrations of oxaliplatin to determine the 
dose required for peak induction of γ-H2AX foci in the nuclei.  
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Cells were counted with a haemocytometer. The coverslip was placed over the counting 
surface before loading the cell suspension. After cells were trypsinized, they were 
suspended in fresh media, gently passed a few times through a syringe needle, and diluted 
so the cells or other particles did not overlap each other on the grid. To distinguish between 
dead and viable cells, a sample was diluted (dilution factor 1:1) with trypan blue stain which 
uses a diazo dye that selectively penetrates cell membranes of dead cells, colouring them 
blue. 10 µl of the cell suspension was pipetted into one of the V-shaped wells of the 
haemocytometer and gently expelled under the coverslip covering the mirrored surface. 
Two samples were loaded on the haemocytometer, one into each of the two grids. The full 
grid on a haemocytometer contains nine squares, each of which is 1 mm2. The central 
counting area of the haemocytometer contains 25 large squares and each large square 
has 16 smaller squares. The cells that were counted were on the lines of two sides of the 
large square to avoid counting cells twice. The cells were counted inside the four large 
corner squares and the middle one. The loaded haemocytometer was placed on the 
microscope stage and cells were systematically counted in the selected squares so that 
the total count was approximately 100 cells, the minimum number of cells needed for a 
statistically significant count. If a cell was overlapping a ruling, it was counted as ‘in’ if it 
overlapped the top or right ruling, and ‘out’ if it overlapped the bottom or left ruling. Once 
the total cell count was obtained, the cell concentration was calculated from the following 
formula: Total cells/mL = Total cells counted × dilution factor × 10,000 cells/mL # of 
squares. 
Each well of a 4-well LAB-TEK II chamber slides was plated with 4 × 10² cells in 1 mL 
complete medium. Cells were left to adhere overnight and then treated with oxaliplatin or 
SN-38. Oxaliplatin or SN-38 were diluted in McCoy's 5A (modified) medium to obtain 
concentrations of 0 μM, 1 μM, 5 μM, and 10 μM; 1 mL total volume per well was pipetted 
into each well containing cultured cell lines at 80% to 90% confluence. After 2 hours 
incubation, the drug was removed and the cells were washed with cold PBS. 
For SN-38 treated cells, the concentrations of drug used and the time of exposure induced 
a gradual increase in γ-H2AX and irreparable DNA damage was observed (Section 3.4). 
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Therefore, the experiments were repeated using lower SN-38 concentrations (0 μM, 0.01 
μM, 0.05 μM, 0.5 μM and 1 μM) with a shorter incubation period of 1 hour.  
 
2.4.3. Immunofluorescence Staining 
2 mL of methanol-acetone (50:50) was added to each well for 8 minutes at 4°C to fix the 
cells. Plates were washed twice with PBS and permeabilised with 2 mL/well of 
permeabilisation buffer (0.5% Triton X-100 in PBS) for 15 minutes at room temperature. 
Blocking buffer (0.2% skimmed milk, 0.1 % Triton X-100 in PBS) was added at 2 mL/well 
and cells were incubated overnight at 4°C followed by two cold PBS washes. 
Immunofluorescence staining was carried out with cold solutions, maintained at 4˚C, and 
in subdued lighting, unless otherwise stated. Cells were incubated overnight at 4°C with 
primary mouse monoclonal anti-phospho-γ-H2AX antibody (Millipore) (dilution of 1:1000 
in blocking buffer, 0.5 mL/well). Cells were washed three times with cold washing buffer 
(0.1% Triton X-100 in PBS). Cells were then incubated with the secondary antibody Alexa 
Fluor 488 (Life Technologies) diluted in blocking buffer for 4 hours at room temperature in 
the dark. Slides were washed three times with cold washing buffer (0.1% Triton X-100 in 
PBS), counterstained with 2 μg/mL of PI for 2 minutes at room temperature in the dark, 
rinsed with distilled water for 30 minutes, then allowed to dry in the dark. 
Cell chambers were removed with a slide tool and two drops of ProLong® Gold Antifade 
Mountant (Life Technologies) was added to each well, which was then covered with a 
coverslip (24 × 60 mm) and sealed with transparent nail polish. The slides were left for 30 
minutes at room temperature. Finally, the slides were stored at 4˚C in a light-proof box 
until analysis. 
 
2.4.4. γ-H2AX foci detection 
γ-H2AX foci in single cells were measured using a Leica SPE2 (488 nm laser (Alexa)/432 
nm laser (PI)) confocal microscope equipped with a prism and a detector device to select 
the spectral range from 430–750 nm. The TCS SPE control box contains four solid state 
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lasers: 488, 532, and 635 nm, the standard excitation wavelengths for most common dyes 
and a 405 nm laser, for nuclear staining.  
All laser foci were positioned at only one point in the focal plane from excitation to 
detection. Foci were visualised and analysed by Volocity Acquisition/Visualization 
Software version 5.5 (Perkin Elmer, UK). The parameters, including camera exposure, 
sensitivity, and background, were set according to the controls of each experiment and 
applied to each drug treated sample. For each sample, a minimum of 50 cells were 
analysed. 
The correct objective was selected in the software and the light path was switched to laser. 
The imaging resolution was set to 1024 × 1024 and the speed to 600 Hz. The sequential 
scanning mode was selected and the laser power gain and PMT (photo-multiplier tube) 
offset was adjusted for the first, second, third, and fourth sequence if required. The top 
and bottom of the z-stack was set up, the images were scanned. To save the images, 
series, process, and visualization 3-D projection were selected and all images were 
scanned twice (one for each channel). Duplicate images were created with the overlay 
channel selected to merge the images. Images were processed and further split in two 
channels (red and green [RG]), forming two grey scale images; one for each channel. The 
grey scale images were saved for analysis with CellProfiler software and merged again 
with the native Fiji function. 
 
2.4.5. CellProfiler Software 
CellProfiler software (available from www.cellprofiler.org) was used to process, identify 
objects in selected compartments, and quantitatively measure phenotypes from large sets 
of images automatically that can be exported for further analysis. Advanced algorithms for 
image analysis are available as individual modules that can be placed sequentially to form 
a pipeline, which is then used to identify and measure biological objects and features in 
images, particularly those obtained through fluorescence microscopy. 
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2.4.6. Image analysis using CellProfiler Software 
Original images obtained with the Leica SPE2 (488 laser (Alexa)/432 laser (PI)) confocal 
microscope were loaded into the CellProfiler Pipeline software for use with the following 
module categories: 
• File processing: image input, file output 
• Image processing 
• Object processing: identification of the object of interest 
• Collection of measurements from the object of interest 
• Data tools: measurement exploration, measurement output 
Images were opened with the CellProfiler Image Tools. An image set of 50 cells for each 
drug dose were used for analysis. During ‘Primary Object Identification’, nuclei stain 
channel one (red input image) was selected for nuclei identification. The diameter of each 
nucleus was measured with the CellProfiler Image Tools (60 pixel units) and the typical 
diameter range was set between 35–150 (Min–Max) pixel units for object identification. 
Foci stain channel two (green input image) was selected for γ-H2AX foci identification. The 
diameter was measured with the CellProfiler Image Tools (10 pixel unit) and the typical 
range was set between 35and 150 pixel units for object identification. Objects outside the 
diameter range were automatically discarded (Figure. 2.1). 
 
 
Figure 2.1: Foci identification using CellProfiler foci stain channel two (green input image) 
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The threshold method selected for channel one (nuclei) was Otsu Global, which allows a 
readily identifiable foreground/background, while the Background method was preferred 
for channel two (foci), since it is more appropriate for images where most of the image was 
comprised of background. In the Object Separation Module, clamped objects were 
distinguished by intensity. These methods were chosen using the Test Mode, which allows 
the user to view the results of all setting combinations. 
Objects to export were selected and their individual measurements were saved.  
Experiments were performed once for the DR and the γH2AX foci were expressed as 
mean γH2AX foci/cell +/- SE in 50 cells per experiment. 
 
2.5. Time course experiments in colon cancer cell lines treated with oxaliplatin or 
SN-38 (Chapter 4) 
 
2.5.1. Drug Treatment  
Cells were treated in vitro with 5 μM of oxaliplatin for 2 hours or with 0.01 μM of SN-38 for 
1 hour to establish the time of peak induction of γ-H2AX foci/nucleus. The time course 
experiments with oxaliplatin and SN-38 were carried out at 1, 2, 4, 6, 8, 18 and 26 hours 
and were repeated three times each for validation purposes. 
 
2.5.2. Treatment In vitro with Oxaliplatin or SN-38 
Six sets of 4-well chamber slides were plated with 1 mL of an 8 × 10⁴ cells/mL suspension 
of HT-29 or HCT-116 cells in each well chamber and left to adhere overnight.  
Oxaliplatin or SN-38 were added to McCoy's 5A (modified) medium to obtain a final dilution 
of 5 μM or 0.01 μM, respectively. 1 mL of total volume per well of drug was pipetted into 
each well (media without oxaliplatin/SN-38 was used as a control) containing cultured cell 
lines at 80% to 90% confluence that were incubated for 2 or 1 hours, respectively, at 37°C 
in 5% CO2.  
67 
 
Oxaliplatin or SN-38 was removed and cells were washed twice with PBS. Cells were 
fixed, permeabilised, blocked, and incubated with primary and secondary antibody as 
described in Section 2.4.2. 
 
2.5.3. Immunofluorescence Staining, γ-H2AX Foci Detection and Image Analysis 
using CellProfiler Software 
Immunofluorescence staining, γ-H2AX foci detection and image analysis using CellProfiler 
Software are described in Sections 2.4.3–2.4.6.  
 
2.6. Development of the Protocol for quantification of γH2AX intensity using the 
CellSearch System (Janssen Diagnostics) and the DEPArray™ System (Silicon 
Biosystems) (Chapter 5) 
  
2.6.1 The CellSearch System (Silicon Biosystems) 
CellSearch is an automated enrichment and immunocytochemical detection system for 
CTCs that has been approved by the US Food and Drug Administration for routine clinical 
use in metastatic breast, prostate and colorectal cancer patients. CellSearch enables the 
immunomagnetic detection and enumeration of CTCs in peripheral blood through a 
ferrofluid-based capture reagent of nanoparticles with a magnetic core and antibodies 
targeting the EpCAM antigen for capturing and identification with fluorescent staining 
reagents of CTCs.  Anti-CKPE is specific for the intracellular protein cytokeratin (specific 
for epithelial cells), while DAPI stains the cell nucleus, and leukocytes are selected with 
an anti-CD45-APC. The CellSearch Epithelial Control Cell Kit contains single-use bottles 
of fixed cells from a breast carcinoma cell line (SKBR-3) and control cells. Sample 
processing by the CellTracks Autoprep® System processes and optimizes the sample 
preparation protocol for use with the CellSearch Epithelial Cell and Epithelial Control Cell 
Kits.  
The CellSearch Profile Kit is designed to complement research on CTCs allowing 
standardized and automated immunomagnetic collection and enrichment from whole 
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blood of the cells that can be further processed offline with several research methods. 
Analysis and enumeration of CTCs and control cells are performed using the CellTracks 
Analyzer II with the Linux operating system. When sample processing is complete, images 
are presented in a gallery format for final cell classification. CTCs are identified based on 
morphology and immunophenotype defined ad EpCAM+, CK+, DAPI+, and CD45-. 
 
2.6.2. DEPArray™ System (Silicon Biosystems) 
The DEPArray system (Di-Electro-Phoretic Array system; Silicon Biosystems  Bologna, 
Italy), is a semiautomated system based on application of dielectrophoresis (DEP) 
principles that allows the isolation of CTCs and other rare cells from mixed-cell populations 
[267] (Figure. 2.2). After an enrichment phase, CTCs were fluorescently labelled and 
loaded into the DEPArray cartridge, inserted into the DEPArray system and automatically 
injected into the main chamber. The cartridge electrodes create a dielectric field that trap 
CTCs in electric cages generated. A six-channel fluorescent microscope and CMOS 
camera enabled the identification of single cells that express the desired pattern of 
fluorescent markers and are moved to a ‘parking area’ through an automated process. 
Cells could be further recovered individually or in groups into a PCR tube in a medium 
suitable for downstream analysis. The CellBrowser software analysed each cell image, 
selecting them from a population of cells using a multi-parametric fluorescence and 
brightfield criteria. Cells trapped in the electronic cages were selected based on specific 
selection criteria (perimeter, diameter, circularity measures and desired fluorescence 
patterns) through the brightfield channel and visual inspection. Cells can be recovered 
from the DEPArray cartridge directly to cell culture plates allowing genomic and expression 
analysis down to the single cell level (Figure 2.2).   
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Figure 2.2: Schematic of CellSearch and DEPArray system experimental workflow.  
Step 1: Tumour cells of three different human cultured breast cancer cell lines were spiked 
in healthy donor blood at a concentration of 103 tumour cells per 7.5 ml whole blood. Step 
2: Tumour cells were immunomagnetically enriched using either the CellSearch CTC kit 
or the CellSearch Profile kit followed by a manual staining procedure. Step 3: Cells were 
reconstituted in a final volume of 14 μl and loaded in a DEPArray cartridge.  
Step 4: Analysis and sorting procedures were performed on the DEPArray system.  
Step 5: Single cells and groups of cells of interest were isolated with the DEPArray system. 
Step 6: Mutation or transcriptional analysis of isolated tumour cells.  
From: Peeters DJ et al. Br J Cancer 2013. 108(6):1358–1367 [268] 
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2.6.3. γ-H2AX immunofluorescence staining for adherent colon cancer cell lines 
treated with oxaliplatin, SN-38 or topotecan 
Materials, investigational drugs, cell sample and culture conditions, γ-H2AX 
immunofluorescence staining, foci detection and analysis are described in Sections 2.1–
2.4.  
 
2.6.4. Treatment with Oxaliplatin or SN-38 
Twelve sets of four well chamber slides were plated up with 1 mL of 8x10⁴/mL of HT-29 
and HCT-116 cells each, and left to adhere overnight. Cells were treated in vitro with  
5 uM of oxaliplatin for 2 hours or 0.01 uM of SN-38 for one hour and fixed after 2–4 hours 
as previously established by the results of the dose response and time course experiments 
(Chapters 3 and 4).  
 
2.6.5. Treatment with Topotecan 
To provide further validation of the methods developed additional experiments were 
performed using cells treated with the Topo I inhibitor topotecan; the use of an additional 
Topo I inhibitor would allow confirmation as to whether the methods developed using the 
Topo I inhibitor SN-38 were appropriate.  
Cells were treated with 1 uM topotecan hydrochloride for 2 hours at 37⁰C in the presence 
of 5% CO2 or were left as untreated control cells. This dose of topotecan and the time of 
exposure to treatment were chosen as they have previously been shown to induce γ-H2AX 
in HT-29 cells [214]. After treatment cells were washed, trypsinised and resuspended in 
PBS. Cell number and viability were determined by trypan blue assay, and the cells stored 
in freezing medium in 1 mL 1x105 cell/mL aliquots until analysis. 
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2.7. γ-H2AX Immunofluorescence Staining Protocol for Suspension Cells  
(Chapter 5) 
 
2.7.1. Cell Treatment  
HT-29 and HCT-116 colon cancer cells were plated in T75 flasks at a density of  
8 x 10⁴/ml and left to adhere overnight. Oxaliplatin (5 uM), SN-38 (0.01 uM) were prepared 
as previously described and 1 ml of each was added to a separate 15 ml Falcon conical 
centrifuge tube containing 1 ml of HT-29 or HCT116 cultured cells and left for 2 and 1 
hours, respectively, as determined from previous experiments (Chapters 3 and 4). The 
Falcon conical tubes were centrifuged at 1500 rpm (430 g) for 5 minutes at room 
temperature and the samples were washed three times with PBS. 
 
2.7.2. γ-H2AX Immunofluorescence Staining 
1 mL PBS was added to the cells and gently mixed by hand. Cells were fixed with 2 mL 
ice-cold 4% PFA, mixed by hand and incubated for 5 minutes at room temperature. The 
samples were centrifuged at 1500 rpm (430 g) for 5 minutes at room temperature, the 
supernatant was discarded. Cells were washed three times for 5 minutes in ice-cold PBS 
and the samples were again centrifuged at 1500 rpm (430 g) for 5 minutes. The 
supernatant was discarded leaving 200 µl of PBS containing the cell pellet which was 
transferred into 1.5 mL microcentrifuge tubes (Sigma-Aldrich Co.). Microcentrifuge tubes 
were placed into a Shandon EZ single cytofunnel (one sample at the time), kept in a 
diagonal position and spun at 650 rpm for 5 minutes in a cytospin machine. Samples were 
permeabilised in ice-cold permeabilisation buffer (permeabilisation buffer: 0.2% triton x-
100 in ice-cold PBS) for three minutes at room temperature then washed three times for 5 
minutes each in ice-cold PBS. Samples were blocked with blocking buffer (10% FBS, 5% 
BSA in PBS) for 1 hour at room temperature. Unless otherwise stated, 
immunofluorescence staining was performed with the slide tray in fridge to minimise 
movement of slides, with a reservoir of water at the bottom to provide humidity and reduce 
antibody evaporation from slide during incubation. On each slide, a circular rim was drawn 
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with a radius of approximately 1 cm around edge of cells. 90 μl of the primary γ-H2AX 
antibody (Mouse anti-H2AX monoclonal primary antibody diluted in blocking buffer 
(1:1000) (Merck Millipore, UK) (stored at -20˚C) 1:500 in 1% FBS in PBS) was pipetted 
into the gap marked with the pen ink, fully covering the cells and incubated at 4°C 
overnight. Slides were washed with cold-ice PBS three times. When the cells were dry  
90 μl of the secondary antibody (AF-488 goat antimouse IgG 1:500 in 1% FBS in PBS) 
was added and the slides were incubated for 1 hour in the dark at room temperature. The 
slides were washed three times for 5 minutes each with ice-cold PBS and then stained 
with Hoechst 33342 (10 µg/mL; Life Technologies H3570) for 30 minutes in the dark and 
further washed as described above. Slides were rinsed in distilled water twice to remove 
salts from PBS, protecting them from light and were then allowed to dry in the dark. Once 
dry, the pen barriers were removed, 25 μl of Prolong Gold (Invitrogen, Life Technologies 
Ltd.) was added to the area above and below the cells and then covered with micro cover 
glasses (24 x 60 mm; VWR SuperSlips) to ensure coverage of the whole area traversed 
by cells and Prolong Gold. The edges were sealed with clear nail varnish and the slides 
were stored at 4°C until analysis. 
 
2.8. Materials and Methods for CellSearch System (Janssen Diagnostics)  
(Chapter 5) 
2.8.1. Materials for CellSearch Epithelial Cell Kit 
γ-H2AX antibody (Anti-phospho-Histone H2A.X (ser139), clone JBW301, FITC 
conjugated) (Merck, catalogue number 16-202A) diluted to 57 µg/mL in Bond primary 
antibody diluents 
CK-PE (CK-Phycoerythrin) (CK-PE antibody) (Abcam) 
Dapi (4’-6-Diamidino-2-phenylindole) (ThermoFisher Scientific) 
CD45-APC (CD45-Allophycocyanin) (CD45-APC Antibody) (ThermoFisher Scientific) 
Anti-EpCAM Ferrofluid (Janssen Diagnostics): Contains a suspension of 0.022% magnetic 
particles conjugated to a mouse monoclonal antibody specific for the cell surface marker 
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EpCAM present on epithelial cells in a buffer containing 0.03% BSA and 0.05% ProClin® 
300 preservative.  
Staining Reagent (Janssen Diagnostics): Contains 0.0006% mouse monoclonal 
antibodies specific to cytokeratins conjugated to phycoerythrin (PE); 0.0012% mouse anti-
CD45 monoclonal antibody conjugated to APC in buffer containing 0.5% BSA and 0.1% 
sodium azide.  
Nucleic Acid Dye (Janssen Diagnostics): Contains 0.005% 4’, 6-DAPI and 0.05% ProClin® 
300.  
Capture Enhancement Reagent (Janssen Diagnostics): Contains 0.02% proprietary 
reagent for controlled ferrofluid aggregation, 0.5% BSA, and 0.1% sodium azide inbuffer.  
Permeabilisation Reagent (Janssen Diagnostics): Contains 0.011% proprietary 
permeabilisation reagent and 0.1% sodium azide in buffer.  
Cell Fixative (Janssen Diagnostics): Contains 25% proprietary fixative ingredients, 0.1% 
BSA, and 0.1% sodium azide in buffer.  
2 × 110 mL bottle Dilution Buffer (Janssen Diagnostics): Contains buffer with 0.1% sodium 
azide. 
CellSearch Conical Centrifuge Tubes (15 mL) and Conical Tube Caps (Janssen 
Diagnostics) 
Cartridges and Cartridge Plugs (Janssen Diagnostics) 
CellSave Preservative Tubes (Janssen Diagnostics) 
CellTracks Autoprep System (Janssen Diagnostics) 
CellTracks Analyzer II (Janssen Diagnostics) 
CellSearch Epithelial Cell Control Kit (Janssen Diagnostics) 
CellTracks Autoprep Instrument Buffer (Janssen Diagnostics) 
Horizontal swing out style rotor (swing bucket) centrifuge capable of 800 × g 
Test tube racks 
Calibrated micro-pipettes and tips 
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2.8.2. Method for CellSearch System (Janssen Diagnostics) 
2.8.2.1. Sample Preparation 
From the peripheral blood draw of healthy volunteers, (National Research Ethics Service 
Committee, NRES, London, Bloomsbury, 12/LO/1654). 7.5 mL of blood was collected in 
CellSave tubes, mixed by inversion (x5) and combined with 6.5 mL of Dilution Buffer 
(CellSearch CTC Kit, Cat No 7900001) in a 15 mL conical tube and again mixed by 
inversion (x 5). The sample was centrifuged at 800 g for 10 minutes at room temperature 
and processed on the CellTracks Autoprep system (Cat No 9541) within one hour of 
sample preparation. A CTC Control Sample (CellSearch CTC Control Kit, Cat No 
7900003) was prepared for each run and stored at 4°C. Prior to analysis the control sample 
was allowed to reach room temperature, vortexed for 5 seconds to mix, inverted five times 
then added to a 15 mL conical tube and placed on the CellTracks AutoPrep system for 
analysis. The CellSearch platform has a 4th channel (FITC) that allows molecular analysis 
to be performed. 
The γ-H2AX antibody (Merck) was diluted to 57 μg/mL in Bond primary antibody diluent 
and loaded into position 1 of the reagent carrier. This concentration was based on methods 
taken from publications by the Division of Cancer Treatment and Diagnosis at the National 
Cancer Institute (http://dctd.cancer.gov/). 
Once on the CellTracks Autoprep system, the plasma and buffer layer were aspirated from 
the blood sample. To obtain a magnetic separation, ferrofluids containing nanoparticles 
with a magnetic core surrounded by apolymeric layer coated with antibodies to EpCAM 
were then added and incubated leaving unbound cells and plasma that were eventually 
aspirated out. 
The presence of CTCs was identified with the addition of staining reagents and 
permeabilisation buffer to fluorescence label the immunomagnetically labelled cells. The 
fluorescent reagents that were added were cytokeratins 8, 18, 19 (CK-PE),  
4’ 6–DAPI and an antibody to CD45 conjugated to allophycocyanim (CD45-APC; Janssen 
Diagnostics). CK-PE is specific for epithelial cells, marking the intracellular protein 
cytokeratins, DAPI stains the cell nucleus and CD45-APC is specific for leukocytes. 
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Cells were then resuspended in the MagNest cell presentation fixture, characterised by a 
strong magnetic field responsible to move the magnetically-labelled target cells to the 
outward edge of the cartridge, where they distributed uniformly over the analysis surface 
and were oriented for analysis at a single focal depth. The cartridge containing stained 
CTCs was then removed, left in the dark for 20 minutes and finally inserted into the 
CellTracks Analyzer II (Cat No 9555 RUO), a four-colour semi-automated fluorescence 
microscope, for scanning. 
 
2.8.2.2. CTC Analysis and Enumeration Using the CellSearch Method 
On the CellTracks Analyzer II, the cartridges along with the control were scanned capturing 
image frames covering the entire surface of the cartridge and displaying tumour cells 
positive for cytokeratin and DAPI that were reviewed by the operator afterwards. 
The CellTracks Analyzer II presented the images with overlays of CK-PE and DAPI signals 
to show whether the nuclear and cytokeratin staining were consistent with a tumour cell. 
The objects in the CK-PE filter channel were required to be a round or oval intact cell, at 
least 4 microns in diameter with a nuclear area smaller than the cytoplasmic area and 
more that 50% of the nucleus needed to be visibly surrounded by the cytoplasm. 
Sometimes, an image could appear very bright as results of a spectral spillover in the CK-
PE channel that was creating a visible cytoplasmic image in the CD45-APC channel. This 
could still be classified as a tumour cell if it maintained negativity for CD45 and positivity 
for CK-PE, differentiating from leukocytes that would be positive for CD45-APC and DAPI 
but negative for CK-PE. Artefacts were recognised as appearing with the same shape in 
all channels. All samples were reviewed by two trained laboratory staff, as well as myself.  
 
The Autoprep and the following steps were performed using the manufacturer’s 
instructions summarised as follows: 
• Autoprep was switched on 
• ‘run batch’ was selected 
• CTC Kit was loaded into reagent carrier 
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• The instructions on Autoprep to set up batch were followed, User Defined Marker 
was selected and γ-H2AX was entered. 
When completed, cartridges were removed and stopper was inserted. Cartridges were laid 
flat in the dark for 20 minutes before scanning on the CellTracks Analyzer II. System 
verification of the Analyzer II was performed and control and sample cartridges were 
scanned. Cartridges were automatically imaged with the following filters: 
PE (CK-PE Antibody) 
Dapi (nuclear marker) 
APC (CD-45- APC Antibody) 
FITC for 4th channel marker (γ-H2AX, 3 seconds exposure). 
Controls were analysed to check that Low and High cell populations fell within the expected 
range (one control was run per day of sample processing). Cells were analysed with the 
criteria for identifying CTCs as previously mentioned. γ-H2AX positive cells were selected 
by nuclear FITC staining. Cartridges were stored in the dark at 4°C for future analysis 
(DEPArray) or contents transferred to 50% glycerol for -20°C storage. 
 
2.8.3. Validation of the CellSearch System protocol for Detection of γ-H2AX on CTCs 
Validation of the assay used in this thesis for the detection of γ-H2AX on CTCs using the 
CellTracks Autoprep System and the CellTracks Analyzer II was conducted in the 
laboratories of the UCL ECMC GCLP Facility, UCL Cancer Institute between 01.06.2013 
and 30.06.2013. Development and validation of a new biomarker detection assay with 
these systems is limited. The CellTracks Autoprep System is fully automated and the only 
parameter which can be changed is the concentration of the antibody, which was set at 57 
µg/mL. The only parameter which can be changed on the CellTracks Analyzer II is the 
exposure time for the FITC channel, which was set at 3 seconds. Both settings are based 
on methods taken from publications by the Division of Cancer Treatment and Diagnosis at 
the National Cancer Institute (http://dctd.cancer.gov/). 
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Healthy donor blood was spiked with HT-29 colon adenocarcinoma cells. Cells were left 
untreated, or treated either with 1 uM topotecan hydrochloride for 2 hours at 37°C in the 
presence of 5% CO2, or with 5 Gγ X-ray with 30 minutes post-incubation. The doses of 
topotecan and Gγ X-ray and the time of exposure to treatment were chosen as they have 
previously been shown to induce γ-H2AX in CTCs from peripheral blood [214, 269]. 
 
2.8.3.1. Method Validation 
Three validation runs were performed on different days. For each validation run, 4 x 7.5 
mL healthy donor blood was collected in CellSave tubes. Prepared aliquots of HT-29 cells 
were thawed and washed in 10 mL PBS. Cells were then pelleted by centrifugation at 1500 
rpm for 5 minutes, before being resuspended in 10 mL PBS. 50 µL of one of the following 
four cell suspensions (~500 cells per suspension) was added to 7.5 mL healthy donor 
blood: 
• Healthy donor blood (blank) 
• Healthy donor blood spiked with untreated HT-29 cells 
• Healthy donor blood spiked with topotecan treated HT-29 cells 
• Healthy donor blood spiked with X-ray irradiated HT-29 cells. 
 
For each run, four samples from one healthy donor and a CellSearch CTC control sample 
were run using a CellSearch Circulating Tumour Cell Kit on the CellTracks Autoprep 
System and the CellTracks Analyzer II. Different healthy donors were used for each of 
three validation runs. γ-H2AX-FITC antibody was used on sample numbers 2–4 at 57 
µg/mL. Exposure time for the fourth channel was set at 3 seconds on the CellSearch 
Analyser II. The criteria to define a CTC were as described previously. 
Acceptance criteria for detection of γ-H2AX were:  
• Samples spiked with untreated cells must be ≤3% positive for γ-H2AX 
• Samples spiked with treated cells must be ≥10% positive for γ-H2AX. 
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2.9. Materials and Methods for the DEPArray™ System (Silicon Biosystems) 
(Chapter 5) 
2.9.1. Materials for the DEPArray™ System (Silicon Biosystems) 
DEPArray™ A300K disposable cartridge 
Ultrasonic bath (Sonorex)  
Manipulation buffer SB115 
Sterile holder (e.g., Petri dish) 
P20 Eppendorf R pipette (2-20 μl) 
LoRetentionR dualfilter Eppendorf tips 20 μl Eppendorf 
LoRetentionR dualfilter Eppendorf tips 1000 μl Eppendorf 
0.2 μm filter 
Lint-free cloth 
 
2.9.2. Methods for the DEPArray™ System (Silicon Biosystems) 
2.9.2.1. Sample Preparation and Buffer Compatibility 
The buffer compatibility and the downstream application of the recovered cells by the 
DEPArray system was chosen according to the sample type, in this case live cells (Table 
2.2). 
 
Table 2.2: Downstream application and manipulation buffers 
Sample Downstream application Manipulation buffer 
 
Live cells 
Cell culture Complete culture medium 
Immunofluorescence, other applications Complete culture medium 
DNA/RNA analysis Complete culture medium 
 
Fixed cells 
Ampli 1TM whole genome amplification kit SB115 (Silicon Biosystems spa) 
FISH or other downstream molecular 
analyses 
SB115 (Silicon Biosystems spa) 
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The appropriate DEPArray parameters were selected to define the set-up execution. A 
single cell suspension was prepared for each sample, and the total number of cells and 
staining were analysed using a fluorescent microscope. The presence of cell debris or 
large cell clusters was also evaluated as they can decrease the success of cell 
manipulation and the total number of cells to be loaded in the DEPArray A300K cartridge 
(version 1.3.0). 
HT-29 and HCT-116 cells were prepared as discrete cells as described in Section 2.4 and 
2.7 followed by the CellSearch Sample Pre-Processing Protocol for the DEPArray System. 
Cells were washed with 1 mL of SB115 buffer, and sealed with parafilm. Cells were 
centrifuged at 1000 g for 5 minutes at room temperature using a swinging-bucket rotor. 
The supernatant was removed and put into labelled tubes for storage until the end of 
analysis and 1 mL of manipulation buffer was added to the remaining cells; centrifugation 
and removal of the supernatant was then repeated. The cell pellet was reconstituted in an 
adequate volume of buffer, mixed well and counted using a Burker’s Hemocytometer. A 
percentage of the sample loaded in the DEPArray A300K cartridge was analysed by the 
system and an aliquot of the cell culture medium (830 μl) was prepared and equilibrated 
at room temperature. After equilibration, 2 x 900 μl of SB115 buffer was filtered with 0.2-
micron filter and then degassed for 10 minutes on full power using a Bath Ultrasonic QS5 
(BAT 1904; Scientific Laboratory Supplies). 
 
2.9.2.2. Cartridge Loading 
The DEPArray A300K cartridge was placed in a sterile Petri dish in preparation for loading. 
The DEPArray A300K cartridge was opened and 830 μl of sonicated de-gassed SB115 
medium was added to chamber B and 14 μl of the cell sample was added to chamber S. 
The volume was checked before loading, adjusted by centrifugation (14100 rcf) in a fixed 
rotor centrifuge for 30s, in order to leave approximately 10 μl PBS containing the cell pellet. 
The DEPArray A300K cartridge was inserted in the machine. The SB115-30K-rev3 or 
SB115-16K-rev3 parameters were selected (SB115-30K was preferable to get a good 
distribution of cells; 16K was used in cases where cell numbers were <20,000; Table 2.3). 
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Appropriate temperature and other parameters were selected as indicated in the 
DEPArray System Protocol. The filters/channels for the sample scanning and Bright field 
required for DEPArray functionality were selected (i.e. add or remove FITC):  
Filter 1 = target filter i.e. for PE Cytokeratin. 
Filter 2 = -ive/other i.e. APC for CD45 
Filter 3 = DAPI for DNA – UV filter (to prevent photo bleaching) 
Filter 4 = Bright field  
Fluorescent channels were chosen to analyse the images of all the events detected. 
Images were analysed by creating a Region of Interest (ROI) in correspondence to the 
positive label and were further processed in order to obtain information on fluorescent and 
morphological parameters displayed at the Cell Browser (Section 2.9.3). 
To remove particles detected more than once during image analysis, the Duplicate 
Compare was selected and the appropriate parameters were used: 
PE – Gain 2%, Exp 100,000, Signal detection Faint  
APC – Gain 2%, Exp 300,000, Signal detection Faint  
DAPI – Gain 1%, Exp 100,000, Signal detection Bright 
FITC 1 - Gain 1%, Exp 100,000, Signal detection Faint 
FITC 2 – Gain 4%, Exp 800,000, Signal detection Faint 
Scan Area ‘Full’ was selected followed by Sorting Mode ‘Standard’. The sample was 
observed while loading to avoid loading failure, in which case manual recovery was 
performed. 
After analysis the execution was stopped and the DEPArray A300K cartridge removed. 
The cell sample volume was readjusted to 14 μl as before and loaded with the buffer in a 
new DEPArray A 300K cartridge. The system automatically performed the Calibration and 
the Sample Load steps. The Cage Parameters Programme (manipulation buffer and the 
cage pattern) was selected using the parameters described in Table 2.3. 
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Table 2.3: DEPArray Programme Parameters 
Sample 
Total cells in  
13−14 µl, n 
Button  
selection 
Manipulation 
buffer 
 
Live cells 
n <20,000* PBS-16k-rev3  
Cell culture  
medium 
20,000 ≤ n <40,000* PBS-30k-rev3 
40,000 ≤ n ≤100,000 PBS-30k-rev3 
 
Fixed cells 
n <20,000* SB115-16k-rev4  
SB115 20,000 ≤ n <40,000* SB115-30k-rev3 
40,000 ≤ n ≤100,000 SB115-30k-rev3 
*Range recommended for single-cell sorting execution 
 
After automatic calibration and sample loading, image analysis started automatically. 
There are two steps during this process: Chip scan and Image Analysis steps. The Chip 
scan step consisted of scanning the chip using fluorescence and bright field channels 
allowing the images (events) acquired to be counted and their position inside the chip 
to be calculated. In addition, morphological and intensity measurements were extracted 
from the scanned images. Following the Chip scan and Image Analysis steps, events 
were detected based on an image thresholding algorithm that was selected during the 
Cell Sorting Execution Start Up in the Chip Scan Setting form. The acquired images 
were cropped in areas of 3 x 3 electrodes around every event detected creating, for 
each scan filter build, an image gallery displayed at the Cell Browser step (Section 
2.9.3). Particle geometries, morphological measurements and intensity were obtained 
and analysed in the Image Gallery. Measurements were carried out for each detected 
event on the ROI and calculated based on the intensity of fluorescence signals. The 
analysis was performed in all fluorescence channels to get the correct measurements 
for each filter (Figure 2.3). If a duplicate particle was detected in the overlapping area 
between two images, it was removed. 
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Figure 2.3: An example of a use case in which the DEPArray analysis is performed using 
DAPI and FITC channels without the PE channel: for PE, merging of the ROIs found in the 
DAPI and FITC channels (red ROI in the centre crop) was used for measurement 
calculations. 
 
2.9.3. Cell Browser 
The Cell Browser software allows the identification, selection and assignment of particles 
of interest to user-defined groups. The particles are retrieved as input and the cells are 
produced as the output. The input population included the particles produced by the Image 
Analysis step and identified using a unique ID code. When the Cell Browser step was 
initiated the input population was displayed in the Table Analysis mode while the 
morphological and fluorescence intensity measures were displayed in the Image Gallery 
Bar. The particles of interest were selected after the creation of groups for processing with 
Recovery Manager. 
A Cell Browser group was used to categorize different cell populations, and the cells were 
sorted based on different characteristic such as intensity fluorescence and morphological 
trait. Several parameters were used to classify the input particles based on cell 
morphology and label signals, which were calculated during the detection of the 
fluorophore intensities. The trapping parameters were: 
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• In Cage: allowed the identification of the particles correctly trapped in the cage, 
suitable for the cell routing 
• In Grid: allowed the automatic removal of unstained contaminants from the cell 
population and evaluation of distance between the barycentre of the particle and 
the electrode centre. 
Morphological parameters were: 
• Circularity: roundness of the particle 
• Perimeter: perimeter in microns of the ROI 
• Diameter: circumference of the circle extrapolated from the area in microns. 
 
The perimeter and diameter were calculated on the ROI based on fluorescence detection. 
As a result, the measurements do not correspond to the actual dimensions of the entire 
cell. 
Intensity parameters were: 
• Mean intensity: mean of all gray levels measured within the ROI (usually selected 
for diffused cell staining in the nucleus, cytoplasm or on the cell plasma membrane, 
e.g.  pancytokeratins, DAPI) 
• Max intensity: maximum of all gray levels measured within the ROI preferentially 
used for a punctuate cell staining in the nucleus, cytoplasm or on the cell plasma 
membrane 
• Mean intensity with background subtraction: indicate how much the cell contrasts 
with the background. 
 
The Histogram Analysis mode was initially used to filter the particles captured by the 
dielectrophoretic field displaying the distribution frequency of selected parameters using a 
histogram graph. The Population Filter and the Plotted Parameters tool were used to select 
the input populations and parameters to plot. For each histogram, gating cursor bars were 
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used to select the output subpopulation. At each selection process, the Gated Particles 
Counter showed the total number of particles represented and the number that were gated. 
Once the analysis and selection were complete, the subpopulations could be further 
analyzed. The gating process described above reduced the number of particles that 
needed to be visually examined and represented the particles that were captured by the 
dielectric field (low APC signal, high FITC signal and high circularity FITC). The Scatter 
Plot Analysis mode was used to display the gated subpopulation as a collection of points 
in a scatter plot, plotting one parameter related to the positive marker  
(e.g. mean_intensity_PE) and the other related to the negative marker  
(e.g. mean_intensity_FITC). Each point displayed in the scatter plots represented one or  
more particles which could be displayed as gallery images. The output subpopulation was 
gated and loaded in Table Analysis mode where it was possible to individually view 
particles that met the desired characteristics and assigning them to the appropriate group. 
Once a group was created, the individual cells were reviewed and visually confirmed that 
they were single cells with the desired morphology. 
During the exporting of the data the system automatically acquired all the images that had 
been selected, creating an Image Gallery for each cell acquired. A panel of selected cells 
were displayed (Figure 2.4); the first column showed the cell ID, the second column 
displayed the name of the selected group and the remaining columns showed the Image 
Gallery channels as created in the Cell Browser. To view the visible attributes of the 
particles, this parameter was selected with the appropriate parameters to display  
(e.g. mean_intensity_dapi and mean_intensity_pe; Figure 2.5). High resolution images of 
cells for recovery were taken if required using the 20x objective and saved (one for each 
fluorescence channel and bright field channel).  
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Figure 2.4. Example of the Image Gallery created in the Cell Browser 
 
 
Figure 2.5. Example of the visible attributes of the particles created in the Cell Browser 
 
2.9.3.1 Cell Routing and Recovery 
The cells selected at the Cell Browser were moved across the chip active area in order to 
be recovered for downstream analysis. The Cell Routing and Recovery steps were 
performed using the automatically activated Recovery Manager™ as follows: 
Park Routing: cells to be routed were selected from the groups created at the Cell Browser 
and moved by the system from the Main Chamber to the Park Chamber. In the Camera 
Live section the movement of the cells was followed in real time. While in process, the 
tubes were added to required positions. All cells were checked to confirm they had routed 
successfully using DAPI filter to see the presence of nuclei where cells should be. 
The Recovery supports for the downstream analysis were selected along with the recovery 
positions for the collection of target cells. Before starting the collection of cells, the 
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Washing step and a Priming Recovery of clean buffer was performed to clean the Exit or 
Recovery Chamber. The number of drops to recover was automatically selected by the 
software. In the Recovery Support section the option Set Priming Recovery Position was 
selected. In the Exit and Recovery section, the Group name or Cell ID was selected to the 
desired position. After the recovery positions were defined, the Exit routing was activated 
and the first recovery support to collect target cells was inserted into the DEPArray 
Machine. After the cells had been transferred to the Recovery section they were washed, 
Priming Recovery was then performed which eliminated putative sources of 
contaminations (e.g. cell debris, not selected cells, etc.) present in the Exit Chamber. The 
tubes containing the cells of interest were closed and carefully labelled and the cartridge 
was removed. During recovery a PDF panel of recovered cells was created from the Cell 
Browser and a printable report was saved.  
The data obtained during the cell sorting with the DEPArray could be analysed off-line and 
elaborated using the Cell Browser software with the DEPArray in Post Processing mode. 
Every time a New Post Processing Session was created all settings (histograms, scatter 
plots, etc.), particle populations and selections were restored from the original data. 
Backup software allowed experimental and user data to be saved on an external backup 
unit allowing for data processing and elaboration. Data automatically generated, during 
sorting executions, or during post processing (e.g. cells scan images, and/or cells panels) 
were exported.  
 
2.10. Materials and Methods for CellSearch Sample Pre-Processing Protocol for the 
DEPArray System (Silicon Biosystems) (Chapter 5) 
 
2.10.1. Materials for CellSearch Sample Pre-Processing Protocol for the DEPArray 
System (Silicon Biosystems) 
Manipulation buffer SB115 
BSA 2% (Sigma-Aldrich; Order no: A3059-10G) in PBS 1X (Gibco; Order no: 20012-019) 
Protein Lobind Tube 1.5 mL (Eppendorf; Order no: 0030.108.116) 
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Gel Loading Tip Round (Corning; Order no: 4853) 
Swinging-bucket Rotor Centrifuge  
 
2.10.2. Methods for CellSearch Sample Pre-Processing Protocol for the DEPArray 
System (Silicon Biosystems) 
2% BSA solution was prepared in PBS 1X (Gibco Order no: 20012-019) from liophilized 
power, essentially globulin and protease free, ≥98% and stored at 4°C while a bottle of 
DEPArray Sample Manipulation Buffer (6 mL) was thawed at room temperature. Two 
aliquots of 325 μl of DEPArray Sample Manipulation Buffer were prepared in 1.5 mL tubes. 
One aliquot of 1.5 mL of PBS mL was also prepared as a control. Three separate 1.5 mL 
Lo-Bind tubes were labelled, one with the Sample ID and one each with Supernatant 1 
and Supernatant 2. The CellSearch Cartridge was opened. A 200 μl gel-tip was loaded 
onto a P200 pipette (set at 200 μl) and was slowly pipetted five times in the PBS-BSA 2% 
aliquot to coat the tip with PBS-BSA. The tip was then dipped into PBS solution to coat the 
external surface, leaving the tip empty. The 200 μl pre-rinsed gel-tip was used to withdraw 
the sample from the CellSearch Cartridge. The sample was resuspended by pipetting and 
transferred from the CellSearch cartridge to a clean 1.5 mL sample tube.  
325 μl of manipulation buffer was transferred from one of the two aliquots to the CellSearch 
Cartridge. The buffer was thoroughly resuspended inside the CellSearch cartridge by 
repeatedly pipetting against the inner surface and all the fluid was then transferred to the 
Sample Tube. This step was repeated with the second prealiquoted 325 μl of manipulation 
buffer. The Sample tube was centrifuged at 1000 g for 5 minutes in a swinging-bucket 
rotor. The supernatant was withdrawn over the pellet leaving approximately 30 μl of 
supernatant over the cell pellet. The supernatant was transferred to a new LoBind tube 
(identify it as ‘Supenatant 1’) and stored until DEPArray analysis. 
1 mL of DEPArray Sample Manipulation Buffer was added to the sample without 
resuspending and the same process was followed leaving about 10 μl of fluid over cell 
pellet, and transferred in a new LoBind tube that was stored until DEPArray analysis. The 
total volume required was 14 μl; the pellet was resuspended with manipulation buffer and 
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the sample volume was measured and adjusted with manipulation buffer. If the volume 
was higher than 14 μl, the sample was centifuged for 5 min at 300 g and the extra volume 
was removed. 
 
2.10.3. DEPArray Analysis of γ-H2AX expression in treated and untreated colon 
cancer cells 
The buffer compatibility and the downstream application of the recovered cells by the 
DEPArray System was chosen according to the sample type (live cells) (Section 2.9.2.2.) 
and the DEPArray set-up execution system was selected according to the manufacturers 
protocol. Cells were prepared using standard protocols (CellSearch Sample Pre-
Processing Protocol for DEPArray System; see Section 2.9). 
The cartridges containing the cells were loaded and the scan filters selected. After 
automatic calibration and sample loading, the Chip scan step and Image Analysis step 
started automatically followed by the cell selection workflow. A Cell Browser group was 
used to categorise different cell populations, and cells were sorted based on different 
characteristic such as intensity fluorescence and morphological trait. 
Several parameters were used to classify the input particles based on cell morphology and 
label signals, which were calculated during the detection of fluorophore intensity. The cells 
selected by the Cell Browser were moved across the active area of the chip in order to be 
recovered appropriately for downstream analysis.  
Three colon cancer cell samples were treated (sample 1, treated with SN-38 [0.01 µM], 
sample 2, untreated control, sample 3, treated with oxaliplatin [5 µM]) and were analysed 
as trial experiments to set up the workflow on the DEPArray System as follows:  
• Step A: CTC enumeration with CellSearch system: The required exposure time for 
γ-H2AX with FITC identification was 3 seconds, as previously identified and 
validated in Section 5.2 After the CellTracks Analyzer II scan the sample was 
processed in the DEPArray system. 
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• Step B: sample analysis with the DEPArray System: Optimisation of the optical 
parameter to detect γ-H2AX signals and the Cell Browser workflow scheme for 
target cell identification were performed as described in Section 2.9.3. 
 
To maintain the CellSearch System set up, an exposure time (FITC) of 800 ms and gain 
4X was selected. 
 
2.10.4. γ-H2AX Staining for Suspension Cells and Slide Preparation for Validation 
with Fluorescence Microscopy 
After fixation with PFA 4%, cells were split into two samples, one sample was centrifuged 
in the Cytospin machine on the slide in the slide container (Shandon EZ single cytofunnel) 
while the other half was left in suspension to be further processed with the DEPArray 
platform. Following permeabilisation and blocking (Section 4.3), the suspended cells and 
slides were stained (or left unstained) with primary (Mouse anti-H2AX monoclonal) and 
secondary antibody (Goat anti-mouse Alexa Fluor 488 IgG). Cells were analysed with 
confocal microscope and Cell Profiler software as described previously. 
 
2.11. Methods for the Clinical Application and Characterisation of CTCs (Chapter 6) 
2.11.1. Development of the CTC Protocol  
The Research Ethics Committee (REC) submission, Site-Specific Information (SSI) form 
and Research and Development (R&D) submissions were uploaded and completed via 
the Integrated Research Approval System (IRAS) and were approved by the local REC 
(National Research Ethics Service Committee, NRES, London, Bloomsbury, 12/LO/1654) 
and by the Local Trust Research and Development department at University College of 
London Hospital (UCLH). 
Patient information was confidential by assigning a unique identification number for each 
patient and the study data and medical record was processed using computerised 
methods to assign appropriate coding; access to patient data was restricted. The protocol 
allowed two vials (15 ml) of the blood volume to be taken pre-chemotherapy and two vials 
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(15 ml) post-infusion of oxaliplatin or irinotecan to allow adequate blood volume for CTC 
enumeration and molecular analysis via the CellSearch platform. 
 
2.11.2. Patient Selection and Consent 
Patients with metastatic colorectal cancer who were to start chemotherapy with FOLFOX 
(chemotherapy containing oxaliplatin) or FOLFIRI (chemotherapy containing irinotecan) 
were consented into the study to investigate γ-H2AX expression in CTCs (National 
Research Ethics Service Committee, NRES, London, Bloomsbury, 12/LO/1654). They 
were identified from the weekly UCLH colorectal-oncology MDT meetings, as well as from 
the LOC database where it was possible to select the outpatient list of candidates who 
were scheduled to initiate chemotherapy. A written permission to approach patients 
scheduled for chemotherapy in outpatient clinics at LOC was previously obtained by their 
Consultants and the list was reviewed weekly by myself to identify potential patients. 
Patients older than 18 years who had a confirmed histopathological diagnosis of 
colorectal cancer and signed informed consent were eligible for the study. Patients were 
excluded if they had already started a new cycle of chemotherapy with FOLFOX or 
FOLFIRI; previous treatment with these chemotherapies was allowed.  
 
2.11.3. Sample and Patient Information Collection 
Blood samples for CTC isolation, enumeration and analysis were taken pre- and post-
infusion of FOLFOX or FOLFIRI on day 1 Cycle 1. Peripheral blood samples of up to  
10 ml were collected in four CellSave Preservative tubes (Cat No 7900005; Veridex LLC, 
NJ, U; two tubes pre- and two tubes post-chemotherapy). Samples were anonymised and 
transported from the UCLH or the LOC outpatients department to the UCL Cancer 
Institute, where they were received by GCP and GCLP trained personnel (Victoria  
Spanswick, Leah Ensell, Helen Lowe). Each specimen was processed within 96 hours of 
being received, as per the CellSearch and UCL Cancer Institute lab protocols. 
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Clinical data including demographic, clinicopathologic information, details of previous lines 
of treatment and disease recurrence were collected on patients from the UCLH or LOC 
(MOSAIQ) patient information system.
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2.11.4. Sample Preparation and Analysis 
Blood was processed for CTC enrichment and enumeration as described in Section 2.8.2 
using the CellSearch platform. Anti-phospho-Histone H2AX (ser139), clone JBW301, FITC 
conjugated antibody (Millipore) was used on all samples after having been validated for 
use in cell lines and CTCs at the UCL Cancer Institute, as described in Section 2.8.  
 
2.12. Statistical Analyses 
Data are presented as mean (+/- standard deviation or standard error). Graphical 
summaries of the detection of γ-H2AX expression on treated and untreated cell lines (HT-
29 and HCT-116) are presented. Where data were sufficient, statistical analyses were 
performed for the detection of γ-H2AX expression on treated and untreated cell lines (HT-
29 and HCT-116) using an unpaired T-test on mean FITC intensity (representing γ-H2AX 
expression) either using raw data or FITC intensity minus the background intensity. A 
significant difference between treatment groups was determined to be p<0.05. 
For the clinical application and characterisation of CTCs from patients with CRC, the 
number of patients selected was in the range of 15–20. Previous studies demonstrated a 
general low [270] CTC detection rates and counts in the CellSearch system in mCRC and 
a much lower yield of CTCs in this tumor type compared with breast or prostate cancer 
[188, 190]. In one study for the metastatic CRC patients (n = 413), the median CTC counts 
per 7.5 mL peripheral blood was 0 [190, 270]. 
Due to the low rate and variability of CTC detection in patients with CRC we could not 
predict the number of patients to enroll in order to detect a sufficient number of CTCs to 
demonstrate an effective methodology. This was an exploratory clinical study and no 
formal statistical calculation of sample size was performed.  
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CHAPTER 3  
Defining the dose response in colon cancer cell lines treated with varying 
concentrations of oxaliplatin and SN-38 
3.1. Introduction 
DSBs in chromatin are characterized by histone H2AX phosphorylation on Ser-139  
(γ-H2AX) that can be visualized by immunofluorescence microscopy shortly after induction 
as discrete nuclear foci [271, 272], with each focus representing a single DSB [272]. The 
number and intensity of foci per nucleus correlates with the dose of the agent used to 
induce the DSBs [273] and has recently been proposed as a PD biomarker following 
treatment with topo I inhibitors, including topotecan [214, 244]. As detailed in Section 
1.2.6., finding faster and non-invasive methods to assess the effect of chemotherapeutic 
agents on tumour cells during the course of treatment can allow for an immediate 
determination of the effect of a drug on its putative target. γ-H2AX induction has been 
recently investigated in CTCs from patients receiving treatment to monitor the PD effects 
of anticancer therapies over treatment cycles [214]. The number of γ-H2AX-positive cells 
was assessed using the CellSearch system in conjunction with γ-H2AX-AF488 antibody 
staining and was expressed as a percentage of γ-H2AX positive CTCs. 
γ-H2AX-positive CTCs were identified in all post-treatment samples and persisted during 
treatment, although there was individual variability in the number of CTCs collected post-
treatment. However, an assay to quantify γ-H2AX expression in individual CTCs is 
currently not available. 
A feasibility study was therefore conducted to quantify differences in γ-H2AX signal 
intensity in colon cancer cells pre- and post-treatment using both the CellSearch System 
(Janssen Diagnostics) and the DEPArray System (Silicon Biosystems).  
Human colon adenocarcinoma cancer cell lines were initially treated with different 
concentrations of oxaliplatin and SN-38 to identify the dose that induced the highest 
number of γ-H2AX foci/nucleus for evaluation in time course experiments (Chapter 4). 
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3.2. Results 
3.2.1. Dose Response in HT-29 Colon Cancer Cells treated with Oxaliplatin 
Dose response experiments were conducted to determine the dose and time of exposure 
to oxaliplatin and SN-38 needed to induce significant levels of γ-H2AX. This information 
was required for subsequent time course experiments (Chapter 4). 
As detailed in Chapter 1, oxaliplatin, a platinum-based chemotherapy agent, exerts its 
cytotoxic effect in colorectal cancer cells mostly by inducing DNA damage [274] and 
apoptosis. Once oxaliplatin is activated in the plasma to form di chloro (DACH) platinum 
compounds, it exerts the majority of its effects on genomic DNA, creating adducts and 
inducing DSB through three types of crosslinks: DNA intra-strand crosslinks, DNA inter-
strand crosslinks, and DNA–protein crosslinks. 
The kinetics of oxaliplatin-induced DNA damage was investigated in a previous study [266] 
by analysis of the expression levels of phospho-p53 (Ser-15) and γ-H2AX. Oxaliplatin 
treatment induced phosphorylation and upregulation of γ-H2AX in a concentration- and 
time-dependent manner in human HCT-116 colorectal cancer cells and was found to be 
associated with p53-dependent and independent pathways, but not with G2/M or S phase 
arrest. 
Expression levels of γ-H2AX were measured in HT-29 cell lines in order to fully 
characterize the DNA damage response during oxaliplatin treatment (Section 2.3–2.4, 
Figure. 3.1). γ-H2AX accumulation was detectable in oxaliplatin treated cells following 2 
hours incubation and the highest peak of foci was obtained with 10 μM of oxaliplatin, a 
significant increase in γ-H2AX expression was observed in all oxaliplatin treated cells 
compared with control treated cells (Table 3.1; Figure. 3.2). Untreated cultures also 
expressed phosphorylated H2AX, consistent with the fact that H2AX is normally 
phosphorylated during DNA replication [275].  
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Figure 3.1: Expression levels of γ-H2AX measured in HT-29 cell lines in response to 
oxaliplatin treatment using CellProfiler Software. Images show the identified cells (red), 
the original obtained image (grey), nuclear outlines (green) over the original image, 
isolated nuclei (identified with different colours to identify individual nuclei), and γ-H2AX 
positive nuclei.  
 
Table 3.1: Expression of γ-H2AX in HT-29 cell lines treated with oxaliplatin 
 
Control 
(oxaliplatin  
0 μM) 
Oxaliplatin 
1 μM 
Oxaliplatin 
5 μM 
Oxaliplatin 
10 μM 
No. of cells (n=1) 50 46 50 50 
γ-H2AX foci 241 465 521 598 
Mean γ-H2AX foci/cell 4.82  
 
10.11  10.42 
 
11.96 
 
Standard deviation 7.43 10.75 9.76 14.86 
T-test (versus control)  0.0034 0.0009 0.0016 
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Figure 3.2:  Expression levels of γ-H2AX in HT-29 cell lines treated with oxaliplatin. 
Results of one experiment expressed as mean foci per cell + SD from a minimum of 50 
cells. Asterisks indicate a significant difference (P<0.05) between treatment and control. 
 
3.2.2. Dose Response in HT-29 Colon Cancer Cells Treated with SN-38 
As discussed in Chapter 1, irinotecan (CPT-11) is an analogue of camptothecin (CPT). 
The mechanism of action of the pro-drug CPT-11 involves the inhibition of topo I, a nuclear 
enzyme involved in DNA structure preservation. The active form of CPT-11, SN-38, binds 
to topo I and prevents its interaction with transient DNA breaks during replication, resulting 
in the formation of cleavable complexes. Replication fork collision with cleavable 
complexes during S-phase is the major cytotoxic mechanism of topoisomerase inhibitors 
in dividing cells [276]. These complexes are converted to permanent DNA DSBs which 
activate the DNA damage checkpoint response to promote cell cycle arrest, thus 
preventing the replication of damaged DNA (G1/S checkpoint) or mitosis (G2/M 
checkpoint) [277].  
HT-29 colon cancer cells were initially treated with increasing concentrations of SN-38 (1, 
5, and 10 μM). However, at the concentrations and time of exposure used, γ-H2AX levels 
continued to increase in treated cells with the extent of DNA damage, and it was not 
possible to perform statistical analysis on these samples. The continuous induction of DNA 
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DSBs was likely due to successive rounds of endoreduplication and attempts by each new 
endoreduplicated population to replicate DNA. 
Subsequently, the HT-29 cell line was treated with lower concentrations of SN-38 (0.01, 
0.05, and 0.5 μM) for 1 hour. γ-H2AX accumulation was significantly increased at 1 hour 
in the 0.01 and 0.05 µM-treated cultures when compared with control treated cells (Figure 
3.3; Figure. 3.4, Table 3.2). Untreated cultures also had minor levels of phosphorylated 
H2AX, consistent with the fact that H2AX is normally phosphorylated during DNA 
replication [275]. 
 
 
Figure 3.3: Expression levels of γ-H2AX measured in HT-29 cell lines in response to 
SN-38 treatment using CellProfiler Software. Images show the identified cells (red), the 
original obtained image (grey), nuclear outlines (green) over the original image, isolated 
nuclei (identified with different colours to identify individual nuclei), and γ-H2AX positive 
nuclei.  
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Table 3.2: Expression levels of γ-H2AX in HT-29 cell lines treated with SN-38 
 
Control 
(SN-38 0 μM)  
SN-38 
0.01 μM 
SN-38 
0.05 μM 
SN-38 
0.5 μM 
SN-38  
1 μM 
No. of cells (n=1) 50 50 50 50 50 
γH2AX foci 215 822 1196 102 104 
Mean γH2AX 
foci/cell 
4.3 
 
16.4 
 
23.9 
 
2.0 
 
2.1 
 
Standard deviation 6.54 6.83 5.80 1.67 1.69 
T-test (versus 
control) 
 6.32-15 5.81-29 0.012 0.012 
 
 
 
 
Figure 3.4: Expression levels of γ-H2AX in HT-29 cell lines treated with SN-38. Results 
from one experiment expressed as mean foci per cell + SD from a minimum of 50 cells. 
Asterisks indicate a significant difference (P<0.05) between treatment and control.  
 
3.3. Conclusions 
The formation of γ-H2AX foci was investigated in human adenocarcinoma HT-29 
colorectal cells by performing dose response experiments with increasing concentrations 
of oxaliplatin and SN-38. As shown in Figures 3.3 and 3.4, an increased number of γ-H2AX 
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foci were observed after treatment with oxaliplatin and SN-38, in agreement with previous 
studies that showed that H2AX was phosphorylated in response to DNA DSBs induced by 
DNA topo I cleavage complexes [276] and oxaliplatin [266]. In colorectal cancer cells, 
treatment with 1, 5, and 10 μM oxaliplatin for 2 hours generated more γ-H2AX foci than in 
untreated cells (Figure 3.2). However, the same concentrations and time of exposure to 
SN-38 yielded more foci per cell; 1, 5, and 10 μM SN-38 induced diffuse DNA damage, 
which was detectable with immunofluorescence analysis and was due to continual DNA 
DSBs. It is possible that the different responses observed between the same 
concentrations of oxaliplatin and SN-38 in HT-29 cells is because the IC50 of oxaliplatin 
is greater than that of SN-38 (22.17 vs 1.93, respectively [278]). Consequently, HT-29 cells 
were incubated with lower concentrations of SN-38 and foci were detectable and 
significantly increased after 1 hour of drug exposure at the 0.01 and 0.05 µM SN-38 doses, 
when compared with the untreated control (Figure 3.4). Based on the results of these dose 
escalation experiments, the final concentrations that were selected for the time course 
experiments (Chapter 4) were 5 μM and 0.01 μM for oxaliplatin and SN-38, respectively.  
The tumour suppressor p53 protein is a transcription factor inducing cell cycle arrest, 
senescence, and apoptosis under cellular stress. Dysregulation of p53 tumour suppressor 
gene is one of the most frequent events contributing to the transformation of CRC, as well 
as the aggressive and metastatic features of CRC. Different types of p53 mutations play 
a pivotal role in determining the biologic behaviour of CRC, such as invasive depth, 
metastatic site and even the prognosis of patients [279]. The HT-29 cell type has been 
reported to express a mutated p53 gene whereas the HCT-116 cell line does not [280]. As 
the p53 gene mutation in HT-29 cells may affect the response to treatment the time course 
experiments (Chapter 4) will assess both cell types. 
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CHAPTER 4 
Time course experiments in colon cancer cell lines treated with oxaliplatin or  
SN-38  
 
4.1. Introduction  
In Chapter 3, the optimum concentration of oxaliplatin and SN-38 for peak induction of γ-
H2AX foci was established in HT-29 human colon adenocarcinoma cancer cell lines. Using 
these concentrations, time course experiments were performed to establish the kinetics of 
γ-H2AX foci formation.  
  
4.2. Results 
4.2.1. Time Course Experiments in HCT-116 and HT-29 Colon Cancer Cells Treated 
with Oxaliplatin 
Expression levels of γ-H2AX were measured in HT-29 and HCT-116 cell lines at different 
time points in order to fully characterize the DNA damage response peak during oxaliplatin 
treatment. Two CRC cell lines were used in these studies to allow for any differences in 
response to treatment or γ-H2AX expression that may occur because of the p53 status of 
the cell; the HT-29 cell type has been reported to express a mutated p53 gene whereas 
the HCT-116 cell line does not [280].  
In response to DNA DSBs, activated ATM is reported to phosphorylate H2AX at Ser-139 
[281]. The number of foci-positive cells and the intensity of γ-H2AX foci was detected at 
early time points following addition of the drug in both cell lines relative to their respective 
untreated controls (Figures 4.1–4.3 and 4.5–4.7, Table 4.1) and remained detectable 
throughout the experimental period. In HCT-116 cells, within 1 hour of treatment, punctate 
foci rapidly peaked and were maintained until 6 hours post dose, after which a gradual 
decline of γ-H2AX foci was observed (Figure. 4.2). After 26 hours of treatment, γ-H2AX 
foci largely disappeared and returned to the baseline distribution. In HT-29 cells, a rapid 
increase of punctate foci was observed by 1 hour post treatment which gradually increased 
to peak 6 hours post treatment, after which a gradual decline of γ-H2AX foci was observed. 
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At 26 hours post treatment γ-H2AX foci were still increased compared with baseline 
(Figure. 4.4). 
Foci represent active DNA repair sites [282] and γ-H2AX loss or dephosphorylation 
correlates time-wise with DNA repair [214]. Untreated cultures also expressed 
phosphorylated H2AX, consistent with the fact that H2AX is normally phosphorylated 
during DNA replication (18). 
 
 
 
 
 
Figure 4.1. Intra-assay variation in γ-H2AX foci induction and detection in  
HCT-116 cells treated with 5 µM oxaliplatin. Triplicate validation of the same experiment 
shown with blue shading. Results are expressed as mean foci per cell + SD from a 
minimum of 50 cells. Asterisks indicate a significant difference (P<0.05) between time point 
and control for corresponding experiment.
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Figure 4.2. Inter-assay variation in γ-H2AX foci induction and detection in  
HCT-116 cells treated with 5 µM oxaliplatin. Results are expressed as mean (of triplicate 
experiments shown in Figure 4.1) foci per group + SD. Asterisks indicate a significant 
difference (P<0.05) between time point and control. 
 
 
 
Figure 4.3. Intra-assay variation in γ-H2AX foci induction and detection in HT-29 cells 
treated with 5 µM oxaliplatin. Triplicate validation of the same experiment shown with blue 
shading. Results are expressed as mean foci per cell + SD from a minimum of 50 cells. 
Asterisks indicate a significant difference (P<0.05) between time point and control for 
corresponding experiment. 
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Figure 4.4. Inter-assay variation in γ-H2AX foci induction and detection in  
HT-29 cells treated with 5 µM oxaliplatin. Results are expressed as mean (of triplicate 
experiments shown in Figure 4.3) foci per group + SD. Asterisks indicate a significant 
difference (P<0.05) between time point and control. 
 
4.2.2. Time Course Experiments in HT-29 and HCT-116 Colon Cancer Cells Treated 
with SN-38 
Expression levels of γ-H2AX were also measured in HT-29 and HCT-116 cell lines at 
different time points in order to fully characterize the DNA damage response peak following 
SN-38 treatment. As with oxaliplatin treated cells, the number of foci-positive cells and the 
intensity of γ-H2AX foci was detected at early time points following addition of the SN-38 
in both cell lines relative to their respective untreated controls (Figures 4.5 and 4.7, Table 
4.1) and remained detectable throughout the experimental period. In HCT-116 cells, within 
1 hour of treatment, punctate foci rapidly peaked and increased until 6 hours post dose, 
after which a gradual decline of γ-H2AX foci was observed (Figure 4.6). At 26 hours post 
treatment γ-H2AX foci were still increased compared with baseline. In HT-29 cells, a rapid 
increase of punctate foci was observed by 1 hour post treatment which was maintained 
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until 6 hours post treatment, after which a gradual decline of γ-H2AX foci was observed 
(Figure 4.8). 
 
Figure 4.5. Intra-assay variation in γ-H2AX foci induction and detection in  
HCT-116 cells treated with 0.01 µM SN-38. Triplicate validation of the same experiment 
shown with blue shading. Results are expressed as mean foci per cell + SD from a 
minimum of 50 cells. Asterisks indicate a significant difference (P<0.05) between time point 
and control for corresponding experiment. 
 
Figure 4.6. Inter-assay variation in γ-H2AX foci induction and detection in  
HCT-116 cells treated with 0.01 µM SN-38. Results are expressed as mean (of triplicate 
experiments shown in Figure 4.5) foci per group + SD. Asterisks indicate a significant 
difference (P<0.05) between time point and control. 
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Figure 4.7. Intra-assay variation in γ-H2AX foci induction and detection in  
HT-29 cells treated with 0.01 µM SN-38. Blue shading represents repeated validation of 
the same experiment. Results are expressed as mean foci per cell + SD from a minimum 
of 50 cells. Asterisks indicate a significant difference (P<0.05) between time point and 
control for corresponding experiment. 
 
 
 
Figure 4.8. Inter-assay variation in γ-H2AX foci induction and detection in  
HT-29 cells treated with 0.01 µM SN-38. Results are expressed as mean (of triplicate 
experiments shown in Figure 4.7) foci per group + SD. Asterisks indicate a significant 
difference (P<0.05) between time point and control. 
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Table 4.1. Inter-assay variation in γ-H2AX foci induction and detection following time 
course experiments* 
  Hours 
 Control 1 2 4 6 8 18 26 
HCT-116 cells treated with 5 µM oxaliplatin 
Mean foci/group 4.89 20.16 17.79 16.46 10.95 13.15 11.73 6.80 
Standard 
deviation 
0.95 1.06 2.74 4.39 2.77 3.77 3.83 2.34 
T-test  <0.0001 0.004 0.020 0.025 0.028 0.041 0.146 
HT-29 cells treated with 5 µM oxaliplatin 
Mean foci/group 6.21 13.55 14.69 16.36 12.63 12.75 8.99 6.45 
Standard 
deviation 
1.63 2.51 2.09 2.79 0.94 1.35 0.68 1.84 
T-test  0.009 0.003 0.005 0.004 0.003 0.041 0.437 
HCT-116 cells treated with 0.01 µM SN-38 
Mean foci/group 4.77 14.19 12.75 19.51 16.54 12.57 10.79 8.57 
Standard 
deviation 
3.42 0.92 2.13 3.46 1.67 1.22 4.20 1.91 
T-test  0.017 0.017 0.003 0.007 0.023 0.120 0.094 
HT-29 cells treated with 0.01 µM SN-38 
Mean foci/group 8.65 16.00 14.62 22.57 18.59 17.17 7.32 6.22 
Standard 
deviation 
3.72 3.64 1.42 8.29 11.38 9.70 0.60 0.84 
T-test  0.035 0.047 0.042 0.133 0.132 0.300 0.187 
 
 
*Data are shown for triplicate experiments except for HCT-116 cells treated with 0.01 µM 
SN-38 at 18 hours which are from duplicate experiments.
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4.3. Conclusions 
γ-H2AX foci formation was investigated in human adenocarcinoma HT-29 and HCT-116 
colorectal cells by performing dose response experiments using increasing concentrations 
of oxaliplatin and SN-38 (Chapter 3; HT-29 cells only) and time course experiments to 
study temporal differences in γ-H2AX signal intensity post treatment. 
As shown in Figures 4.1–4.8, an increased number of γ-H2AX foci formations were 
observed after treatment of the cells with oxaliplatin and SN-38 in agreement with previous 
studies [283]. 
In colorectal cancer cells, treatment with 5 μM oxaliplatin and 0.01 μM SN-38 at different 
time points (0, 1, 2, 4, 6, 8, 18 and 26 hours) caused a sustained increase of γ-H2AX foci 
positive cells detected from early time points in both cell lines relative to their respective 
untreated controls, confirmed by three inter and intra-assay validations (Figures 4.1–4.8, 
Table 4.1). The rise of foci was observed between two and six hours post-treatment, after 
which they gradually decreased returning close to the baseline distribution at 26 hours due 
to DNA repair. 
Minor differences were observed between the two CRC cell lines in response to treatment 
with oxaliplatin and SN-38; in both cells, there was a rapid peak to a mean of ~10 foci/group 
in the first hour post-treatment which plateaued at a steady rate until 18 hours post-dose 
where the mean γ-H2AX foci/group declined to ~10 (7.32-11.73), and 6-8 foci/group by 26 
hours post dose (6.22-8.57). Oxaliplatin and SN-38 are pharmacologically distinct and 
have different mechanisms of action. Various mechanisms of action are ascribed to 
oxaliplatin however like other platinum-based compounds, oxaliplatin exerts its cytotoxic 
effect mostly through DNA damage by causing DNA lesions (crosslinks), arresting DNA 
synthesis and through the inhibition of messenger RNA synthesis [274]. The active form 
of SN-38, irinotecan, inhibits the action of topo I, preventing relegation of the DNA strand 
by binding to the topo I-DNA complex. The formation of a cleavable drug–topo I–DNA 
complex results in lethal double-strand DNA breakage and cell death [284]. These 
differences in the mode of action of the drugs resulting in DNA damage may contribute to 
the minor differences in the formation of γ-H2AX foci that were nevertheless observed. As 
108 
 
noted previously, the genetic status of the different cell lines may also contribute to 
differences observed between the two cell lines used; the presence of p53 gene mutations 
(as well as BRAF mutations) in HT-29 cells [280] may result in the cells responding to 
treatment differently. Indeed, differences in response to treatment have been observed for 
patients with p53 mutations; in the Phase 2 EXPERT-C trial, which added cetuximab in 
the adjuvant setting for high-risk stage II rectal cancer patients, exploratory retrospective 
analysis suggested p53 mutation status did predict benefit from cetuximab [285]. 
Based on the results of these experiments, we decided that the best time for CTC 
collection on patients would have been 2 hours post infusion of FOLFOX or FOLFIRI. This 
time was chosen for several reasons: 1. γ-H2AX induction was observed with both cell 
lines and treatments at this time point; 2. 2 hours post-infusion would avoid patients having 
to undergo a prolonged stay in the hospital following completion of their treatment. The 
amount of γ-H2AX induction 2 hours following treatment was therefore evaluated to 
determine if valuable data for their quantification using the CellSearch and DEPArray 
platform could be obtained (Chapter 5).  
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CHAPTER 5 
Development of the Protocol for quantification of γ-H2AX intensity using the 
CellSearch System (Janssen Diagnostics) and the DEPArray™ System (Silicon 
Biosystems) 
 
5.1 Introduction 
γ-H2AX’s role as a biomarker for DNA damage has been extensively studied and its utility 
in the clinical setting has been demonstrated by several studies [236-238, 271]. Detection 
of γ-H2AX foci after exposure to DNA-damaging agents is a more reliable DSB marker 
than other repair proteins as it is formed de novo in cells, it is far more sensitive than other 
methods in detecting DSBs at clinically relevant doses and allows the distinction of the 
temporal and spatial distribution of DSB formation. An assay to measure patient drug 
response at the molecular level could permit a faster assessment of patient response, 
without the need to wait several weeks [217, 286] for tumour response/stability using 
imaging techniques. 
Tumour biopsies are pivotal to evaluate the effect of drugs on DNA metabolism [214]. 
However, the time course to evaluate PD responses would require patients to undergo 
several biopsies, which is unfeasible. Less invasive methods based on collection of CTCs 
in the bloodstream pre- and post-treatment, and the monitoring of drug on-target effects 
such as changes in γ-H2AX levels directly on CTCs is currently under investigation [214]. 
Presently, several techniques for γ-H2AX detection are available including constant or 
pulsed field gel electrophoresis, comet assays [251], flow cytometry, western blotting [262] 
and immunofluorescence with antibodies directed against both H2AX and γ-H2AX. 
However, fluorescence microscopy is the preferred and most sensitive method for γ-H2AX 
detection for clinical applications as it is able to detect a single DSB [244]. Analysis by 
microscopy may discriminate γ-H2AX responses induced by different drugs based on the 
different timing of interference with DNA replication and, unlike flow cytometry, can 
distinguish foci from the background allowing the analysis of tissue samples rather than 
single cells. Other types of assays, such as chemoluminescent-based detection [287] and 
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whole cell ELISA [288] also utilise cell and tissue extracts, however they are not yet 
available in the clinic setting. 
There is therefore an ongoing demand for the development of a high throughput γ-H2AX 
foci-counting system for clinical utilisation to allow a faster analysis and automated 
microscopic examination [214, 244, 288]. 
γ-H2AX induction has recently been studied in cancer cells treated with different 
chemotherapy agents and in CTCs from patient blood samples processed using the 
CellSearch System in conjunction with γ-H2AX-AF488 antibody staining. γ-H2AX signal 
was detected as percent γ-H2AX-positive CTCs per total CTCs recovered following 
chemotherapy [214]. However, at present this is still an unmet need since the current 
methods available for the detection of DNA damage in patient samples have showed a 
limited applicability in the clinic to monitor tumour response to chemotherapy.  
It is still unknown whether γ-H2AX in CTCs will correlate with clinical efficacy, and clinical 
trials are currently investigating the correlation between drug effects on disease 
progression to γ-H2AX-positive CTCs. Examples of such studies include NCT00576654 
and NCT01386385 which are evaluating the effect of veliparib in combination with 
chemotherapies in advanced solid tumours or advanced non-small cell lung cancer, 
respectively. Based on the current data, and on the lack of a system that allows a 
quantification of the γ-H2AX signal induction post treatment in CTCs from patients with 
mCRC, we investigated the feasibility of a quantitative assay using both the CellSearch 
System (Janssen Diagnostics) and the DEPArray System (Silicon Biosystems) with the 
aim of measuring and identifying differences in signal intensity caused by induction of γ-
H2AX in treated and untreated cancer cells, for use as an early indicator of response to 
treatment. 
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5.2. Validation of the CellSearch System to detect γ-H2AX induction in treated CRC 
cells spiked into peripheral blood from healthy donors: Results  
Validation of the assay developed for the detection of γ-H2AX on CTCs using the 
CellTracks Autoprep System and the CellTracks Analyzer II was previously performed in 
the laboratories of the UCL ECMC GCLP Facility, UCL Cancer Institute between 1 – 30 
June 2013 (Section 2.8.3) by Victoria Spanswick, Leah Ensell and Helen Lowe using 
healthy donor blood that was spiked with untreated, topotecan treated or X-ray irradiated 
HT-29 cells. These experiments have been included into this thesis as they provide 
important background information for the subsequent work that was performed on blood 
samples from patients with CRC (Chapter 6). Figure 5.1 shows an example of the images 
that are provided from the CellTracks Analyzer II. The CellTracks Analyzer II also provides 
data on the overall number of CTCs present within the sample as well as the number and 
percentage of CTCs which are positive for γ-H2AX. Tables 5.1–5.4 show the data from the 
spiked peripheral blood of three healthy volunteers. The data demonstrate that the 
methodology used can consistently identify the overall number of CTCs, with the overall 
number over all the spiked experiments ranging from 266–399 with 0–2 cells identified in 
untreated control blood samples. For blood spiked with only HT-29 cells, low numbers of 
CTCs positive for γ-H2AX were detected, all of which were below the pre-defined threshold 
of ≤3% positive for γ-H2AX. In blood that was spiked with HT-29 cells X-ray irradiated or 
treated with topotecan had CTCs positive for γ-H2AX above the pre-defined acceptance 
threshold of ≥10% positive for γ-H2AX.  
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Figure 5.1: Detection of γ-H2AX induction in whole blood samples spiked with HT-29 
treated tumour cells using the CellSearch Analyzer II. HT-29 cells were treated with 
either 5 Gγ X-ray (30 minutes incubation) or 1 uM topotecan (2 hour incubation) to allow 
maximum γ-H2AX induction. Cells were stained with anti-γ-H2AX antibody. 
 
Table 5.1 Validation run 1 results 
 
Sample ID 
γH2AX-AF488 
antibody 
concentration 
 
Number  
of tumour 
cells 
 
Unassigned 
events 
Tumour 
cells 
positive for 
γ-H2AX 
Tumour 
cells  
positive for 
γ-H2AX (%) 
Blank n/a 1 58 n/a n/a 
HT-29 57 µg/mL 339 148 9 2.65 
Topotecan 57 µg/mL 399 189 115 28.82 
X-ray 57 µg/mL 326 168 110 33.74 
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Table 5.2 Validation run 2 results 
Sample ID 
γH2AX-AF488 
antibody 
concentration 
Number  
of Tumour 
Cells 
Unassigned 
events 
Tumour cells 
positive for 
γ-H2AX 
Tumour 
cells  
positive for 
γ-H2AX (%) 
Blank n/a 0 29 n/a n/a 
HT-29 57 µg/mL 266 148 7 2.63 
Topotecan 57 µg/mL 312 124 141 45.19 
X-ray 57 µg/mL 391 130 168 42.97 
 
Table 5.3 Validation run 3 results 
Sample ID 
γH2AX-AF488 
antibody 
concentration 
Number  
of tumour 
cells 
Unassigned 
events 
Tumour cells 
positive for γ-
H2AX 
Tumour 
cells 
positive for 
γ-H2AX (%) 
Blank n/a 2 69 n/a n/a 
HT-29 57 µg/mL 350 181 8 2.29 
Topotecan 57 µg/mL 370 156 132 35.68 
X-Ray 57 µg/mL 382 108 134 35.08 
 
 
Table 5.4 Combined validation run results  
Sample ID 
γH2AX-AF488 
antibody 
concentration 
Mean 
number  
of tumour 
cells 
Mean 
unassigned 
events 
Mean (+/- SE) 
tumour cells 
positive for γ-
H2AX 
Tumour 
cells 
positive for 
γ-H2AX (%) 
Blank n/a 1 52 n/a n/a 
HT-29 57 µg/mL 318 159 8 (0.6) 2 
Topotecan 57 µg/mL 360 156 129 (7.6) 37 
X-Ray 57 µg/mL 366 135 137 (16.8) 37 
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5.2.1. Validation of the CellSearch System to detect γ-H2AX induction in treated 
CRC cells spiked peripheral blood from healthy donors: Conclusions 
Acceptance criteria for detection of γ-H2AX, as set by the NCI, state that untreated cells 
must be ≤3% positive for γ-H2AX and treated cells must be ≥10% positive for γ-H2AX. All 
three validation runs performed met these pre-defined validation criteria confirming that 
the γ-H2AX antibody used for these experiments (Anti-phospho-Histone H2A.X (ser139), 
clone JBW301, FITC conjugated) is appropriate for use with the CellSearch Circulating 
Tumour Cell (CTC) Kit and the CellTracks Autoprep System at a concentration of 57 µg/mL 
(Stock antibody diluted 1:32 in Bond primary antibody diluent). Exposure for the fourth 
channel should be set at 3 seconds on the CellTracks Analyzer II. 
 
 
5.3. Colon cancer cells treated with oxaliplatin and SN-38 enriched by CellSearch 
System and analysed by DEPArray using two exposure times 
DR and TC experiments were performed on HT-29 and HCT-116 colon cancer cells to 
define the dose of oxaliplatin and SN-38, and the time required to obtain the highest peak 
of γ-H2Ax induction in colon cancer cells as described in Chapters 3 and 4. To reproduce 
the analytical process for CTCs, we evaluated γ-H2AX signal using both the CellSearch 
System (Janssen Diagnostics) and the DEPArray System (Silicon Biosystems). 
HT-29 cells (at a concentration of 8 × 104 cells/mL) were incubated with oxaliplatin 5 µM 
or SN-38 0.01 µM for 2 hours and 1 hour, respectively. Control cells were untreated. Cells 
were maintained in suspension after washing and trypsinazation. Fixing, permeabilisation, 
blocking, and staining with γ-H2AX antibody were performed as described in Chapter 2. 
 
5.3.1. CTC Detection and Analysis on CellTracks Analyser II  
The CellTracks Analyser II displays CTC candidate Images generated after a blood 
specimen has been processed on the CellTracks Autoprep System. A CTC was defined 
as being positive for CK-PE and nuclear staining (DAPI), negative for leukocyte staining 
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(CD45-APC) and as having the correct morphology, and CK-PE and DAPI overlay to be 
characterised as a tumour cell. 
Treated and untreated HT-29 colon cancer cells were spiked into 7.5 ml of peripheral 
bloods that was mixed and combined with 6.5 ml of dilution buffer (CellSearch CTC Kit) 
and processed on the CellTracks Autoprep system along with CTC Control Sample 
(CellSearch CTC Control Kit). The γ-H2AX antibodies used in this experiment (Mouse anti-
H2AX monoclonal primary antibody and Goat anti-mouse Alexa Fluor 488 IgG secondary 
antibody) were not the recommended antibodies for the CellSearch System, however they 
were compatible for analysis in the 4th channel (FITC) of the CellSearch platform. 
Once on the CellTracks Autoprep system, the presence of CTCs was identified with the 
addition of the staining reagents CK-PE, DAPI, CD45-APC and permeabilisation buffer. 
The cartridge containing stained CTCs was then inserted into the four-colour semi-
automated fluorescence microscope CellTracks Analyzer II. Images were presented in a 
gallery format for final cell classification and were reviewed by the operator and myself. 
Cells were defined as positive for γ-H2AX on the CellSearch System according to the 
previously validated assay. For oxaliplatin and SN-38 treated cells, 15.28% and 18.37% 
were classified as positive for γ-H2AX, respectively, compared with 5.10% for untreated 
controls (Figure 5.2). 
The CellSearch Cartridge was opened, the cells were withdrawn using a 200 μl gel-tip pre-
rinsed in order to reduce cell loss and transferred to the DEPArray machine. This process 
involved a series of cell manipulation steps such as centrifugation, volume adjustment and 
resuspension of the samples that could reduce the total number of final cells for analysis.   
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Figure 5.2. HT-29 cells treated with (A) oxaliplatin, (B) SN-38 and (C) untreated control: 
CellTracks Analyser CTC candidate images demonstrating the criteria for CTC analysis.  
DAPI/CK-PE represents cells stained with CK-PE with the cell nuclei (DAPI) overlaid; CK-
PE represents cells stained only with CK-PE; DAPI represents cell nuclei; CD45-APC 
represents haematopoietic origin; ƴH2AX represents staining for γ-H2AX molecular 
characterisation. Images with an orange box are positive for nuclear γ-H2AX staining.  
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5.3.2. DEPArray System Analysis of Colon Cancer Cells Treated with SN-38 
The data obtained during the cell sorting executed with the DEPArray System were 
analysed off-line with the Cell Browser where fluorescent particles were measured and 
cells were selected and identified for PE+/DAPI+/APC-. 
From the analysis of the first sample treated with SN-38 and run with DEPArray platform, 
165 PE+/DAPI+/APC- cells were identified out of 860 particles detected. Most of the 
PE+/DAPI+/APC- cells did not show a clear positivity in the FITC channel resulting in a 
low number of cells being identified as CTCs. DEPArray analysis allowed the identification 
of only six putative target cells and only one cell presented a good signal background ratio 
(Figure 5.3, Table 5.5; id=3794-last row). The images of the other five putative target cells 
appeared grainy as a consequence of the low FITC signal/background ratio. 
 
Figure 5.3. DEPArray images of PE+/DAPI+/APC- colon cancer cells following treatment 
with SN-38.  
Rows show the cell ID, columns display the name of the Channel Selection the cell 
belonged to with respective values. Cells in rows one to five appear coarse as a 
consequence of the low FITC signal/background ratio. Cell number id=3794 (row six) 
presented a good signal background ratio.  
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Table 5.5. DEPArray signal (FITC channel) and background gray levels of 
PE+/DAPI+/APC- colon cancer cells following treatment with SN-38 
 Cell ID 
 1964 1731 4915 148 4328 3794 
Signal ~1421 ~1470 ~1525 ~1664 ~1791 ~2478 
Background ~1286 ~1270 ~1297 ~1296 ~1258 ~1308 
 
 
5.3.3. DEPArray system analysis of untreated control colon cancer cells 
For this analysis, two different exposure times for the identification of the 
signal/background ratio of γ-H2AX (FITC) were selected: 
• FITC I: 100 ms and gain 1X (standard set up used in the DEPArray System for the 
identification of FITC background signal) 
• FITC II: 800 ms and gain 4X (to maintain CellSearch System set up). 
Out of 1101 particles detected, 192 PE+/DAPI+/APC– cells were identified. FITC II 
measurement results were comparable with the value obtained for SN-38 treated cells. 
One cell (id=540) presented a good signal/background ratio (signal 3272 gray levels, 
background 1479 gray levels; Figure 5.4, Table 5.6), however it was comparable with the 
putative target cells identified in the SN-38 treated cells. The other cells showed a small 
difference between the signal and the background as for SN-38 treated cells. 
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Figure 5.4: DEPArray images of untreated PE+/DAPI+/APC- colon cancer cells. The rows 
show the cells ID, the columns display the name of the Channel Selection the cell belongs 
with respective values. Only one cell (id 540) showed good signal background ratio. 
 
Table 5.6. DEPArray signal and background gray levels of untreated PE+/DAPI+/APC- 
colon cancer cells 
 Cell ID 
 4039 3716 3426 540 481 392 
Signal ~1711 ~2083 ~1449 ~3272 ~2022 ~2153 
Background ~1380 ~1422 ~1405 ~1479 ~1413 ~1466 
 
In this control experiment FITC II could not be taken into account because it was not 
introduced during the analysis of the SN-38 treated cells, and in the oxaliplatin treated 
cells (data not shown) the FITC II was not saved and selected for analysis, therefore the 
data of FITC I and FITC II in positive and negative controls were not available for 
comparison. 
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The validation of the DEPArray analyses by Silicon Biosystems detailed in this section are 
shown in Table 5.7.  
 
Table 5.7. Validation of the DEPArray analysis by Silicon Biosystems 
 Sample 1 (treated 
with SN-38) 
Sample 2 (control) 
No. particles detected 860 1101 
No. particles 
PE+/DAPI+/APC- 
165 192 
No. cells with good 
signal/background ratio 
1 1 
 
 
5.3.4. Discussion and Conclusions: colon cancer cells treated with oxaliplatin and 
SN-38 run with the DEPArray platform after CellSearch System using two different 
exposure times 
On the CellTracks Analyzer II, the cell cartridges along with the control cartridge were 
scanned displaying tumour cells positive for cytokeratin and DAPI, which were reviewed 
by two trained laboratory staff, myself and Silicon Biosystems. CTCs were identified based 
on morphology, positivity for CK-PE and DAPI and negativity for CD45-APC. The 
CellTracks Analyzer II presented the images with overlays of CK-PE and DAPI signals to 
show whether the nuclear and cytokeratin staining were consistent with a tumour cell. The 
objects in the CK-PE filter channel were required to be a round or oval intact cell, at least 
4 microns in diameter, a nuclear area smaller than the cytoplasmic area and more that 
50% of the nucleus needed to be visibly surrounded by the cytoplasm. It was however 
possible for an image to appear very bright as results of a spectral spillover in the CK-PE 
channel creating a visible cytoplasmic image in the CD45-APC channel; if this occurred it 
could still be classified as a tumour cell if it was negative for CD45 and positive for CK-PE, 
differentiating the cell from leukocytes that were positive for CD45-APC and DAPI but 
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negative for CK-PE. Artefacts were recognised as appearing with the same shape in all 
channels.  
The rate of γ-H2AX positive cells after treatment with oxaliplatin or SN-38 and CellSearch 
analysis was low: 177 cells out of the 1158 (15.28%) cells treated with oxaliplatin and 217 
cells out of 1181 (18.37%) cells treated with SN-38 were detected as being γ-H2AX 
positive compared with 5.10% for the untreated controls. In many of the positive cells, the 
stain for γ-H2AX was faint (Figure 5.2 [A-C]). A possible explanation for this is 1. the use 
of different treatment protocols for the fixation and staining of the cells, and 2. the different 
antibodies (Mouse anti-H2AX monoclonal primary antibody (Merck Millipore) and Goat 
anti-mouse Alexa Fluor 488 IgG secondary antibody (Life Technologies Ltd.) rather than 
the anti-phospho-Histone H2A.X (ser139), clone JBW301, FITC conjugated (Millipore) 
normally used and validated for γ-H2AX detection by CellSearch; however, the antibodies 
were compatible for analysis in the 4th channel (FITC) of the CellSearch platform.  
The CellSearch System allows detection of the FITC stain in the nuclei of the cells if they 
were γ-H2AX positive, but the distinct foci were not visible due to the low magnification 
limitation of the CellSearch System platform (20x). 
The parameter selection process of the DEPArray ‘Sorting Mode’ was initially set as 
‘Standard’. Optimal exposure time (μs) for label detection and the gain were set up as per 
protocol (Section 2.9.2). The Filter Wheel was set at the default value and the FITC was 
selected for the event detection. Fluorescent channels were chosen for analysis of images 
through a ROI in correspondence to the label positivity that was further processed and 
displayed at the Cell Browser. Exposure time and gain parameters for signal detection 
were displayed on a Gray Level Histogram. Frame by frame analysis of the intensity of the 
detected signals was performed through image visualisation modalities that distinguished 
background signal from positive signals. The Chip Scan setting was chosen for the 
fluorescence channels and the exposure time and gain (noise to background ratio) were 
set for each channel. During image analysis, the images acquired from the chip scan were 
further counted, their position inside the chip was calculated and morphological and 
intensity measurements extracted from the scanned images. The presence of cell debris 
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or large cell clusters were evaluated as this could potentially decrease the success of cell 
manipulation within the system and the number of total cells loaded in the DEPArray 
A300K cartridge. The chip was scanned using fluorescence and the bright field channels 
were set allowing the images (events) acquired to be counted and to extract morphological 
and intensity measurements from the scanned images. The selected cells were visually 
checked to avoid false objects in the recovery chambers and detection was changed as 
required.  
This initial experiment was performed to verify the workflow on the DEPArray system and 
the exposure time and gain (noise to background ratio) was initially set up as required and 
checked for each channel.  
Events were detected based on an image threshold algorithm (or detection engine) and 
the particle geometry intensity was analysed in the image gallery and calculated based on 
the intensity of fluorescence signals. Analysis was performed in all fluorescence channels 
to obtain correct measurements for each filter (Figures 5.3–5.4). Cells were sorted based 
on different characteristic such as intensity fluorescence, morphological trait and intensity 
parameters. 
Initially, it was decided to set up the mean intensity with the background subtracted to 
provide an estimation of the ratio of the signal to background, indicating how much the 
cells contrast with the background. The particles captured were filtered by the histogram 
analysis mode using a histogram graph. The input populations and their parameters were 
plotted, and the output sub-population was selected reducing the number of particles that 
needed to be visually examined in the table analysis mode, representing the particles that 
were captured by the dielectric field (low APC signal, high FITC signal and high circularity 
FITC). The scatter plot analysis mode was used to display the gated subpopulation (In 
Cage), as a collection of points in a scatter plot; plotting one parameter related to the 
positive marker (e.g. mean_intensity_PE) and the other one related to the negative marker 
(e.g. mean_intensity_FITC). Once a group was created, the individual cells were reviewed 
and visually confirmed that they were single cells and that they had the desired 
morphology. CTC and WBC groups were defined using sliders – plot of mean intensity PE 
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(x axis) was chosen against mean intensity APC (y axis). The desired group and table 
order were selected by mean intensity PE or mean intensity APC. All cells were checked 
to be routed successfully using the DAPI filter to confirm the presence of nuclei where cells 
should be located. Finally, the cells required for recovery were selected and routed to the 
exit chamber eliminating any sources of contaminations such as cell debris or unselected 
cells.  
With the initial standard set up for the identification of FITC background signal (FITC I: 100 
ms and gain 1X) the analysis of the SN-38 treated sample run using the DEPArray platform 
did not show a clear positivity in the FITC channel for most of the PE+/DAPI+/APC- cells. 
Only six putative target cells (Figure 5.3) were identified and only one (id=3794) showed 
a good signal background ratio. Therefore, we analysed the untreated control with FITC I 
(100 ms and gain 1X) and FITC II (800 ms and gain 4X), in order to maintain the CellSearch 
System set up to 3 seconds. FITC II measurement results in the untreated control cells 
(Figure 5.4) were comparable with the values obtained in SN-38 treated colon cancer cells 
(Figure 5.3), and the majority of the other cells showed small differences between the 
signal and the background. In this experiment FITC II could not be taken into account 
because it was not introduced in SN-38 or oxaliplatin cells (data not shown because the 
FITC II analysis was not saved and selected for analysis), therefore the data for FITC I 
and FITC II in positive and negative controls were not available for comparison. 
With the set-up required for the identification of the FITC signal after the CellSearch scan, 
a clear discrimination between cells expressing or not expressing γ-H2AX was not 
observed due to a possible bleaching of the cells as a consequence of the cartridge 
scanning (Section 2.9.2.2). As a result, no difference in signal intensity between the treated 
and untreated cells could be found. The long exposure time and gain required increased 
the level of the background resulting in a low signal/background ratio. 
The results from this study led to the initiation of the following study, the aim of which was 
to identify the most appropriate Cell Browser parameter and the actual value of scan 
settings to be used for the evaluation of label intensity, taking into account: 
• Potential variability in signal detection due to the detection system of the machine 
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• Optical parameters that may require a different set-up based on the cell type and 
labels used for cell staining 
• Reagents used for sample preparation (e.g. cell fixatives and cell permeabilisation 
solutions) that could give a different background level intensity 
• Biological variability between samples; optimisation based on the expression level 
of the target protein which may differ from sample to sample 
• High background due to sample preparation. 
  
The optical parameter optimisation applied to detect discrimination between background 
and positive signals required different set-ups for the Cell Browser: 
1. The first step was to identify the background level intensity for each channel (a 
range between 271 [Minimum] and 322 [Maximum] gray levels was normally 
detected by the DEPArray machine). This signal was considered background 
because the range of gray levels was narrow and the distribution of gray levels was 
centred in the middle of the graph. Depending on the sample type and reagents 
used for the sample preparation, the background level could change. 
2. The second step was to identify the positive signal for each channel (a range 
between 274 [Minimum] and 5997 [Maximum] gray levels was normally detected 
by the DEPArray machine). 
 
To detect a bright or faint signal, a short or long exposure time was indicated, respectively, 
and the gain should not be selected to avoid saturation of the signal. A signal was 
considered positive when the range of gray levels had an intensity higher than the 
background, which could be fainter or brighter depending on the optical parameter set-up. 
To achieve positive information for cell imaging, the maximum gray level should not be 
higher than 10000–14000 (raw data not shown). Measurements were calculated based on 
the intensity of fluorescence signals for every detected event and the data were analysed 
using the mean intensity with background subtraction parameter. Due to time constraints, 
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we were unable to perform additional confirmatory experiments for treated and untreated 
SN-38 cells.  
 
5.4. Colon cancer cells treated with SN-38 or oxaliplatin, run directly on the 
DEPArray platform using two different exposure times, validated with cytospin and 
fluorescence microscopy 
In order to investigate further the potential application of the DEPArray platform, a second 
experiment was performed using untreated colon cancer cells (HT-29) as a negative 
control, and HT-29 cells treated with oxaliplatin (5 µM) or SN-38 (0.01 µM) directly with the 
DEPArray platform (without pre-enrichment by CellSearch; Figure 5.5) using two different 
exposure times (Section 5.3.3). Cells were treated as described in Chapter 2.   
 
 
 
 
 
 
 
 
 
Figure 5.5. Overview of the experiments for colon cancer cells treated with oxaliplatin 5 
µM or SN-38 0.01 µM and run directly on the DEPArray platform followed by validation 
experiments with cytospin and fluorescence microscopy 
 
Experiments were performed in triplicate and in parallel, treating the cells exposed to the 
drugs with and without antibody labelling for γ-H2AX (mouse anti-H2AX monoclonal 
primary antibody [Merck Millipore], and goat anti-mouse Alexa Fluor® 488 IgG secondary 
Untreated cells with anti ƴ-H2AX monoclonal 
antibody 
Treated cells with SN-38 and oxaliplatin with 
anti ƴ-H2AX monoclonal antibody 
Treated cells with SN-38 and oxaliplatin 
without ƴ-H2AX monoclonal antibody 
DEPArray 
Cytospin on slides (confocal microscope) 
DEPArray 
DEPArray 
Cytospin on slides (confocal microscope) 
Cytospin on slides (confocal microscope) 
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antibody [Life Technologies Ltd.]), followed by validation of the γ-H2AX signal with 
fluorescence microscopy (Leica SPE2 confocal microscope; Figure 5.6–5.7). 
HT-29 cells were exposed to SN-38 and oxaliplatin with and without antibody labelling for 
γ-H2AX. Slides were analysed with Leica SPE2 confocal microscope and data analysis 
performed using CellProfiler Software (Chapter 2). 
 
As discussed previously, the high exposure time and gain required with the validated set-
up for CellSearch analysis (3 seconds) could have caused a poor fluorescent signal 
detection due to signal bleaching, resulting in an increased level of background and a low 
signal/background ratio. 
 
 
Figure 5.6: DEPArray images of untreated PE+/DAPI+/APC- colon cancer cells (HT-29). 
The rows show the cell ID, the columns display the name of the Channel Selection the cell 
belongs with respective values.
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Figure 5.7: DEPArray images of SN-38 0.01 µM treated PE+/DAPI+/APC- colon cancer 
cells (HT-29). The rows show the cell ID, the columns display the name of the Channel 
Selection the cell belongs with respective values. 
 
 
5.4.1. DEPArray system analysis of SN-38 or oxaliplatin treated colon cancer cells 
Suspended HT-29 cells treated with SN-38 or oxaliplatin and stained using antibody 
labelling for γ-H2AX (Section 2.10.4) were processed as per standard DEPArray analysis 
(Section 2.8.3.1) and compared with the untreated control group using two different 
exposure times for FITC: 
• FITCI (100 ms and gain 1X)  
• FITCII (800 ms and gain 4X).  
 
Raw data were analysed using an unpaired T-test on mean intensity minus background 
for FITCI and FITCII. The treated cells showed a significantly increased intensity of FITC 
staining compared with the untreated control group: mean 363 vs mean 220 (P<0.0001) 
for FITCI, and mean 5521 vs mean 4365 (P<0.0040) for FITCII (Table 5.8–5.9, Figure 5.8). 
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Table 5.8: HT-29 cells treated with SN-38 0.01 µM compared with the untreated control 
group and run into the DEPArray machine. Data analysis was performed with unpaired T-
Test on mean intensity minus background for FITCI. 
Unpaired t-test FITC1: 100 ms 
 
 FITCI gray intensity for 
cells treated with  
SN-38 (22) 
FITCI gray intensity for 
untreated  
cells (254) 
Mean 362.85 220.54 
Standard deviation 324.58 94.98 
Standard error 69.18 5.96 
P value and statistical significance: The two-tailed P value is <0.0001; confidence interval: the 
mean of treated FITC1 minus untreated FITC1 = 142.31; 95% confidence interval of this 
difference: from 86.28 to 198.351; intermediate values used in calculations: t=4.999, df=274; 
standard error of difference=28.46 
 
 
 
Table 5.9: HT-29 cells treated with SN-38 0.01 µM compared with the untreated control 
group and run into the DEPArray machine. Data analysis was performed with unpaired T-
Test on mean intensity minus background for FITCII. 
Unpaired t-tests FITCII: 800 ms 
 FITCII gray intensity for 
cells treated with SN-38 
(n=22) 
FITCII gray intensity for 
untreated  
cells (n=254) 
Mean 5521.49 4364.97 
Standard deviation 3472.34 1575.11 
Standard error 740.30 99 
P value and statistical significance: The two-tailed P=0.0040; confidence interval: the mean of 
treated FITC2 minus untreated FITC2 = 1156.52; 95% confidence interval of this difference: 
from 372.05 to 1941.00; intermediate values used in calculations: t=2.90, df=274; standard 
error of difference=398.48 
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Figure 5.8: HT-29 cells treated with SN-38 0.01 µM compared with an untreated control 
group using two different exposure times for FITC I (100 ms and gain 1X) and FITCII (800 
ms and gain 4X). Data are expressed as mean of triplicate experiments +/- SE. The treated 
group showed a significantly increased intensity of FITC staining compared with the 
untreated control group: mean 363 vs mean 220 (p<0.0001) for FITCI, and mean 5521 vs 
mean 4365 (p<0.0040) for FITCII 
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Figure 5.9: Validation of the γ-H2AX signal with fluorescence microscopy using HT-29 
cells exposed to SN-38 with and without antibody labelling for γ-H2AX. 
A and B represent HT-29 cells treated with SN-38 without anti-H2AX antibody staining; C 
and D represent untreated HT-29 cells stained with anti-H2AX; E and F represent HT-29 
cells treated with SN-38 and stained with anti-H2AX. A, C and E show nuclei stain (channel 
one: red input image) selected for nuclei identification; B, D and F, show foci stain (channel 
two: green input image) selected for γ-H2AX foci identification. 
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Slides were analysed with Leica SPE2 confocal microscope and data analysis performed 
using CellProfiler Software. 
 
For oxaliplatin treated cells, the majority of treated cells were lost during the washing and 
spinning steps and the total number of cells available for analysis were insufficient for 
validated analysis (Figure 5.10). 
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Figure 5.10: Validation of the γ-H2AX signal with fluorescence microscopy using HT-29 cells exposed to oxaliplatin with and without antibody labelling 
for γ-H2AX.  
A and B represent HT-29 cells treated with oxaliplatin without anti-H2AX antibody staining; C and D represent untreated HT-29 cells stained with anti-
H2AX; E-H represent HT-29 cells treated with oxaliplatin and stained with anti-H2AX. A, C, E, G show nuclei stain (channel one: red input image) selected 
for nuclei identification; B, D, F, H show foci stain (channel two: green input image) selected for γ-H2AX foci identification. Slides were analysed with 
Leica SPE2 confocal microscope and data analysis performed using CellProfiler Software. 
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5.4.2. Colon cancer cells treated with oxaliplatin or SN-38, run directly on the 
DEPArray platform using two different exposure times, validated with cytospin and 
fluorescence microscopy: Discussion and Conclusions 
Based on these results, it was demonstrated that the DEPArray system was able to 
quantify differences in signal intensity as a result of drug induction of γ-H2AX in colon 
cancer cells. The use of fluoresce microscopy validated the data observed with the 
DEPArray platform. There were no detectable γ-H2AX cells observed in HT-29 cells 
treated with SN-38 but without the γ-H2AX antibody or in untreated cells with the γ-H2AX 
antibody present. In contrast, in SN-38 treated cells with the γ-H2AX antibody present 
there was a visible increase in γ-H2AX positive cells. Unfortunately during the analysis, 
most of the treated cells were lost due to the washing and spinning steps involved and the 
total amount of cells were not sufficient to make accurate and validated comparisons. This 
was particularly evident in cells treated with oxaliplatin limiting the data available for 
analysis. 
Due to the fact that future development work will be required to be repeated on the 
CellSearch System to allow optimisation for patient samples, subsequent experiments 
were carried out on HT-29 cells treated with 1 µM topotecan hydrochloride for 2 hours, 
followed by staining for γ-H2AX and analysis on the CellSearch system prior to DEPArray 
analysis. 
 
5.5. Colon cancer cells treated with topotecan and run with DEPArray platform after 
CellSearch System using two different exposure times 
The aims for this study were to investigate whether scanning of CTCs with the CellSearch 
System could have affected the intensity of the FITC signal background and 
signal/background ratio detected by DEPArray process. 
Cells that were previously treated with topotecan and used for the validation of the assay 
employed in this thesis for the detection of γ-H2AX on CTCs using the CellTracks Autoprep 
System and the CellTracks Analyzer II (Section 2.8) were utilised. In brief, HT-29 cells 
were thawed and washed in 10mL PBS, pelleted by centrifugation and re-suspended in 
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10mL PBS. 50 µL of the appropriate cell suspension (~500 cells) was added to 7.5 mL 
healthy donor blood. Cells were left untreated or treated with 1µm topotecan hydrochloride 
for 2 hours at 37°C in the presence of 5% CO2. 
 
5.5.1. Analysis with the CellSearch System 
For each run, four samples from one healthy donor and a CellSearch CTC control sample 
were run using a CellSearch CTC Kit on the CellTracks Autoprep System and the 
CellTracks Analyzer II. Cells were prepared for the CellTracks Autoprep System and split 
into two samples of 750 cells each. Anti-phospho-Histone H2AX (ser139), clone JBW301, 
FITC conjugated antibody (Millipore) was used and the exposure time for the fourth 
channel was set at 3 seconds on the CellSearch Analyser II. Spiked and unspiked samples 
were prepared for analysis (Section 2.7.1), run on the CellTracks Autoprep System and 
on the CellTracks Analyzer II along with a control sample. γ-H2AX-FITC was diluted as 
specified in the protocol and used on the spiked samples.  
Acceptance criteria for detection of γ-H2AX, as set by the NCI [289], state that untreated 
cells must be ≤3% positive for γ-H2AX and treated cells must be ≥10% positive for γ-H2AX. 
All three validation runs met these pre-specified criteria. Based on these results, HT-29 
cells treated with topotecan were used for these experiments as they were previously 
confirmed to be ≥10% positive for γH2AX (Table 5.4; Figure 5.11). 
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Figure 5.11. HT-29 cells treated with topotecan hydrochloride run on the CellTracks 
Autoprep System and on the CellTracks Analyzer II. Example of CTCs positive (top two 
panels) and negative (bottom panel) for γ-H2AX. Merge represents cells stained with CK-
PE with the cell nuclei (DAPI) overlaid; CK-PE represents cells stained only with CK-PE 
(intracellular cytokeratins 8, 18, and/or 19); DAPI represents cell nuclei; CD45-APC 
represents cells stained for CD45-APC (haematopoietic origin). γ-H2AX represents cells 
positive (top panels) or negative (bottom panel) for γ-H2AX. 
 
Two identical samples of HT-29 cells were run on the CellSearch machine but only one 
cartridge was scanned before running both cartridges in the DEPArray platform to 
establish what impact the CellSearch had on subsequent detection by DEPArray. This 
experiment was repeated in triplicate. The presence of CTCs was identified as described 
in Section 2.8.2. One cartridge containing stained CTCs was removed and inserted into 
the CellTracks Analyzer II for scanning and the second cartridge was left unscanned; both 
cartridges were then processed with the DEPArray System (Section 2.9) to compare the 
signal strength. The CellSearch analysis determined that in the scanned sample, 
approximately 45% of the topotecan treated cells were positive for γ-H2AX (FITC) staining; 
this experiment is referred to as the first validation. 
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5.5.2. Analysis with DEPArray platform 
For Sample Preparation and Buffer Compatibility see Section 2.8.3 and 2.9. The DEPArray 
execution system was selected according to the protocol. Cells were sorted based on 
fluorescence intensity and morphological trait and recovered for downstream analysis. 
FITCI and FITCII scans were performed on both samples on the DEPArray and the raw 
data were analysed (Table 5.10 and Figure 5.12). 
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Table 5.10. DEPArray analysis of HT-29 cells treated with topotecan from the CellSearch 
cartridge stained with the H2AX-FITC antibody in the fourth channel and scanned using 
CellTracks system or unscanned (first validation). Data analysis was performed with 
unpaired T-Test on mean intensity minus background for FITCI and FITCII. The scanned 
group showed a statistically significant increase of FITC staining intensity compared with 
the unscanned group for both FITC I (P value: 0.0035) and for FITC II (P value: 0.0049). 
 
 
 Scanned FITCI Unscanned FITCI 
Mean  24.27 16.28 
Standard deviation  16.51 18.58 
Standard error  1.72 2.12 
N. cell  92 77 
 Scanned FITCII Unscanned FITCII 
Mean  613.60 473.79 
Standard deviation  313.22 321.95 
Standard error  32.66 36.69 
N. cell 92 77 
Scanned  FITCI Unscanned FITCI 
P value  0.0035  
Confidence interval 
    
The mean of scanned FITCI minus 
unscanned FITCI = 7.99 
95% confidence interval of this 
difference: from 2.66 to 13.32 
Scanned FITC2  Unscanned FITCII 
P value  0.0049  
Confidence interval 
    
The mean of scanned FITCII minus 
unscanned FITCII = 139.81 
95% confidence interval of this 
difference: from 43.07 to 236.54 
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Figure 5.12. DEPArray analysis of HT-29 cells treated with topotecan from the CellSearch 
cartridge stained with the H2AX-FITC antibody in the fourth channel and scanned using 
CellTracks system (Sample 1) or unscanned (Sample 2) (first validation). A statistically 
significant increase of intensity was showed in the scanned samples for FITC I (P=0.0035) 
and FITCII (P=0.0049). 
 
Out of 1500 cells that were initially run on the CellSearch, 750 cells were recovered, split 
into two samples of 375 cells each and one sample was loaded into the DEPArray and 
scanned. 77 and 92 PE CK positive and APC (CD45) negative cells were found in the 
unscanned and in the scanned samples, respectively. Raw data were analysed using an 
unpaired T-test on mean intensity minus background for FITC I and FITC II. The scanned 
group showed a statistically significant increase of FITC staining intensity compared with 
the unscanned group for both FITC I (P value: 0.0035) and for FITC II (P value: 0.0049).  
The data were further analysed by Silicon Biosystems; in the scanned sample (Sample 1) 
out of 967 particles detected, only 83 PE+/DAPI+/APC– cells were identified, three of 
which had comparable FITC II signal and background levels (Figure 5.13).  
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Figure 5.13: Screenshot from the Silicon Biosystems DEPArray system analysis of 
Sample 1 (scanned) showing three cells with FITC II signal and background level 
comparable. 
In the first and second column from left, the signal in the cells appears faint; in the third 
column the nuclei look picnotic as in apoptosis. 
 
In the unscanned sample (Sample 2), out of 1237 particles detected, 65 were 
PE+/DAPI+/APC- and most of these cells did not show a clear positivity in the FITC 
channel. In this case, DEPArray analysis identified four cells in which the FITC II signal 
and background level were at least comparable (Figure 5.14). A summary of the first 
validation run is shown in Table 5.11. 
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Figure 5.14: Screenshot from the Silicon Biosystems analysis of Sample 2 (unscanned) 
showing four cells with FITC II signal and background level comparable 
 
Table 5.11. Validation of the DEPArray analysis by Silicon Biosystems 
 Sample 1 (scanned) Sample 2 (unscanned) 
No. particles detected 967 1237 
No. particles 
PE+/DAPI+/APC- 
83 65 
No. cells with comparable 
FITC II signal/background 
levels 
3 4 
 
 
5.5.3. Additional validation of CTC Analysis and Enumeration of HT-29 cells and 
their γ-H2AX (FITC) expression when treated with topotecan (second and third 
validation) 
Additional validation experiments were repeated using cells that were similarly treated with 
topotecan at the same concentration and for the same period of time and processed on 
CellTracks Autoprep system along with CTC Control Sample (CellSearch CTC Control Kit) 
as previously described (Section 2.8). 
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For the two additional validation experiments, 5078 and 4026 cells were run using the 
CellSearch platform. The γ-H2AX antibody was diluted as per protocol and loaded in the 
CellSearch machine. For each additional validation, two identical samples were processed 
with CellSearch, but on the CellTracks Analyzer II only one cartridge along with the control 
was scanned, displaying tumour cells positive for CK and DAPI. The other cartridge was 
left unscanned and they were both processed with the DEPArray afterwards to compare 
the signal strength (Figures 5.15–5.18). The presence of CTCs in the CellSearch System 
(Janssen Diagnostic) was identified as previously described. CTCs positive for γ-H2AX 
(FITC) staining were 1431 (28.2%) and 902 (22.4%) for the two additional validations, 
respectively. The cartridges containing stained CTCs were then removed and inserted into 
the CellTracks Analyzer II for scanning. 
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Figure 5.15. A screenshot from the CellTracks Analyser demonstrating the Criteria for 
CTC Analysis. Topotecan treated HT-29 cells for the second validation: CTC candidate 
images and interpreter detection.  
DAPI/CK-PE represents cells stained with CK-PE with the cell nuclei (DAPI) overlaid; CK-
PE represents cells stained only with CK-PE; DAPI represents cell nuclei; CD45-APC 
represents haematopoietic origin; γ-H2AX represents staining for γ-H2AX molecular 
characterisation. Images with an orange box are positive for nuclear FITC staining.  
 
 
144 
 
 
Figure 5.16. A screenshot from the CellTracks Analyser demonstrating the Criteria for 
CTC Analysis. Untreated HT-29 cells from second validation: CTC candidate images and 
interpreter detection.  
DAPI/CK-PE represents cells stained with CK-PE with the cell nuclei (DAPI) overlaid; CK-
PE represents cells stained only with CK-PE; DAPI represents cell nuclei; CD45-APC 
represents haematopoietic origin; ƴ-H2AX represents staining for γ-H2AX molecular 
characterisation. Images with an orange box are positive for nuclear FITC staining.  
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Figure 5.17. A screenshot from the CellTracks Analyser demonstrating the Criteria for 
CTC Analysis. Topotecan treated HT-29 cells for the third validation: CTC candidate 
images and interpreter detection.  
DAPI/CK-PE represents cells stained with CK-PE with the cell nuclei (DAPI) overlaid; CK-
PE represents cells stained only with CK-PE; DAPI represents cell nuclei; CD45-APC 
represents haematopoietic origin; ƴ-H2AX represents staining for γ-H2AX molecular 
characterisation. Images with an orange box are positive for nuclear FITC staining.  
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Figure 5.18. A screenshot from the CellTracks Analyser demonstrating the Criteria for 
CTC Analysis. Untreated HT-29 cells for the third validation: CTC candidate images and 
interpreter detection.  
DAPI/CK-PE represents cells stained with CK-PE with the cell nuclei (DAPI) overlaid; CK-
PE represents cells stained only with CK-PE; DAPI represents cell nuclei; CD45-APC 
represents haematopoietic origin; ƴ-H2AX represents staining for γ-H2AX molecular 
characterisation. Images with an orange box are positive for nuclear FITC staining.  
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5.5.4. Analysis of γ-H2AX (FITC) expression with the DEPArray platform of HT-29 
cells treated with topotecan that were scanned and unscanned with the CellTracks 
Analyzer II system  
The DEPArray set-up execution system was selected according to the protocol, HT-29 
samples treated with topotecan were loaded, and cell sorting and recovery were performed 
using the CellSearch system. FITC I and II scans were performed with the DEPArray 
platform on the two additional validation samples for each experiment (Section 5.2.3). The 
total number of cells recovered from the CellTracks Analyzer II scanned cartridges were 
937 and 773, and the cells recovered from the unscanned cartridge after CellSearch 
analysis were 949 and 1011, for the two additional validations respectively. 
 
The raw data were downloaded after each experiment and analysed using an unpaired T-
test on mean intensity minus background for FITCI and FITCII (Tables 5.12–5.13; Figures 
5.19–5.20). 
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Table 5.12. DEPArray analysis of HT-29 cells treated with topotecan from the CellSearch 
cartridge stained with the H2AX-FITC antibody in the fourth channel and scanned using 
CellTracks system or unscanned (second validation). The data were analysed using 
unpaired T-test on mean intensity minus background for FITCI and FITCII. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Scanned FITCI Unscanned FITCI 
Mean  26.82 48.93 
Standard deviation  14.99 396.08 
Standard error  0.49 12.86 
N. cell  937 949 
 Scanned FITCII Unscanned FITCII 
Mean  732.46 807.32 
Standard deviation  233.59 385.27 
Standard error  7.53 12.51 
N. cell 937 949 
Scanned FITCI Unscanned FITCI 
P value  0.088 
Confidence interval 
    
The mean of scanned FITCI minus 
unscanned FITCI = −22.10 
95% confidence interval of this 
difference: from −47.54 to 3.34 
Scanned FITCII Unscanned FITCII 
P value  0.0001 
Confidence interval 
    
The mean of scanned FITCII minus 
unscanned FITCII = −74.66 
95% confidence interval of this 
difference: from −103.43 to −45.89 
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Table 5.13. DEPArray analysis of HT-29 cells treated with topotecan from the CellSearch 
cartridge stained with the H2AX-FITC antibody in the fourth channel and scanned using 
CellTracks system or unscanned (third validation). Data analysis was performed with 
unpaired T-test on mean intensity minus background for FITCI and FITCII. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Scanned FITCI Unscanned FITCI 
Mean  29.76 47.29 
Standard deviation  19.66 20.13 
Standard error  0.71 0.63 
N. cell  773 1011 
 Scanned FITCII Unscanned FITCII 
Mean  817.43 1257.23 
Standard deviation  466.52 599.99 
Standard error  16.78 18.87 
N. cell 773 1011 
Scanned FITCI Unscanned FITCI 
P value  0.0001 
Confidence interval 
    
The mean of scanned FITCI minus 
unscanned FITCI = −17.54 
95% confidence interval of this 
difference: from −19.41 to −15.67 
Scanned FITCII Unscanned FITCII 
P value  0.0001 
Confidence interval 
    
The mean of scanned FITCII minus 
unscanned FITCII = −439.79 
95% confidence interval of this 
difference: from −491.07 to −388.53 
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Figure 5.19. DEPArray analysis of HT-29 cells treated with topotecan from the CellSearch 
cartridge stained with the H2AX-FITC antibody in the fourth channel and scanned using 
CellTracks system or unscanned (second validation). A. FITCI scanned/unscanned and 
B. FITCII scanned/unscanned. A statistically significant increase of intensity was showed 
in the unscanned samples for FITCII (P=0.0001), but not for FITCI (P=0.0881) 
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Figure 5.20. DEPArray analysis of HT-29 cells treated with topotecan from the CellSearch 
cartridge stained with the H2AX-FITC antibody in the fourth channel and scanned using 
CellTracks system (Sample 1) or unscanned (Sample 2) (third validation). A. FITCI 
scanned/unscanned and B. FITCII scanned/unscanned. A statistically significant increase 
of intensity was shown in the unscanned samples for both FITCI and FITCII (P=0.0001). 
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The results showed a statistically significant increase of intensity in the unscanned 
samples for FITCII (P=0.0001) in the second validation, and for both FITCI and FITCII in 
the third (P=0.0001) validation. FITCI in the second validation was not statistically 
significant (P=0.09). Unfortunately, as in the previous experiments, most of the 
PE+/DAPI+/APC- cells did not show a clear positivity in the FITC channels. DEPArray 
analysis allowed the identification of only four cells in which FITCII and background 
intensity level were at least comparable. Fluorescent staining of γ-H2AX was very faint 
and needed to be set up for a clear detection. 
 
5.5.5. Further statistical analyses of the second and third validation runs using 
mean intensity only on FITCII data 
Additional analyses of raw data for the second and third validation runs were analysed 
using an unpaired T-test on mean intensity for FITCII, rather than mean intensity minus 
the background. The results confirmed a statistically significant increase in intensity in the 
unscanned samples for FITCII in both the second (P=0.03) and third (P=0.0001) 
validations. Analyses were also performed grouping data for low and high intensity FITCII 
signal. A statistically significant increased intensity (P=0.02) was confirmed in the second 
validation of the unscanned sample for high intensity value (Figure 5.21 and Table 5.14), 
while in the third validation the FITCII intensity between the scanned versus unscanned 
samples was statistically significant for both low and high value intensities (Figure 5.22 
and Table 5.15). 
The distribution of the FITCII intensity for these analyses of the second and third DEPArray 
validation experiments of CellTracks Analyser II scanned and unscanned cells was also 
assessed. These data demonstrate that the distribution and therefore γ-H2AX staining of 
the CellTracks Analyser II unscanned samples appeared to be more specific than the 
scanned samples for both validation runs (Figure 5.23).  
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Table 5.14. DEPArray analysis of HT-29 cells treated with topotecan from the CellSearch 
cartridge stained with the H2AX-FITC antibody in the fourth channel and scanned using 
CellTracks system or unscanned (second validation). Data analysis was performed with 
unpaired T-test on mean intensity for FITCII and on data grouped for low (LV) and high 
values (HV). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Scanned FITCII Unscanned FITCII 
Mean  2277 2325 
Standard deviation  349.2 600.8 
Standard error  
11.41 
 
19.50 
 
N. cell 937 949 
P value  0.0344 
 Scanned FITCII LV Unscanned FITCII LV 
Mean  2060 2064 
Standard deviation  91.26 125 
Standard error  4.22 5.77 
N. cell 467 473 
P value  0.6198 
 Scanned FITCII HV Unscanned FITCII HV 
Mean  2493 2585 
Standard deviation  376 754 
Standard error  17.4 34.6 
N. cell 470 476 
P value  0.0179 
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Figure 5.21. DEPArray analysis of HT-29 cells treated with topotecan from the CellSearch 
cartridge stained with the H2AX-FITC antibody in the fourth channel and scanned using 
CellTracks system or unscanned (second validation). A. Data were analysed for FITC II 
using mean intensity. B. The results confirmed a statistically significant increase in 
intensity in the unscanned samples for FITCII for low intensity value (LV) (P=0.03). C. A 
statistically significant increased intensity was confirmed in the second validation of the 
unscanned sample for high intensity value (HV) (P=0.02)
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Table 5.15. DEPArray analysis of HT-29 cells treated with topotecan from the CellSearch 
cartridge stained with the H2AX-FITC antibody in the fourth channel and scanned using 
CellTracks system or unscanned (third validation). Data analysis was performed with 
unpaired T-test on mean intensity for FITCII and on data grouped for low (LV) and high 
values (HV). 
 
 
 
 
 
 
 
 
 Scanned FITCII Unscanned FITCII 
Mean  
2330.11 
 
2815.49 
 
Standard deviation  
479.33 
 
650.98 
 
Standard error  
17.24 
 
20.48 
 
N. cell 773 1011 
P value  0.0001 
 Scanned FITCII LV Unscanned FITCII LV 
Mean  
1969.93 
 
2388.177 
 
Standard deviation  
140.82 
 
199.46 
 
Standard error  
7.17 
 
8.88 
 
N. cell 
385 505 
P value  0.0001 
 Scanned FITCII HV Unscanned FITCII HV 
Mean  
2687.49 
3241.97 
 
Standard deviation  
426.06 
 
665.58 
 
Standard error  
21.74 
 
29.71 
 
N. cell 388 506 
P value  0.0001 
156 
 
 
 
 
 
 
 
Figure 5.22. DEPArray analysis of HT-29 cells treated with topotecan from the CellSearch 
cartridge stained with the H2AX-FITC antibody in the fourth channel and scanned using 
CellTracks system or unscanned (third validation). A. Data were analysed for FITC II using 
mean intensity. The results were statistically significant for FITCII intensity between the 
scanned versus unscanned samples and for both low (LV; B) and high value (HV; C) 
intensities (P= 0.0001).  
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Figure 5.23. Distribution of the FITCII intensity observed following DEPArray analyses for 
the second and third validation experiments of CellTracks Analyser II scanned and 
unscanned cells. These data demonstrate that the distribution and therefore γ-H2AX 
staining of the CellTracks Analyser II unscanned samples appeared to be more specific 
than the scanned samples for both validation runs. 
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5.5.6. Discussion and conclusions of the validation experiments for the colon 
cancer cells drug treated and run with the DEPArray platform after the CellSearch 
System  
Data from these validation experiments were reviewed by myself and by the Silicon 
Biosystems team.  
In the first experiment (Section 5.3) the samples were treated with oxaliplatin and SN-38 
and run with the DEPArray after CellSearch system. This initial experiment was performed 
to verify the workflow on the DEPArray system. The analysis was performed based on 
mean intensity with the background subtracted to provide an estimation of the ratio of the 
signal to background.  
FITCI is usually used for DEPArray analysis. In this case, the background intensity should 
be less than 500 gray, while the exposure time for FITCII for DEPArray analysis 
corresponded to an exposure time of 3 seconds with the CellSearch platform.  
With the initial standard set up for the identification of FITC background signal (FITC I: 100 
ms and gain 1X) the analysis of the SN-38 treated sample run using the DEPArray platform 
did not show a clear positivity in the FITC channel for most of the PE+/DAPI+/APC- cells. 
The untreated control was further analysed with FITC I (100 ms and gain 1X) and FITC II 
(800 ms and gain 4X), that was added to the analysis in order to maintain the CellSearch 
System set up to 3 seconds but we could not discriminate between cells expressing or not 
expressing γ-H2AX, probably due to a possible bleaching of the cells as a consequence 
of the cartridge scanning (Section 2.9.2.2). As a result, no difference in signal intensity 
between the treated and untreated cells could be found. The long exposure time and gain 
required increased the level of the background resulting in a low signal/background ratio. 
The CellSearch System allows detection of the FITC stain in the nuclei of the cells if they 
were γ-H2AX positive, but the distinct foci were not visible due to the low magnification 
limitation of the CellSearch System platform (20x). In this validation experiment where 
samples were treated with oxaliplatin and SN-38 and run with the DEPArray after 
CellSearch system the Alexa Fluor 488-detected in the FITC channel was used which is 
more stable than the FITC antibody used with the CellSearch platform that can bleach 
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more easily. In the same experiment, PI was used instead of DAPI, and this could have 
created a steric hindrance for the binding of the antibody. Furthermore, the images showed 
that the PE signal was saturated which could have contributed to a shift, in part, of the 
signal to the FITC channel, as well as to mixed results. The possibility that the scanning 
caused an excitement of the fluorocrome on the γ-H2AX antibody resulting in an increased 
intensity of the FITC signal with the DEPArray analysis is unlikely, due to the time interval 
(one week) between the CellSearch scan and DEPArray run.  
In the second experiment (Section 5.4) the cells were run directly in the DEPArray system 
(and not scanned on the CellSearch/CellTracks Analyzer II system). Based on these 
results, it was demonstrated that the DEPArray system was able to quantify differences in 
signal intensity as a result of drug induction of γ-H2AX in colon cancer cells. 
Unfortunately during the analysis, most of the treated cells were lost due to the washing 
and spinning steps involved and the total amount of cells were not sufficient to make 
accurate and validated comparisons.  
The third experiment (Section 5.5) was therefore planned due to the fact that future 
development work will be required to be repeated on the CellSearch System to allow 
optimisation for patient samples. 
Three validations were carried out on HT-29 cells treated with 1 µM topotecan 
hydrochloride for 2 hours, followed by staining for γ-H2AX and analysis on the CellSearch 
system prior to DEPArray analysis. 
 
1st validation: Table 5.10.  
Two different exposure times were used, FITCI (100 ms and gain 1X) and FITCII (800 ms 
and gain 4X). The results showed a statistically significant increase in intensity of the FITCI 
and FITCII signal in the sample that was previously scanned in the CellSearch platform. 
However, the 750 cells that were initially retrieved from the CellSearch system were further 
split into two samples and only one sample was run due to an operator mistake, therefore 
data were not available for comparison and to confirm the findings of the experiment. It 
would have been preferable to have had both sets of data to allow for a more accurate 
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statistical comparison compared with the data available from one sample (92 cells from 
the scanned cartridge and 77 cells from the unscanned cartridge). Furthermore, several 
cells appeared to be apoptotic and because of the typical changes occurring during this 
process, the fluorescent staining of cytokeratin and γ-H2AX could have been negatively 
affected. 
As a result of the inconclusive nature of the first experiment run, additional validation runs 
were performed.  
 
2nd and 3rd validation: Tables 5.12., 5.13.  
In these validations, the number of cells recovered was increased and the intensity of the 
other channels in the DEPArray machine was adjusted to avoid saturation. The results 
showed a statistically significant increase of intensity in the CellSearch/CellTracks 
Analyzer II unscanned samples when compared with the scanned samples for FITCII 
(P=0.0001) in the second validation, and for both FITCI and FITCII in the third validation 
(P=0.0001). FITCI in the second validation was not statistically significant (P=0.09) and 
therefore a difference in signal intensity between the CellSearch/CellTracks Analyzer II 
scanned and unscanned sample was not confirmed. Unfortunately, as in the previous 
experiments, most of the PE+/DAPI+/APC- cells did not show a clear positivity in the FITC 
channels. DEPArray analysis allowed the identification of only four cells in which FITCII 
and background intensity level were at least comparable (Figure 5.14). Fluorescent 
staining of γ-H2AX was also very faint. In these experiments the FITCI signal was very low 
(below 50) compared to the cut off value of approximately 1000 (Table 5.10, 5.12, 5.13). 
In fact, the signal and the background should not be similar and should differ in gray levels.  
Moreover the magnitude used by the DEPArray system is 20x; this parameter cannot be 
modified and may not be powerful enough to detect a γ-H2AX signal in the cell nuclei. 
As results of the very low FITCI signal intensity, the data for the second and third 
validations of the third experiment were re-evaluated taking into consideration only the 
mean intensity values of FITCII, rather than the mean intensity with the background 
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subtracted. Although it can be useful to formulate an idea of the ratio between the actual 
γ-H2AX signal and the background, this could be misleading since it derives from a 
mathematical interpolation of the raw data. As already noted, the mean intensity parameter 
is the mean of all gray levels measured within the ROI. It has been suggested to be used 
for diffused cell staining in the nucleus, cytoplasm or on the cell plasma membrane. This 
is differentiated from the maximum intensity parameter which represents the maximum of 
all gray levels measured within the ROI and is usually used to define cell staining in the 
nucleus, cytoplasm or on the cell plasma membrane.  
After having analysed the selected cells, it was noted that they fell within a wide range of 
signal intensities with two groups of CTCs being distinguished: the first group had a high 
mean intensity value and a second group had low mean intensity values. Statistical          
analyses were performed on the two separate groups to determine if it was appropriate to 
separate the groups for further analyses. The results from these additional analyses 
confirmed a statistically significant increase in intensity in the unscanned samples for 
FITCII in both the second (P=0.03) and third (P=0.0001) validations when compared with 
the scanned samples. In addition, when the distribution of the FITCII intensity for these 
analyses was evaluated the distribution and therefore γ-H2AX staining of the CellTracks 
Analyser II unscanned samples appeared to be more specific than the scanned samples 
for both validation runs (Figure 5.24).  
In conclusion, the studies reported here appear to show that when cells are identified 
using the CellSearch system and scanned with the CellTracks Analyser II prior to 
DEPArray analysis for γ-H2AX intensity, the signal for γ-H2AX is lost when compared to 
cells that are not scanned with the CellTracks Analyser II. Therefore, future validation of 
these methods should exclude analysis of isolated cells with the CellTracks Analyser II, 
instead moving straight to analysis with the DEPArray system.  
The combination of CellSearch enrichment and DEPArray sorting have been already 
shown to deliver 100% pure cells appropriate for reproducible downstream next-
generation sequencing analysis.  
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Future development in this field could be focused to integrate CellSearch and DEPArray 
to develop companion diagnostics through the enumeration, isolation, and molecular 
characterization of CTCs, allowing to isolate rare-cell and genetic analyses accelerating 
the validation of personalized therapies for those patients more likely to respond to 
targeted drug treatments, monitoring a patient’s status by showing if their prognosis is 
favorable.  
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CHAPTER 6: Clinical Application and Characterisation of CTCs 
6.1. Introduction 
As previously discussed, CTC counts could suggest on-going metastasis [243] and they 
have been correlated with PFS and OS in several tumour types [217]. Using the 
CellSearch platform, several cut-offs (≥5 CTCs at baseline in breast and prostate cancer 
and >3 in colorectal cancer) [219] have been identified to be associated with shorter 
median PFS and OS [166, 217]. Furthermore, pre- and post-treatment CTC counts are 
currently used as prognostic and predictive biomarkers of response to treatment and 
persistent elevated levels of CTCs after treatment were associated with an adverse 
outcome [290]. 
New molecular methods such as the detection of circulating γ-H2AX expression as a 
marker of response to treatment in CTCs from patients after chemotherapy could 
potentially be utilised as a predictive biomarker of early response to treatment [290]. 
The detection of γ-H2AX in CTCs has been validated and the protocol developed by the 
National Institute of Health (NIH) was tested in the GCLP laboratory at UCL using the 
CellSearch platform. Unfortunately, the quantification of the signal intensity of DBS in 
CTCs was not possible with this platform due to limitations of the magnitude of the signal 
amplification. Therefore, in the current study a system was developed to demonstrate the 
feasibility of γ-H2AX signal quantification as a predictive biomarker of response in CTCs 
in colorectal cancer. The aims of this study were to: 
1.  Investigate the relationship between γ-H2AX expression in CTCs and the γ-H2AX 
response to treatment 
2. Quantify γ-H2AX expression in CTCs using a combined modality approach using 
the CellSearch and DEPArray platforms 
3. Evaluate γ-H2AX in CTCs as a predictive biomarker (i.e. investigate its utility in 
predicting early response to treatment) 
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6.2. Patient Recruitment, demographics and baseline characteristics 
Between May 2014 and March 2015, 16 patients with colorectal cancer starting 
chemotherapy with FOLFOX or FOLFIRI were consented into the study to investigate γ-
H2AX expression in CTCs (National Research Ethics Service Committee, NRES, London, 
Bloomsbury, 12/LO/1654). Patient demographics and baseline characteristics are shown 
in Table 6.1. Patients information was not available for three patients and two patients 
were incorrectly enrolled as not having sites of metastases and had not received any prior 
lines of chemotherapy. For the remaining 11 patients, 64% were male, median (range) 
age was 68 (32–74), the most common histology type was adenocarcinoma of the colon 
(55% of patients), the most common site of metastases was the liver (91% of patients), 
median (range) prior lines of chemotherapy was 2 (1–6), and the most common last 
chemotherapy was FOLFIRI in combination with bevacizumab (Avastin; 45% of patients). 
 
Table 6.1. Patient demographics and baseline characteristics 
Sample 
number 
Sex Age Histology Site(s) of metastases 
Lines of prior 
chemotherapy 
Last 
chemotherapy 
001 NA      
002 F 64 Adc colon Liver 1 Folfox 
003 M 64 Adc rectum Nodal 3 Folfiri + avastin 
004 M 32 Adc colon Liver, peritoneum 1 Folfox + avastin 
005 F 74 Adc colon 
Liver, lung, omental, 
peritoneal 
6 Folfiri 
006 M 68 
Adc cecal, 
ascending Colon 
No metastases 0 Folfox 
007 F 74 Adc colon Liver, peritoneum 2 Folfiri + avastin 
008 M 73 Adc colon Liver, lung 1 Folfiri + avastin 
009 M 72 Adc rectum Liver, pelvis, LN 2 Folfiri + avastin 
010 F 65 Adc colon No metastases 0 Adjuvant folfox 
011 M 68 Adc colo-rectum Liver, lung, bone, brain 2 Folfiri + avastin 
012 NA      
013 F 60 Adc rectum Liver, portal vein, LN 1 Folfox + avastin 
014 M 58 Adc colo-rectum Liver, LN 1 Folfox + avastin 
015 M 73 Adc colon Liver 2 Folfiri 
016 NA      
Adc, adenocarcinoma; F, female; M, male; LN, lymph node; NA, patient information not 
available 
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6.3 Patient Laboratory Measurements Results 
The majority of patients did not have any CTCs in the samples collected pre- or post-
infusion. Only one of 16 patients (011) had both a pre-chemotherapy CTC that was 
negative for γ-H2AX and a CTC following chemotherapy that was positive for γ-H2AX. Two 
samples contained CTCs that were positive for γ-H2AX in both the pre- and post-
chemotherapy samples (001, 015), three had CTCs positive for γ-H2AX only in the pre-
chemotherapy samples (003, 004, 014) and in sample 008 we found only one CTC positive 
for γ-H2AX in the sample post-chemotherapy but no CTC samples were obtained from the 
pre-infusion blood (Table 6.2). 
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Table 6.2. CTC collection and γ-H2AX analysis of patient samples pre- and post-
chemotherapy with FOLFOX or FOLFIRI using the CellSearch platform and Analyzer II 
Sample 
number 
CTCs obtained 
pre-
chemotherapy 
Pre-chemotherapy 
CTCs positive for 
γ-H2AX 
CTCs obtained 
post-
chemotherapy 
Post-
chemotherapy 
CTCs positive for 
γ-H2AX 
001 1 1 1 1 
002 0 0 0 0 
003 1 1 1 0 
004 1 1 1 0 
005 2 0 0 0 
006 0 0 0 0 
007 0 0 0 0 
008 0 0 1 1 
009 0 0 0 0 
010 0 0 0 0 
011 1 0 1 1 
012 0 0 0 0 
013 0 0 0 0 
014 2 2 0 0 
015 21 5 17 4 
016 0 
Sample could not be 
scanned due to 
ferrofluid 
aggregates in the 
cartridge 
0 0 
 
 
6.4. Discussion and Conclusions 
The aim of this study was to determine if the CellSearch platform and the CellSearch 
Analyzer II were suitable tools to isolate CTCs and determine γ-H2AX expression in CTCs 
from peripheral blood samples from patients with CRC prior to, and following treatment 
with FOLFOX or FOLFIRI, followed by the use of the DEPArray machine. If both the 
number of CTCs could be identified and γ-H2AX expression levels determined before and 
after treatment with chemotherapy it may be possible to determine if the patient is 
responding to their chemotherapy treatment. As described earlier, CTC counts correlate 
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with clinical outcome in several cancers including breast, prostate, colorectal and lung 
cancer [290]. In addition, pre- and post-treatment CTC counts can be used as prognostic 
and predictive biomarkers of response to treatment [290]. Many anticancer treatments, 
including chemotherapy, act by damaging DNA and hindering cell function and 
proliferation. γ-H2AX accumulates in cells as an early response to DNA double-strand 
breaks, which is the most deleterious lesion as a result of anticancer therapy and therefore 
γ-H2AX is generally considered as a surrogate marker of DNA damage [291]. γ-H2AX 
could therefore be used as a predictive biomarker of early response to treatment and may 
help aid a more personalised treatment approach to patients receiving chemotherapy.  
In the current study, it was demonstrated that we were able to isolate CTCs from peripheral 
blood samples from patients with CRC using the CellSearch platform and we were able to 
demonstrate the presence of CTCs that expressed γ-H2AX. However, in all but one 
sample (015), the numbers of CTCs were lower than would be expected as CTCs have 
been reported to be found in frequencies in the order of 1–10 CTCs per ml of peripheral 
blood in patients with metastatic disease [178, 291]. Up to 15 ml of peripheral blood was 
used in the current experiment and therefore we would have expected over 15 CTCs per 
sample if patients had metastatic disease. It is unknown as to why low numbers of CTCs 
were observed. As one sample contained a relatively high number of CTCs, it is unlikely 
that methodological reasons are due to the low number of CTCs observed. Reasons could 
be due to patients having a small tumour burden, or the low number of patients enrolled in 
this study compared with those previously reported, which may have contributed to the 
non-conclusive results obtained.  Unfortunately, due to time constraints it was not possible 
to collect additional samples. 
Similarly, the data from the CTCs that expressed γ-H2AX were also inconclusive, with only 
one patient having a pre-chemotherapy CTC that was negative for γ-H2AX and a CTC 
following chemotherapy that was positive for γ-H2AX. There were a number of patients 
who had CTCs that were positive for γ-H2AX prior to chemotherapy, this could be due to 
several reasons including CTCs undergoing apoptosis prior to their chemotherapy, 
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possibly as a carryover from previous treatment lines as patients who had received 
previous treatments were allowed to enter the study.  
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CHAPTER 7: Overall Discussion and Conclusions 
Colorectal cancer is the third most common cancer in males and females and the fourth 
overall in the UK, accounting for 13% of all new cases [1]. There are currently no predictive 
biomarkers available to assess the response to chemotherapy for a patient with CRC. γ-
H2AX foci represent double strand DNA breaks and therefore DNA damage. γ-H2AX 
induction has been studied in cancer cells treated with different chemotherapy agents and 
in CTCs from patient blood samples processed using the CellSearch system in conjunction 
with γ-H2AX-AF488 antibody staining. γ-H2AX signal was detected as a percentage of γ-
H2AX-positive CTCs per total CTCs recovered following chemotherapy [214]. However, 
at present this is still an unmet need since the current methods available for the detection 
of DNA damage in patient samples have showed a limited applicability in the clinic to 
monitor tumour response to chemotherapy. Compared with other approaches, the 
combination of CTC enrichment with nuclear γ-H2AX detection is a distinctive and 
innovative technique that could provide valuable information on a patients’ response to 
treatment and their prognosis. The development of a high throughput γ-H2AX foci-counting 
system for clinical utilisation to allow a faster analysis and automated microscopic 
examination may provide this [214, 244, 288]. It is still unknown whether detecting γ-H2AX 
in CTCs will correlate with clinical efficacy and clinical trials are currently investigating the 
correlation between drug effects on disease progression with γ-H2AX-positive CTCs. 
Examples of such studies include NCT00576654 and NCT01386385 which are evaluating 
the effect of veliparib in combination with chemotherapies in advanced solid tumours or 
advanced non-small cell lung cancer, respectively. 
The studies presented here were performed to address the lack of a method allowing the 
quantification of the γ-H2AX induction in CTCs; the study aimed to develop a method to 
quantify changes in γ-H2AX (as a marker of DNA damage and therefore response to 
treatment) in CTCs from mCRC patients undergoing treatment with FOLFOX or FOLFIRI, 
using the DEPArray System as a new approach. 
The initial feasibility experiments investigated the induction of γ-H2AX foci on human 
adenocarcinoma colorectal cells (HT-29 cells) by performing dose response experiments 
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with increasing concentrations of oxaliplatin and SN-38, and to select doses of these drugs 
that induce a peak of γ-H2AX foci for use in future experiments. An increase in the number 
of γ-H2AX foci were observed after treatment with oxaliplatin and SN-38 (Figures 3.2 and 
3.4), in agreement with previous studies that showed that H2AX was phosphorylated in 
response to DNA DSBs induced by DNA topo I cleavage complexes [276] and oxaliplatin 
[266]. In colorectal cancer cells, treatment with 1, 5, and 10 μM oxaliplatin for 2 hours 
generated more γ-H2AX foci than in untreated cells, and more foci formed with increasing 
drug concentrations (Figure 3.2). Using the same doses and time of drug exposure as that 
used for oxaliplatin, following SN-38 treatment more foci per cell were detected likely due 
to the occurrence of continual DNA DSBs. It is possible that the different responses 
observed between the same concentrations of oxaliplatin and SN-38 in HT-29 cells is 
because the IC50 of oxaliplatin is greater than that of SN-38 (22.17 vs 1.93, respectively 
[278]). When HT-29 cells were incubated with lower concentrations of SN-38 foci were 
detected after 1 hour of drug exposure at the 0.01 and 0.05 µM SN-38 doses (Figure 3.4). 
Based on these results, the final concentrations that were selected for the time course 
experiments (Chapter 4) were 5 μM and 0.01 μM for oxaliplatin and SN-38, respectively.  
Following the feasibility experiments, a time course study was performed to determine any 
changes in the levels of, and temporal differences including the time of γ-H2AX foci peak 
in human adenocarcinoma colorectal cells following treatment with oxaliplatin and SN-38. 
The tumour suppressor p53 protein is a transcription factor inducing cell cycle arrest, 
senescence, and apoptosis under cellular stress. Dysregulation of TP53 tumour 
suppressor gene is one of the most frequent events contributing to the transformation of 
CRC, as well as the aggressive and metastatic features of CRC. Different types 
of TP53 mutations play a pivotal role in determining the biologic behaviour of CRC, such 
as invasive depth, metastatic site and even the prognosis of patients [279]. The HT-29 cell 
type has been reported to express a mutated p53 gene whereas the HCT-116 cell line 
does not [280]. As the TP53 gene mutation in HT-29 cells may affect the response to 
treatment the time course experiments assessed both cell types. The aim of these time 
course experiments was to determine the optimum time for CTC collection from patients 
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post infusion of FOLFOX or FOLFIRI and to provide data for the γ -H2AX quantification 
using the CellSearch and DEPArray platform. These studies demonstrated a sustained 
increase in the number of γ-H2AX foci formations following treatment of the HT-29 and 
HCT-116 cells with oxaliplatin and SN-38 (Figures 4.1–4.8) in agreement with previous 
studies [283]. The rise of foci was observed between 2–6 hours post-treatment, after which 
they gradually decreased returning close to the baseline distribution at 26 hours due to 
DNA repair. Minor differences were observed between the two CRC cell lines in response 
to treatment with oxaliplatin or SN-38; in both cells, there was a rapid peak to a mean of 
~10 foci/group in the first hour post-treatment which plateaued at a steady rate until 18 
hours post-dose where the mean γ-H2AX foci/group declined to ~10 (7.32-11.73), and 6-
8 foci/group by 26 hours post dose (6.22-8.57). The minor differences that were 
nevertheless observed with the different treatments and cell lines used could be explained 
by the different mode of action of the drugs as well as intrinsic differences in the cell lines. 
As noted above, the genetic status of the different cell lines may contribute to differences 
observed between the two cell lines used; the presence of TP53 gene mutations (as well 
as BRAF mutations) in HT-29 cells may result in the cells responding to treatment 
differently [280]. Oxaliplatin and SN-38 are pharmacologically distinct and have different 
mechanisms of action. Various mechanisms of action are ascribed to oxaliplatin however 
like other platinum-based compounds, oxaliplatin exerts its cytotoxic effect mostly 
through DNA damage by causing DNA lesions (crosslinks), arresting DNA synthesis and 
through the inhibition of messenger RNA synthesis [274]. The active form of SN-38, 
irinotecan, inhibits the action of topo I, preventing relegation of the DNA strand by binding 
to the topo I-DNA complex. The formation of a cleavable drug–Topo I–DNA complex 
results in lethal double-strand DNA breakage and cell death [284]. These differences in 
the mode of action of the drugs resulting in DNA damage, as well as genetic differences 
of the cell lines used, may contribute to the different temporal effects in the formation of γ-
H2AX foci that were observed. Based on these results, the optimal time for CTC collection 
from patients was determined to be 2 hours post infusion of FOLFOX or FOLFIRI. This 
time point was chosen as: 1. γ-H2AX induction was observed with both cell lines and 
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treatments at this time point; 2. 2 hours post-infusion would avoid patients having to 
undergo a prolonged stay in the hospital following completion of their treatment. 
Next, a protocol for the quantification of γ-H2AX intensity using the CellSearch System 
and the DEPArray System was developed which aimed to evaluate the γ-H2AX signal 
using both systems with in vitro validation using human adenocarcinoma colorectal cells 
treated with oxaliplatin, SN-38 or topotecan which could be used for future clinical 
applications as an early indicator of response to treatment. The CellSearch System 
(CellSearch Circulating Tumour Cell Kit; CellTracks Autoprep System; CellTracks 
Analyzer II) was previously validated to detect γ-H2AX induction in topotecan treated or 
X-ray irradiated and untreated HT-29 CRC cells spiked into peripheral blood from healthy 
donors (Section 5.2). The CellTracks Analyzer II provides data on the overall number of 
CTCs present within the sample as well as the number and percentage of CTCs which are 
positive for γ-H2AX. The results from these validation experiments demonstrated that the 
CellSearch Circulating Tumour Cell Kit and the CellSearch CellTracks Autoprep System, 
using the Anti-phospho-Histone H2A.X (ser139), clone JBW301, FITC conjugated γ-H2AX 
antibody (57 µg/mL), with the CellTracks Analyzer II (with exposure for the fourth channel 
[FITC] set at 3 seconds) can identify the overall number of CTCs consistent with those that 
were included in the spiked samples (Tables 5.1–5.4) and can detect γ-H2AX in the cells. 
In blood that was spiked with HT-29 cells X-ray irradiated or treated with topotecan had 
CTCs positive for γ-H2AX above the pre-defined NCI acceptance threshold of ≥10% 
positive for γ-H2AX whereas untreated HT-29 spiked samples had low numbers of CTCs 
positive for γ-H2AX were detected, all of which were below the pre-defined threshold of 
≤3% positive for γ-H2AX. 
I evaluated the CellSearch System combined with the DEPArray platform using HT-29 
cells treated with oxaliplatin or SN-38 spiked into peripheral blood from healthy volunteers. 
The samples were processed on the CellTracks Autoprep system using a different γ-H2AX 
antibody (Mouse anti-H2AX monoclonal primary antibody and Goat anti-mouse Alexa 
Fluor 488 IgG secondary antibody) than previously used. This method was shown to be 
effective for determining CTCs based on cell morphology, positivity for CK-PE and DAPI 
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and negativity for CD45-APC however the rate of γ-H2AX induction in oxaliplatin and SN-
38 treated cells was low following CellSearch analysis with many of the positive cells 
having a faint signal for γ-H2AX; 177 cells out of the 1158 (15.28%) cells treated with 
oxaliplatin and 217 cells out of 1181 (18.37%) cells treated with SN-38 were detected as 
being γ-H2AX positive compared with 5.10% for the untreated controls (Figure 5.2). This 
could be explained by 1. the use of different treatment protocols for the fixation and staining 
of the cells, and 2. the different antibodies used as described above. The CellSearch 
System allows detection of the FITC stain in the nuclei of the cells if they were γ-H2AX 
positive, but the distinct foci were not visible due to the low magnification limitation of the 
CellSearch System platform (20x). The cells used in these experiments were then 
evaluated on the DEPArray platform. Following several DEPArray set-up modifications 
(Section 5.3.4) which were required for the identification of the DEPArray FITC signal after 
the CellSearch scan of the cell samples, a clear discrimination between cells expressing 
or not expressing γ-H2AX was not observed due to a possible bleaching of the cells 
because of the CellSearch cartridge scanning. Thus, no difference in signal intensity 
between the treated and untreated cells could be found; the long exposure time and gain 
required increased the level of the background resulting in a low signal/background ratio.  
As γ-H2AX positive cells could not be identified using the DEPArray System after the 
CellSearch System, we evaluated the DEPArray platform without using the CellSearch 
methods beforehand. HT-29 cells were either untreated or treated with oxaliplatin or SN-
38 with and without antibody labelling for γ-H2AX, the cells were then evaluated using the 
DEPArray system with two different exposure times for FITC. The results from these 
experiments showed a significantly increased intensity of FITC staining for SN-38 treated 
cells compared with the untreated control group for both FITC I (P<0.0001) and FITC II 
(P<0.004; Tables 5.8–5.9; Figure 5.8) demonstrating that the DEPArray system was able 
to quantify differences in signal intensity as a result of drug induction of γ-H2AX in colon 
cancer cells. The use of fluoresce microscopy validated the data observed with the 
DEPArray platform. There were no detectable γ-H2AX cells observed in HT-29 cells 
treated with SN-38 but without the γ-H2AX antibody or in untreated cells with the γ-H2AX 
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antibody present. In contrast, in SN-38 treated cells with the γ-H2AX antibody present 
there was a visible increase in γ-H2AX positive cells. Unfortunately during the analysis, 
most of the treated cells were lost due to the washing and spinning steps involved and the 
total amount of cells were not sufficient to make accurate and validated comparisons. This 
was particularly evident in cells treated with oxaliplatin. 
As any future development methods will require analysis on the CellSearch System to 
allow optimisation for patient samples, subsequent experiments were carried out on HT-
29 cells treated with topotecan spiked into peripheral blood from healthy volunteers 
followed by staining for γ-H2AX and analysis on the CellSearch system prior to DEPArray 
analysis to investigate whether scanning of CTCs with the CellSearch System could have 
affected the intensity of the FITC signal background and signal/background ratio detected 
by DEPArray process. These experiments were performed using treated cells that were 
used for the validation of the detection of γ-H2AX on CTCs using the CellSearch 
CellTracks Autoprep System with and without prior scanning with the CellTracks Analyzer 
II. In the first experiment the results showed a statistically significant increase in intensity 
of the FITC I and FITC II signal in the sample that was previously scanned in the 
CellSearch platform and then assessed on the DEPArray platform. However, due to an 
experimental error, the results of the first experiment could not be further evaluated and 
confirmed and therefore two additional experiments were performed. The results showed 
a statistically significant increase of intensity in the CellSearch/CellTracks Analyzer II 
unscanned samples when compared with the scanned samples for FITC II (P=0.0001) in 
the second validation, and for both FITC I and FITC II in the third validation (P=0.0001). 
FITC I in the second validation was not statistically significant (P=0.09) and therefore a 
difference in signal intensity between the CellSearch/CellTracks Analyzer II scanned and 
unscanned sample was not confirmed. Unfortunately, as in the previous experiments, most 
of the PE+/DAPI+/APC- cells did not show a clear positivity in the FITC channels. 
DEPArray analysis allowed the identification of only four cells in which FITC II and 
background intensity level were at least comparable (Figure 5.14). Due to low FITC I signal 
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intensity, the data for the second and third validations were re-evaluated taking into 
consideration only the mean intensity values of FITC II, rather than the mean intensity with 
the background subtracted. Following the analysis of selected cells, it was noted that they 
fell within a wide range of signal intensities with two groups of CTCs being distinguished: 
the first group had a high mean intensity value and a second group had low mean intensity 
values. Statistical analyses were performed on the two separate groups to determine if it 
was appropriate to separate the groups for further analyses. The results from these 
additional analyses confirmed a statistically significant increase in intensity in the 
unscanned samples for FITCII in both the second (P=0.03) and third (P=0.0001) 
validations when compared with the scanned samples. In addition, when the distribution 
of the FITCII intensity for these analyses was evaluated the distribution and therefore γ-
H2AX staining of the CellTracks Analyser II unscanned samples appeared to be more 
specific than the scanned samples for both validation runs (Figure 5.23). These studies 
appear to show that when cells are identified using the CellSearch system and scanned 
with the CellTracks Analyser II prior to DEPArray analysis for γ-H2AX intensity, the signal 
for γ-H2AX is lost when compared to cells that are not scanned with the CellTracks 
Analyser II. Therefore, future validation of these methods should exclude analysis of 
isolated cells with the CellTracks Analyser II, instead moving straight to analysis with the 
DEPArray system. 
Once a protocol had been developed for the identification of γ-H2AX foci on isolated CTCs, 
it was utilized to demonstrate the feasibility of γ-H2AX signal quantification as a predictive 
radiological biomarker of response (i.e. investigate its utility in predicting early response to 
treatment) in CTCs from patients with CRC. These experiments aimed to determine if the 
CellSearch platform and the CellSearch Analyzer II were suitable tools to isolate CTCs 
and determine γ-H2AX expression in CTCs from peripheral blood samples from patients 
with CRC prior to, and following treatment with FOLFOX or FOLFIRI, followed by the 
DEPArray platform. If both the number of CTCs could be identified and γ-H2AX expression 
levels determined before and after treatment with chemotherapy it may be possible to 
determine if the patient is responding to their chemotherapy treatment. As described 
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earlier, CTC counts correlate with clinical outcome in several cancers including breast, 
prostate, colorectal and lung cancer [290]. Due to the mechanism of action of most 
anticancer treatments, γ-H2AX accumulates in cells as an early response to DNA double-
strand breaks, therefore γ-H2AX is generally considered as a surrogate marker of DNA 
damage [291]. γ-H2AX could be used as a predictive biomarker of early response to 
treatment and may help aid a more personalised treatment approach to patients receiving 
chemotherapy [290]. In the study performed here, we were able to isolate CTCs from 
peripheral blood samples from patients with CRC using the CellSearch platform and we 
were able to demonstrate the presence of CTCs that expressed γ-H2AX. However, in all 
but one sample the numbers of CTCs were lower than would be expected and the reasons 
for this are unknown; CTCs have been reported to be found in frequencies in the order of 
1–10 CTCs per ml of peripheral blood in patients with metastatic disease [178, 291]. As 
one sample contained a relatively high number of CTCs, it is unlikely that methodological 
reasons have caused the low number of CTCs observed. Potential explanations include 
patients having a small tumour burden, or the low number of patients enrolled in this study 
compared with those previously reported, which may have contributed to the non-
conclusive results obtained. Unfortunately, due to time constraints it was not possible to 
collect additional samples. Similarly, the data from the CTCs that expressed γ-H2AX were 
also inconclusive, with only one patient having a pre-chemotherapy CTC that was negative 
for γ-H2AX and a CTC following chemotherapy that was positive for γ-H2AX. There were 
a number of patients who had CTCs that were positive for γ-H2AX prior to chemotherapy, 
this could be due to several reasons including CTCs undergoing apoptosis prior to their 
chemotherapy, possibly as a carryover from previous treatment lines as patients who had 
received previous treatments were allowed to enter the study.  
Additional aims of this study which were not undertaken due to time constraints were to 
quantify γ-H2AX expression in CTCs using a combined modality approach using the 
CellSearch and DEPArray platforms and to evaluate γ-H2AX in CTCs as a predictive 
biomarker (i.e. investigate its utility in predicting early response to treatment). Further 
research is required to determine if the CellSearch and DEPArray platforms could be 
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utilised together to determine if both CTC counts and the expression of γ-H2AX in CTCs 
from peripheral blood samples of patients with CRC could be used to predict early patient 
outcomes to chemotherapy treatment.  
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